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Abstract
The human immunodeficiency virus (HIV) is the causative agent of acquired
immunodeficiency syndrome (AIDS), a disease that to this day has resulted into
more than 25 million deaths in the world. Despite the development of multiple
antiretroviral drugs in the last twenty years, no effective vaccine or cure is cur-
rently available. Developing new drug classes with alternative mode of actions
is a promising and innovative approach. Before the start of this PhD, a peptide
inhibitor called VIRIP was discovered that binds to the N-terminal fusion peptide
(FP) of gp41, an extracellular viral protein essential for fusion with human host
cells and hence viral infectivity. A combined molecular dynamics (MD) simulation
and specifically optimised binding free energy calculation approach was used
to analyse the interactions between gp41 FP and the multiple VIRIP derivatives.
Enhanced VIRIP derivatives were suggested and a selection was subsequently
tested in cellulo. While the FP as target has been studied extensively in membrane
and solution environments, its structure remained largely ambiguous to this day.
Therefore, another goal was the characterisation of the FP in solution environ-
ments using atomistic MD simulations. Finally, another interesting antiviral target
emerged during my research, namely the multimerisation process of the Rev
protein. Interactions between individual Rev monomers were studied using the
MD and binding free energy calculation protocol. The hot spot residues in each
binding interface were revealed and their energy values were found to be in
correlation with previous experimental measurements. It is expected that this
information may guide the development of novel Rev specific antiretrovirals.
iii

Beknopte samenvatting
Het humaan immuundeficiëntievirus (HIV) is verantwoordelijk voor het veroor-
zaken van het verworven immuundeficiëntiesyndroom (AIDS). Deze ziekte heeft
tot meer dan 25 miljoen doden geleid tot op de dag van vandaag. Er is nog
steeds geen effectief vaccin of geneesmiddel ontdekt voor deze ziekte, ondanks de
ontwikkeling van meerdere antiretrovirale middelen in de laatste twintig jaar. De
ontwikkeling van nieuwe middelen met alternatieve mechanismes is een interes-
sante en vernieuwende aanpak. Voor het begin van dit onderzoek is een peptide
genaamd VIRIP ontdekt. Dat peptide bindt aan het N-terminaal fusiepeptide
(FP) van gp41, dat essentieel is voor fusie van virale partikels met gastheercellen
en bijgevolg van virale infectiviteit. Een combinatie van moleculaire dynamica
(MD) simulaties en specifiek geoptimaliseerde bindingsenergie-methoden werd
gebruikt voor de analyse van de interacties tussen gp41 FP en VIRIP-derivaten.
Verbeterde VIRIP-derivaten werden voorgesteld en een selectie werd in cellen
getest. Hoewel het FP als doelwit uitgebreid is bestudeerd in membraan en
oplossing, is de structuur tot op de dag van vandaag dubbelzinnig. Daarom was
een ander doel van dit onderzoek de karakterisatie van het FP in oplossing met
behulp van MD-simulaties. Ten slotte hebben we een ander interessant antiviraal
doelwit onderzocht, namelijk de multimerisatie van het Rev eiwit. Interacties
tussen individuele Rev monomeren werden bestudeerd door middel van het
zonet vermelde MD- en bindingsenergie-protocol. De belangrijkste residu’s in
elke bindingsplaats werden opgehelderd en de energiewaarden correleerden met
vroegere experimentele metingen. Het is te verwachten dat deze informatie de
ontwikkeling van nieuwe Rev-specifieke antiretrovirale middelen kan stimuleren.
v
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Part I
Aims
The human immunodeficiency virus (HIV) is the causative agent of acquired
immunodeficiency syndrome (AIDS). This disease has resulted into more than
25 million deaths in the world to this day. Despite the development of multiple
antiretroviral drugs in the last twenty years, no effective vaccine or cure is currently
available. Antiretroviral treatment is thwarted by an increased emergence of resis-
tance in HIV-infected patients due to the high mutation and replication rate of HIV.
This results in elevated genetic variability making current antiretroviral drugs less
effective. Resistant effects can be limited by improving current antiretroviral drug
classes even further. Alternatively, developing new drug classes with alternative
mode of actions would be a more promising and innovative approach. Preferably,
those new drug classes should contain very high resistance barriers to avoid
accumulation of mutations in viral proteins. The inclusion of these novel drugs
targeting other steps in the viral replication cycle is becoming attractive for the
effectiveness of antiretroviral therapies.
At the start of this PhD, a peptidic inhibitor called VIRIP (VIRus INhibitory
Peptide) has been reported by the group of prof. dr. Frank Kirchhoff and prof. dr.
Jan Münch at the Institute of Molecular Virology, Ulm University Medical Center,
Germany. This peptide binds to the N-terminal fusion peptide (FP) of gp41, an
extracellular viral protein essential for fusion with human host cells and hence
viral infectivity. The gp41 FP is an interesting novel antiretroviral target due to
its highly conserved nature and importance during viral replication. Multiple
VIRIP derivatives have been developed, but the mode of action of VIRIP remained
largely unclear. Therefore, the first objective of this PhD is the analysis of the
interactions between gp41 FP and the multiple VIRIP derivatives. To this end,
a combined molecular dynamics (MD) simulation and a specifically optimised
binding free energy calculation approach was used. Based on this analysis, another
aim was to suggest VIRIP derivatives with improved antiretroviral activity to
test a selection in cellulo by the group of prof. dr. Frank Kirchhoff and prof. dr. Jan
Münch.
1
2While the FP as target has been studied extensively in both membrane and solution
environments, its structure remains largely ambiguous to this day. Therefore, a
second objective is to characterise the FP in solution using atomistic MD simu-
lations. These calculations were performed in collaboration with dr. Kashif Sadiq
and dr. Gianni De Fabritiis of the Computational Biophysics Laboratory, Universi-
tat Pompeu Fabra, Barcelona. These studies do not only give an atomistic glimpse
of the conformational distribution of the FP, they can also suggest conformations
that would be interesting to target by fusion inhibitors.
During the course of my research, another interesting antiviral target emerged:
the multimerisation process of the Rev protein. This protein mediates nuclear
export of viral mRNA and as a consequence is important for the onset of the late
HIV replication cycle. Multiple Rev monomers multimerise and form a functional
multimeric complex with viral RNA. This multimerisation event is indispensable
for the Rev function, as such development of small molecule inhibitors targeting
the multimerisation process would be a novel antiretroviral approach. Crystal
structures of dimeric and tetrameric Rev structures were recently resolved, but
unfortunately did not allow for a full understanding of the multimerisation process.
Therefore, a third objective is to study the interactions between individual Rev
monomers using the previously mentioned combined MD and binding free energy
calculation protocol.
Finally, a last objective is to utilise the information from the multimerisation
interaction study to conduct a virtual screening study using a 3D pharmacophore
model for the discovery of novel Rev multimerisation inhibitors. This study is
performed in collaboration with the group of prof. dr. Dirk Daelemans of the Rega
Institute, KU Leuven, who has developed and optimised various in vitro and in
vivo methods to study the multimerisation of Rev. Note that the results of this
study are not included in this thesis for protection of intellectual property.
The aims of the thesis can be summarized as follows and are investigated in the
listed result chapters:
Chapter Aim
4 Analyse interactions between gp41 FP and VIRIP derivatives
4 Suggest VIRIP derivatives with improved antiretroviral activity
5 Characterise the FP in solution using atomistic MD simulations
6 Study the interactions between individual Rev monomers
/ Virtual screening of novel Rev multimerisation inhibitors
Part II
Introduction
In this part, we will introduce a background of the human immunodeficiency
virus and provide some general concepts applied in this thesis. The part is divided
in the following chapters.
Chapter 1 | HIV: the role of gp41 FP and Rev
This chapter outlines the biological background of the doctoral research. HIV-1
and its structure and replication cycle are introduced in detail. We explain the
current state of research of the two targets in this thesis, the gp41 fusion peptide
and the regulatory Rev protein.
Chapter 2 | Molecular dynamics simulations
Here, we introduce MD simulations as a valuable tool to investigate molecules
of interest. A perspective of the method compared to experimental methods is
presented. We explain the theoretical concepts of MD simulations in detail and
offer some limitations and challenges in the field.
Chapter 3 | Binding free energy calculations
The concepts in the previous chapter can be implemented to estimate binding
affinities between biomolecules, an important task in drug development. An
overview of the current binding free energy methods is presented, where we
shortly discuss their strengths and weaknesses. The method used in this thesis,
MM-PB/GBSA, is summarised in detail. Furthermore, we present a number of
applications and underline a number of considerations of the method.
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Chapter 1
HIV: the role of gp41 FP and Rev
"Take Your Protein Pills And
Put Your Helmet On"
Space Oddity, David Bowie
1.1 Human Immunodeficiency Virus: An introduction
In 1981, an unknown illness was reported in previously healthy men in Los
Angeles. Patients were characterised by an unusual amount of opportunistic
infections and rare malignant tumours, such as Kaposi’s sarcoma and Burkitt’s
lymphoma. The disease was found to spread through sexual transmission or
blood transfusion and was called acquired immunodeficiency syndrome (AIDS)
before the causative agent was discovered. Many different theories were proposed
as the cause of the peculiar disease, but it took until 1983 before the human
immunodeficiency virus (HIV) was identified as the etiological agent of AIDS
[1, 2]. Until today, AIDS has evolved into one of the greatest pandemics caused by a
previously unrevealed infectious agent in modern history, with millions of people
infected around the world. AIDS is not only a disease. It has strong economic
implications, especially in certain Sub-Saharan African countries where mostly
young people are affected; resulting in a significantly reduced life expectancy and
increased poverty levels.
HIV is a retrovirus, belonging to the class of the lentiviridae. Lente is Latin for
"slow" as exemplified by the long incubation period of the virus in the host. HIV
is characterised by a complex immunology [3] and is closely related to other
mammalian retroviruses such as simian immunodeficiency virus (SIV), feline
immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV). Two
different types can be distinguished: HIV-1 (a global variant) and HIV-2 (mainly
restricted to Western-Africa). HIV-1 is the most virulent and widespread variant
and it is therefore the most studied type. The viral particles target white blood cells
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harbouring CD4-receptors, such as T helper cells (these are lymphocytes important
in the adaptive immune system by release of cytokines) and macrophages (these
are lymphocytes part of the innate immune system that digest pathogens and
remove cellular waste). Upon infection, HIV subdues the host cell machinery and
the viral genetic material is irreversibly integrated in human cells. HIV infection
leads to a significant decrease in cellular immunity due to T cell degradation,
thereby abrogating the immune system response. That decrease ultimately results
in the disease we call AIDS.
In 1987, the first antiretroviral drug zidovudine (AZT) was approved for the
treatment of AIDS and HIV infection [4]. Until now, more than 25 antiretroviral
drugs have been licensed. Five different HIV drug classes can be distinguished,
each one targeting different steps in the replication cycle (see Figure 1.1): viral
entry inhibitors (EIs) including fusion inhibitors (FIs) and coreceptor antagonists,
reverse transcriptase inhibitors (RTIs) such as nucleoside analogue (NRTIs) and
non-nucleoside analogue inhibitors (NNRTIs), integrase inhibitors (INIs) and
protease inhibitors (PIs). An overview of all the currently licensed drugs can be
found in a review article by De Clercq [5].
Today, HIV-positive patients are treated with highly active antiretroviral therapy
(HAART) regimens, which contain a combination of three or four drugs that target
at least two different viral proteins. While HAART can successfully suppress the
viral loads for multiple years in HIV-positive patients, the virus is never entirely
eradicated and remains in the human body in latent reservoir cells [6]. The disease
can thus be treated but it can never be entirely cured with the current HAART
regimens. There are, however, a few notable exceptions. Recently, a patient who
received haematopoietic stem cell transplantations to treat leukaemia was found
to no longer harbour detectable HIV viraemia, even after quitting antiretroviral
therapy [7, 8]. A similar result was found in two other HIV-positive patients
who were given bone marrow transplants to treat cancer [9, 10]. Thus, except
for the special case of replacing stem cells in the bone marrow, the virus is never
completely eliminated from the body.
While those latest experiments suggest that HIV infection might be curable one day,
stem cell transplantation is unfortunately not a realistic treatment option due to
the high risks and expensive procedures involved. Hence, there is still a profound
need to develop novel antiretroviral drugs effective against highly resistant virus
strains to complement or extend current HAART regimens. Moreover, while
the number of AIDS-related deaths has decreased remarkably from the success
of antiretroviral therapies, the number of people living with HIV-1 continues
to increase [11]. Current antiretroviral drugs also have a significant number
of shortcomings, such as toxicity issues, high manufacturing or licensing costs
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and emergence of side effects. As such, a thorough biological and structural
understanding of HIV is required to develop novel antiretroviral drugs or possible
vaccines. This effort depends on collaboration between researchers in academia,
governmental organisations and the pharmaceutical industry. In this chapter, we
aim to provide an overview of the structure and genome of HIV, the HIV infection
cycle and a summary of the targets in this thesis, gp41 FP and Rev.
Figure 1.1: Replication cycle of HIV. After attachment of a HIV virion (1) and subsequent fusion of
viral and cellular membranes (2), the viral genetic material enters the host cell. The HIV genome,
consisting of two single-stranded RNA copies, is converted into double-stranded DNA by reverse
transcriptase (4). Next, the viral DNA is imported into the nucleus (5) and integrated into the host
genome by integrase (6). Multiple viral copies are transcribed (7) and are after export to the cytoplasm
(8) translated into new viral proteins (9). A novel HIV particle is formed (10) and buds out of the host
cell (11). This new HIV virion becomes infective after maturation of viral proteins by the protease
enzyme (12). The boxes indicate the current developed antiretroviral inhibitors licensed on the clinical
market. In this PhD thesis, we target the fusion step (2) and the export of newly transcribed RNA
strands from the nucleus to the cytoplasm by the Rev protein (8). Figure adapted from Voet et al. [12].
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1.2 Structure and genome of HIV
HIV is a retrovirus, that is, an enveloped virus with genetic material stored in a
RNA genome. HIV contains two identical single-stranded positive-sense RNA
copies of 9.7 kb. These RNA strands are converted (reverse-transcribed) into DNA
by the enzyme reverse transcriptase during the replication cycle. The generated
DNA copy can subsequently be integrated in the target cell genome by another
viral enzyme called integrase and host co-factor proteins. The DNA chromosome
integration depends on long terminal repeats (LTRs) at the ends of the RNA
genome, which are also responsible for gene expression after integration.
The HIV genome contains a total of nine genes. Three genes are shared with other
retroviruses and are essential for the viral lifecycle: gag (group specific antigen), pol
(polymerase) and env (envelope). These genes are translated into matrix/capsid
proteins (necessary for stabilisation of the virion), enzymatic proteins (necessary
for replication) and envelope proteins (necessary for viral attachment and fusion
to host cells). In contrast with other retroviruses, a lentivirus such as HIV contains
additional regulatory genes. rev (regulator of viral proteins) and tat (transactivator)
code for regulatory proteins, while nef, vif, vpu (viral protein U) and vpr (viral
protein R) are translated into accessory proteins. The organisation of the viral
genome can be found in Figure 1.2.
The HIV virion is approximately 100 to 120 nm in diameter, which is relatively
large for a virus. The outer shell, the viral envelope, comprises a mixture of
host cell membrane and viral membrane proteins embedded in a phospholipid
bilayer. Inside the envelope, matrix proteins are found that stabilise the virion
by attachment to the inner lipid membrane. Next, a cone-shaped nuclear shell
made of capsid proteins is found. Finally, the two RNA strands and the replication
enzymes such as reverse transcriptase, integrase and protease are contained inside
the core.
1.3 HIV replication cycle
The infection cycle of HIV-1 commences when the viral envelope glycoproteins
attach to human host cells (see Figure 1.1) [14, 15]. The env gene codes for the gp160
protein, which is cleaved by the human protease furin into two non-covalently
linked trimeric proteins, gp120 and gp41. These two proteins form a trimer-of-
heterodimers that attaches to the target cell membrane in multiple steps. First,
gp120 interacts with a CD4 receptor on a host cell. This event triggers a con-
formational change in gp120, allowing binding with a chemokine coreceptor,
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Figure 1.2: Illustration of the HIV-genome and virion. Figure from Frankel and Young [13]. See the
text for details of the abbreviations.
CCR5 (for R5-tropic strains) or CXCR4 (for X4-tropic strains), thereby reducing
the distance between gp120 and the host cell surface. Now that both surfaces lie
in close proximity, gp41 undergoes a conformational change as well and inserts its
N-terminal fragment, called the fusion peptide (FP), into the host cell membrane.
The N- and C-helices of gp41 form an exceptionally stable six-helix bundle after
the insertion event. This oligomerisation is energetically beneficial and multiple
gp41 molecules cooperate to allow fusion of both viral and cell membrane. Finally,
HIV genetic material and viral enzymes are released into the host cell.
After the uncoating of the HIV particle, reverse transcriptase uses the single-
stranded RNA genome to produce single-stranded DNA, which is subsequently
converted into a double-stranded DNA copy of the viral genome. Next, many viral
and host proteins join forces to form a so-called pre-integration complex (PIC),
which is transported into the host cell nucleus afterwards. The reverse transcrip-
tase is tremendously error-prone, lacking a mechanism to correct mistakes while
reproducing the genome. Hence, the enzyme has a high chance of incorporating
errors in the DNA. The diversity of HIV populations in a single patient originates
from the combination of generating genetic mistakes and the high viral production
rate. In addition, the high mutation rate also results in a rapid resistance onset
against antiretroviral treatment.
Upon entering the host cell nucleus, the integrase enzyme integrates the viral
DNA into the human genome. After this irreversible process, the integrated
viral genetic material, designated as provirus, can persist in the host genome for
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many days, even years, acting as a latent viral reservoir. The viral genome can be
activated at a later time to produce new virus particles. This process is initiated
by transcription of the genome into RNA transcripts and successive transport of
these strands to the cytoplasm, where the genes are translated into proteins. In
the early phase, only small regulatory proteins are expressed, such as Tat, Rev
and Nef. Tat stimulates the provirus transcription process by RNA polymerase
II. In the late phase, multiple Rev molecules have been accumulated and will
collaborate to export the late mRNA transcripts to the cytoplasm by binding to the
Rev responsive element (RRE) on unspliced and partially spliced mRNA strands.
These unspliced and partially spliced mRNAs encode for the viral structural
and enzymatic proteins, which assemble at the plasma membrane to form new
particles. Budding of these particles ultimately results in expulsion of new HIV
virions. During the maturation step, protease enzymes process multiple viral
proteins, converting these into infective HIV virions. Those new virus particles
can subsequently infect other host cells and spread the HIV infection over the
entire human body.
1.4 HIV gp41
During the fusion step, the gp41 protein is responsible for connecting the host and
viral membrane. The protein consists of three distinct domains: an internal domain
called the endodomain, a transmembrane domain and an external domain called
the ectodomain [16, 17] (see Figure 1.3A). The ectodomain can also be divided in
different structural regions, the N-terminal fusion peptide (FP), the fusion peptide
proximal region (FPPR), two heptad repeats (HR) called the N-terminal HR (N-HR)
and C-terminal HR (C-HR) and a membrane proximal external region (MPER).
The gp41 protein undergoes major conformational changes during the fusion
process initiated by receptor and coreceptor binding to gp120 [14, 15, 19–21]. A
scheme of the fusion process is shown in figure 1.3C. After insertion of the FP in the
cellular membrane, a pre-fusogenic state is formed where the N- and C-terminal
heptad repeats adopt an extended trimeric coiled coil connecting both viral and
cellular membrane (figure 1.3B). This pre-hairpin intermediate is subsequently
converted into a stable antiparallel six-helix bundle arrangement by folding of the
three C-terminal HRs onto the grooves of the trimeric N-terminal HR bundle. As
a result, the fusion peptide and transmembrane domain are now oriented in the
same direction, thereby bringing viral and cellular membranes in close proximity.
Finally, a fusogenic state is formed where both membranes are fused resulting in
a postfusion conformation, which is thought to be stabilised by the membrane
anchoring regions FPPR and MPER [22, 23].
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Figure 1.3: Overview of the gp41 structure. (A) Sequence of gp41. The protein is divided into an
ecto- and endodomain. The ectodomain comprises a N-terminal fusion peptide (FP), a fusion peptide
proximal region (FPPR), a N-terminal and C-terminal heptad repeat (N-HR and C-HR, respectively)
and a membrane proximal external region (MPER) close to the viral transmembrane domain (TM).
(B) Schematic representation of the gp41 structure in the pre-hairpin intermediate step. During this
step, the structural trimeric bundles (N-HR and C-HR) adopt an extended conformation, which allows
insertion of the N-terminal FP in the host cell membrane. Membrane fusion can be inhibited by
preventing the FP insertion event (by VIRIP and its derivatives) or by competitive binding to N-HR
(by T20), which prevent collapse of the trimeric coil in a six-helix bundle structure. (C) Illustration
of the HIV membrane fusion. First, binding of gp120 to the CD4 receptor triggers a conformational
change, revealing the coreceptor binding site. After binding of the coreceptor, the HIV virion lies close
to the host cell membrane. Next, gp41 shoots its N-terminal FP into the target cell membrane with a
hairpin-like mechanism (gp120 and (co-)receptors are omitted here for clarity). Formation of a gp41
six-helix bundle subsequently provides energy to fuse viral and cellular membranes. Figure adapted
from Forssmann et al. [18]
Up to now, the entire structure of gp41 remains unsolved. However, subdomains
have been crystallised, including HR peptide mixtures, fused constructs and in-
hibitor bound forms. Molecular dynamics (MD) simulations have been employed
by different groups to study the conformational changes in the gp41 protein and
to probe the interactions of potential inhibitors [24–28].1
1We have contributed to this field by exploring the conformational ensemble of gp41 FP in solution,
as discussed in chapter 5.
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1.4.1 Entry inhibitors
Targeting the entry process of HIV-1 is a promising approach, which has already
led to the development of two clinically approved antiretroviral drugs, that is,
T20 (also known as enfuvirtide, marketed as Fuzeon by Roche/Trimeris) [29, 30]
and maraviroc (marketed as Selzentry/Celsentri by Pfizer) [31].2 Maraviroc was
developed by medicinal chemistry optimisation of a hit compound identified
from high-troughput screening experiments. The compound inhibits viral entry
indirectly by blocking attachment of the viral particle to the cellular coreceptor
CCR5. In contrast, T20 is a peptidic inhibitor that mimics the C-terminal HR
residues 127 to 162 by binding to the N-terminal HR of gp41, thereby inhibiting the
six-helix bundle formation essential for fusion. Retroviral inhibitory peptides were
identified serendipitously in a vaccine development experiment at Duke university.
T20 is an optimised form, developed in collaboration with the pharmaceutical
industry. Unfortunately, a number of reports have shown that the efficacy of T20
diminishes in long-term clinical studies due to the emergence of resistant viral
strains [32–37]. Resistance mutations have been shown to manifest in a 10 amino
acid motif in the N-terminal HR, while specific mutations in C-terminal HR are
able to restore the fusion process [38].
To explore the origins of resistance against T20, McGillick et al. [24] used an
extensive MD simulation and binding free energy calculation study of a docked
gp41-T20 complex embedded in an explicit lipid membrane. Using an improved
gp41 model based on a SIV gp41 ectodomain structure [39, 40], a good quanti-
tative agreement with experimental resistance data was found. The structural
information from the MD simulation study has been used to design novel indole
compounds [41] and in later resistance studies as well [42]. Furthermore, they also
found a significant number of favourable interactions between T20 and the lipid
bilayer that stabilise the membrane-protein complex. This notion suggests that
peptides interacting favourably with both gp41 and the membrane can have an in-
creased inhibitor potency. Interestingly, a peptide derived from the C-terminal HR
containing an attached cholesterol group displayed increased antiviral efficiency,
confirming that such an approach is indeed feasible [43].
A study by Singh et al. [44] demonstrated that extending the N- and C-terminal
ends of T20 to a total of 42 residues increases helicity of the peptide in solution.
In a series of MD simulation articles, Martins do Canto et al. [45–49] studied
the interactions of T20 and a second-generation fusion inhibitor T1249 alone in
solution and in the presence of modelled membranes. In the studied time scale,
they found that the peptides adopt a mainly disordered structure in solution [45],
2Structures of T20 and maraviroc can be found in reference [5].
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while a mainly pi-helical structure was found in the presence of membranes [46–
49]. In addition, fusion inhibitors seem to bind less deeply to the liquid-ordered
membrane containing cholesterol and T1249 interacts stronger with the membrane
compared to T20, as shown previously by fluorescence experiments [50].
In addition to T20, a notable number of other C-terminal HR derived peptides
have been investigated. For example, C34 and derived mutants (corresponding
to the N-terminal HR residues of 117 to 150) have been studied in complex with
an N-terminal HR trimer using a combined MD and binding free energy analysis
approach [28]. A good correlation with experimental results was found despite
the observed experimental small binding affinity range. In addition, residue
decomposition of the binding free energy revealed the hot spot residues con-
tributing to the interaction. Using this approach, the importance of a conserved
hydrophobic pocket of gp41 as an attractive drug target [17] was validated by
the presence of strong van der Waals energy values between gp41 residues and
the C34 peptide. Another MD study was performed by Hartono et al. [51] on a
small peptide derived from human lysozyme. This peptide called HL9 contains
only nine residues and could potentially bind through two Trp residues into
the hydrophobic pocket of the gp41 ectodomain. Multiple docking poses were
explored and calculated binding free energy values were in fair agreement with
experimental measurements.
1.4.2 The anchoring inhibitor VIRIP
Most entry inhibitor peptides and small molecules target the hydrophobic binding
pocket of gp41. Unfortunately, virus resistance against T20 and the latest gen-
eration of fusion inhibitors is caused by amino acid substitutions in this region,
thus leading to viral escape from entry inhibitor therapy. While T20 resistance
is mainly caused by single amino acid substitutions in the binding pocket [33],
resistance against newer entry inhibitors such as T1249 and T2635 requires multi-
ple mutations within gp41 [35]. Hence, it is paramount and appealing to target
parts of gp41 that are highly conserved. The fusion peptide (FP) is one of the most
conserved parts of gp41 and recently a 23 amino acid peptide has been found to
show inhibitory activity against this part [18, 52]. This peptide called VIRIP (VIRus
INhibitory Peptide) is naturally occurring in human blood and was identified
by screening of a comprehensive blood-derived peptide/protein library.3 VIRIP
inhibits HIV-1 entry by binding to the gp41 FP, thus preventing its insertion into
the target cell membrane and successive membrane fusion. These results were
3Unfortunately, the wild type sequence of VIRIP is not potent enough to suppress viral levels in
blood.
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unexpected, since gp41 FP is only temporarily exposed during the fusion process
[14]. Based on the wild type sequence of VIRIP (LEAIPMSIPPEVKFNKPFVF),
a number of derivatives have been developed such as VIR-165 (LEAIPCSIPPC-
FAFNKPFVF) and a dimeric form, VIR-576 (LEAIPCSIPPEFLFGKPFVFx2). VIRIP
derivatives are promising for clinical development because of their low toxicity
and immunogenicity, broad activity against HIV-1, and lack of cross-resistance
with other drugs, including those with resistance against T20. An extensive
structure-activity relationship study allowed the design of VIRIP derivatives with
increased affinity and antiviral potency [52]. Recently, one of these derivatives
(VIR-576) was evaluated in a clinical phase I/II trial in treatment of naive HIV-1
infected individuals [18]. The results showed that VIR-576 monotherapy was well
tolerated and reduced the plasma viral loads by more than one order of magnitude
[18]. Long-term experiments illustrated that more than 450 days were required to
generate resistance against optimised VIRIP derivates [53, 54]. Moreover, the resis-
tant mutations significantly decreased the replicative capacity of the HIV strains
[54]. To improve the affinity against gp41 FP even further, a detailed understand-
ing of the structure of the FP fragment is needed. Unfortunately, experimental
structures of the FP have been limited to membrane [55–58] or inhibitor-bound
forms [52], so no free form of the gp41 FP is known. Interestingly, other inhibitors
have also been found to interact with FP, such as synthetic hexapeptides [59] and
peptides of the E2 envelope protein of Hepatitis G virus (HGV) [60–66].
1.4.3 The gp41 FP structure
As mentioned previously, the gp41 FP is not only an interesting target for antiretro-
viral therapy, it also plays a crucial role during the fusion process by constituting
the first viral contact with the cellular membrane. Not surprisingly, a lot of research
has been dedicated to elucidate the secondary structure of the FP in the membrane.
The FP sequence (AVGIGALFLGFLGAASTMGARS) is highly hydrophobic [67]
and mutational analysis revealed critical glycine residues in the FP sequence to
fuse viral and cellular membranes [68, 69] and unfavourable polar substitutions
[70–72]. Nevertheless, until today the secondary structure of the FP remains under
discussion, due to conflicting experimental reports of α-helical [55–58, 73], β-sheet
[74–82] and disordered conformations [83, 84], or a combination of these [85–98].
An overview of the experimentally determined structures is found in Figure 1.4
and Table 1.1. Analysis is blurred due to use of different buffer conditions, peptide
concentrations, or FP constructs with different lengths and solubility. In addition,
possible oligomerisation and subsequent aggregation issues, absence of single-
molecule studies and influence of lipid composition and lipid constructs (e.g.
micelles versus lipid bilayers) prevent a clear interpretation. Consequently, it is
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Figure 1.4: Schematic representation of HIV-1 fusion and overview of the experimentally deter-
mined structures of gp41 FP in membrane-like environments or solution. After recognition of
the host cell membrane CD4 receptor and co-receptors by the gp120 protein (omitted for clarity),
the trimeric gp41 protein (grey) undergoes a conformational rearrangement, thereby exposing and
inserting the gp41 FP (red) in the host cell membrane. The inlet on the right displays some of the
proposed structures of gp41 FP (A-F). (A) α-helical FP23 with FTIR restraints in hexafluoroisopropanol
(PDB-code: 1ERF) [55]. (B) α-helical FP23 with FTR restraints in SDS micelles (PDB-code: 1P5A)
[56]. (C) Solution NMR α-helical FP30 (PDB-code: 2ARI) [57]. (D) Solution NMR α-helical FP23
(PDB-code: 2PJV) [58]. (E) β-sheet model FP23 (model based on PDB-code: 3D58) [24]. (F) Solution
NMR unstructured FP23 in complex with VIR-165 (pink), a disulphide stabilised derivative of the
fusion peptide inhibitor VIRIP (PDB-code: 2JNR) [52]. FP secondary structures are coloured according
to the DSSP convention with blue: α-helix, red: β-sheet, white: coil, black: β-bridge, green: bend,
yellow: turn, purple: pi-helix and grey: 3-10-helix. Figure taken from Venken et al. [110].
questioned if the peptide surroundings are physiologically relevant to understand
membrane fusion in all the previously mentioned studies. Even experiments
under identical sample conditions showed the presence of both α-helical and
β-sheet structures at the same time [91, 97, 99]. Thus, it has been put forward
that not just the peptide length or structure determines fusogenicity, but also
other factors such as the membrane dipole potential [92, 100], insertion depth
[81, 94, 97], insertion angle [85, 88, 89, 101–106], membrane curvature [90, 107]
and corresponding membrane kinetics [91, 108]. It has also been suggested that
the cholesterol content in lipid bilayers could play an important role in mediating
membrane curvature [91–95, 97, 109].
Because many experimental techniques investigate only a time-averaged ensem-
ble of conformations, atomistic MD simulations are an alternative approach to
probe the interactions of gp41 FP with model membrane systems. A monomeric
membrane-bound structure of gp41 FP can be representative for the initial moment
of membrane insertion. One of the first studies was performed by Kamath and
Wong [25, 111] who studied an α-helical conformation of different mutants and
the wild type form of gp41 FP (first 16 residues) in an equilibrated lipid bilayer for
1.4 to 2 ns. Contrary to the mutant forms that adopt conformations parallel to the
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Table 1.1: Overview of gp41 FP structural data
PDB ID Sequence Method # Models Year Authors
1ERF AVGIGALFLGFLGAAGSTMGARS-NH2 FTIR 17 2000 Gordon et al. [55]
1P5A AVGIGALFLGFLGAAGSTMGARS-NH2 FTIR 19 2003 Gordon et al. [56]
2ARI AVGIGALFLGFLGAAGSTMGAASMTLTVQA NMR 30 2005 Jaroniec et al. [57]
2JPV AVGIGALFLGFLGAAGSTVGAASG NMR 38 2007 Li et al. [58]
2JNRa AVGIGALFLGFLGAAGSTMGARS NMR 1 2007 Münch et al. [52]
(a) This FP structure was obtained in complex with VIR-165, a VIRIP derivative with sequence LEAIPCSIPPC-
FAFNKPFVF.
lipid bilayer, the wild type adopts an obliquely inserted angle in the membrane.
In addition, the results indicate that fusogenicity is not explained by variations
in the FP secondary structure, but are rather caused by dissimilar conformational
flexibility patterns between wild type FP and inactive mutants. While these
conclusions are in line with experimental measurements, a V2E mutant inserts
deeper into membranes than wild type FP in experiments [112]. Barz et al. [90]
conducted an extensive MD study by simulating both α-helical and β-sheet FP
dimers. To reduce bias of the starting conformation of the modelled system, the
initial α-helical conformations were modelled both parallel and perpendicular
to the bilayer normal. In addition, α-helix to β-sheet transitions were performed
by resorting to steered MD (SMD) simulations [90]. While the FP adopts a broad
variety of conformations in solution, the diffusion time is much slower in mem-
brane environments, hence non-equilibrium simulations were required to speed
up the secondary structure transition process. This requirement was demonstrated
recently by 100 ns long simulations of FPs with different length (both 17 and
23 residues) and charge of termini, which either remained α-helical or partially
unfolded during the simulation trajectory [113]. In summary, Barz et al. [90]
compared their simulation data to Fourier transform infrared spectroscopy (FTIR)
measurements and suggested that the FP structure depends on the area per lipid
of the membrane surface. In contrast, Grasnick et al. [84] postulated that not an
ordered conformation but rather an irregular FP structure determines fusogenicity,
based on MD simulations using nuclear magnetic resonance (NMR) orientational
constraints [84]. Although a large number of possible structures can fulfil the
experimentally measured constraints, the found peptide conformations were not
compatible with any regular secondary structure. Thus, while the experimental
methods resulted in many different suggestions for the role of the gp41 FP during
membrane fusion, the modelling studies have spurred contradicting results as well.
As such, despite a growing amount of evidence of balanced interplay between
peptide and membrane interactions, the crucial role of the gp41 FP remains to be
investigated more in detail in the future.
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1.5 The HIV Rev protein
Transcription of new HIV RNA strands begins in the nucleus after integration of
the viral DNA in the host cell genome. During the early stage, splicing of the viral
RNA generates fully spliced RNA transcripts. These RNA strands are actively
transported to the cytoplasm by the general cellular RNA export pathway and
encode for the viral regulatory proteins. In the late phase of the viral life cycle,
larger unspliced (intron-containing) viral RNA transcripts are expressed. The
transport of these larger RNA transcripts depends on more sophisticated transport
mechanisms. This transport process requires a delicate interplay between viral
and cellular proteins and is mediated by the Rev protein (Regulator of Expression
of Virion proteins) [114, 115]. This viral protein is indispensable for the onset
of the late replication cycle of HIV. In fact, Rev is one of those small proteins
that are translated first, next to other regulatory proteins such as Tat and Nef.
Longer intron-containing RNA strands code for larger essential proteins such as
Gag, Pol and Env. Nuclear export of those strands is initiated once a substantial
concentration of Rev protein is present in the nucleus. Viral replication is abrogated
without the synthesis of late viral proteins and inhibition of the biological function
Rev would therefore be an attractive novel antiretroviral strategy.
Although Rev mainly resides in the nucleus, it has been shown to continuously
shuttle between the nucleus and the cytoplasm by exploiting the cellular CRM1-
mediated export machinery [116]. In that way, it transports the viral RNA to the
cytoplasm, allows translation of new viral proteins and is subsequently recycled
back into the nucleus. As such, the Rev protein is not only important for the
HIV infection progress, but it also constitutes a paradigm for the study of nuclear
export mechanisms in cells.
1.5.1 The Rev domain organisation
Rev is a protein of approximately 19 kD located predominantly in the host cell
nucleus. It consists of 116 amino acids decomposed in distinct domains, which are
visualised in Figure 1.5. The N-terminal region contains a nuclear entry inhibitory
signal (NIS) of 15 amino acids important for nucleo-cytoplasmatic trafficking,
and is thought to adopt an amphipathic helical structure [117]. In addition, an
arginine-rich motif (ARM) of residues 34-50 serves a dual role. First, it functions as
a nuclear localisation signal (NLS). This motif binds to the host protein importin-β
[118] and returns the Rev protein to the nucleus. Second, the region acts as an RNA
binding domain by attachment to the Rev response element (RRE) on RNA, a stem
loop of 351 nucleotides located in the env gene of unspliced RNA strands [119].
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The interaction between Rev and the RRE is specific as only a few mutations in Rev
[120] or in the RRE [121] can be sufficient to reduce the binding. The interaction is
thought to be exclusively entropically driven [122] owing to shape recognition of
the flexible ARM arginine side chains with the RRE with only a limited amount of
base-specific hydrogen bonds [123, 124]. Furthermore, it has been suggested that
the ARM region can be disordered but may fold upon binding of the RRE [125].
A third essential motif is the nuclear export signal (NES), which resides in the in-
trinsically unstructured C-terminal domain [126]. That leucine-rich motif interacts
with cellular proteins such as CRM1 (also known as exportin1) [127]. However,
there is a marked difference in key hydrophobic residue spacing between cellular
classic NES and viral NES. To effectively bind CRM1, the retroviral NES adopts an
extended conformation, while the NES of cellular proteins such as protein kinase
inhibitor (PKI) folds as an α-helix [128].
In sum, the NLS and NES motifs are essential for Rev-shuttling between the
nucleus and the cytoplasm; while NLS is dedicated to nuclear import guided by
importin-β, in contrast NES is required for export to the cytoplasm by CRM1.
By using this mechanism, HIV has found a way to bypass the nuclear retention
of its intron-containing RNA by linking these RNA species to a cellular protein
transport mechanism (CRM1, importin-β and several other host cell co-factors).
In addition to CRM1, many other cellular proteins like the DEAD box helicases
have been identified as cofactor for Rev function. It has been suggested that these
helicases, such as DDX1 [129–131], DDX3 [132] and DDX5 [133], can synergistically
modulate the function of Rev in the host cell [134]. Hence, the Rev protein requires
a considerable amount of conformational flexibility to attain a combination of
cooperative protein-RNA and protein-protein interactions.
In addition to the previously mentioned interactions, another degree of complexity
arises from the multimerisation of the Rev protein. It has been found that multiple
Rev monomers can bind to a single RRE forming a functional multimeric complex
[135–137]. However, Rev is also able to multimerise in the absence of RNA [138].
The Rev multimerisation domains can be found in the N-terminal regions overlap-
ping with the NIS site (M1) and in the C-terminal regions upstream from the NLS
domain (M2).
1.5.2 The Rev structure
Previously, little was known about the three-dimensional structure of the HIV Rev
multimer. A wide array of biophysical studies have been pursued to decipher
the nature of the Rev protein function, for example: mutational analysis [140–
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Figure 1.5: Overview of the Rev domain structure. Crystallised parts are highlighted with black
boxes. Unresolved regions are visualised with grey stripes. The Rev structure is divided in two
multimerisation domains (M1 + M2). The first multimerisation domain overlaps with a nuclear entry
inhibitory signal (NIS). Similarly, the arginine rich motif (ARM) functions as a nuclear localisation signal
(NLS). Finally, a nuclear export signal (NES) can be found in the intrinsically disordered C-terminal
region. The Rev helix-loop-helix motif is stabilised by hydrophobic residues in the multimerisation
domains (residues I19, L22, I52 and I60) and by a hydrogen bond network in the ARM (residues N26,
R48 and Q49). Image generated from PDB structure 2X7L [139].
Figure 1.6: Rev multimerisation. A Rev multimer can contain multiple interfaces, a dimerisation
interface α comprising residues Leu18, Phe21 and Ile55, and a higher-order multimerisation interface β
composed of residues Leu12, Val16 and Leu60. These interfaces are repeated in a symmetrical pattern
in a hexamer as α, β, α, β, α. Image adapted from Daugherty et al. [140].
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142], circular dichroism (CD) spectroscopy [143, 144], single-molecule fluorescence
spectroscopy [145], Förster resonance energy transfer (FRET) measurements [146],
atomic force microscopy (AFM) [147, 148], and solid state NMR [149]. Those
experiments suggest that the Rev monomer consists of a helix-turn-helix motif.
It was hypothesised that multiple Rev molecules cooperate to form a V-shaped
protein that clamps the viral RNA at the RRE motif. The Rev monomers self-
associate one by one after binding to the RRE to form a symmetrical interface
pattern: α, β, α, β, ... as illustrated in figure 1.6. Thus, two different symmetrical
interfaces are present in the Rev protein [139–141]. We applied the following
naming convention throughout this thesis: a dimerisation interface α, which is
the binding interface occurring first upon formation of a multimeric Rev protein-
protein complex, and a higher order oligomerisation interface β.
Recently, a long-awaited structure of the Rev protein was "Rev-ealed" (pun in-
tended by Hammarskjold et al. [150]) by two independent groups [139, 140]. One
crystal structure consists of the wild type dimeric structure of Rev in complex with
a monoclonal Fab fragment (PDB entry: 2X7L), comprising the Rev β interface
but lacking the α interface [139]. A second crystal structure consists of a mutant
Rev complex (L12S and L60R) containing both α and β interfaces (PDB entry:
3LPH) [140]. Although the Rev structure is only partially resolved (the flexible
C-terminal part is intrinsically unfolded), the helix-turn-helix motif containing the
sites of multimerisation is present in both solved crystal structures and provides
insight into the molecular interactions thriving multimer formation. Backbone
superimposition of the monomer conformations from both crystals results in
a significant structural similarity (root mean square deviation (RMSD) < 1 Å).
Furthermore, an angle of 120◦ was reported between the β interface monomers of
3LPH, while a broader angle of 140◦ is present between the 2X7L monomers. An
overview of the released crystal structures can be found in Table 1.2.
Table 1.2: Overview of crystal structure data of Rev
PDB ID Sequence Residues Structure Resolution R-value R-free Year Authors
2X7La wild type 9 to 65 dimer (β) 3.17 Å 0.235 0.250 2010 Dimattia et al. [139]
3LPHb L12S & R60L 8 to 70 tetramer (α-β-α) 2.5 Å 0.228 0.261 2010 Daugherty et al. [140]
(a) The 2X7L structure also contains two specifically engineered monoclonal Fab fragments that stabilise each
monomer of the dimeric complex. (b) Not all residues are resolved in each monomer.
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1.5.3 Multimerisation
The multimerisation of Rev molecules occurs at flanking sequences of the arginine
rich motif (ARM), which functions both as a nuclear localisation signal (NLS) and
as a RRE-binding site. The multimerisation process is essential for the function
of Rev [137, 151]. In fact, a single Rev molecule bound to the RRE of spliced
mRNA is not able to promote nuclear export [151, 152]. Mutant Rev proteins are
still able to bind to the RRE and form dimers, but the mutations disrupt higher
order oligomerisation and render Rev export deficient [141, 143]. A number of
multimerisation hot spot residues were identified and it was suggested that L18
and I55 are essential for the α interface while L12, V16 and L60 are important for
the β interface.
Currently known inhibitors target the Rev/RRE [153–155] and Rev/CRM1 inter-
actions [156–158]. Unfortunately, the first easily induce resistance due to com-
pensatory nucleotide changes in the RRE [159], while the latter approach can
also disturb nucleocytoplasmatic trafficking of the host. The disruption of the
multimerisation process, which only targets viral proteins, could therefore be an
alternative approach to inhibit propagation of HIV-1 inside the host cells. Recently,
a llama single-domain antibody designated Nb190 has been discovered that blocks
the multimerisation site of Rev and thereby disrupts multimerisation of Rev in vitro
and in vivo [160–162]. This nanobody interacts with residues Lys20 and Tyr23 in the
multimerisation domain of the Rev protein. Therefore, the multimerisation process
is considered an interesting novel target for the inhibition of HIV replication.
References
[1] Barré-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet,
C., Axler-Blin, C., Vézinet-Brun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983).
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency
syndrome (AIDS). Science. 220(4599):868–871.
[2] Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., Kaplan, M., Haynes, B. F., Palker,
T. J., Redfield, R., Oleske, J., and Safai, B. (1984). Frequent detection and isolation of cytopathic
retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 224(4648):500–503.
[3] Silvestri, G. (2013). Embracing the complexity of HIV immunology. Immunol. Rev. 254(1):5–9.
[4] Mitsuya, H., Weinhold, K. J., Furman, P. A., St Clair, M. H., Lehrman, S. N., Gallo, R. C., Bolognesi,
D., Barry, D. W., and Broder, S. (1985). 3’-Azido-3’-deoxythymidine (BW A509U): an antiviral
agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type
III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 82(20):7096–7100.
[5] De Clercq, E. (2009). Anti-HIV drugs: 25 compounds approved within 25 years after the
discovery of HIV. Int. J. Antimicrob. Ag. 33(4):307–320.
22 HIV: THE ROLE OF GP41 FP AND REV
[6] Katlama, C., Deeks, S. G., Autran, B., Martinez-Picado, J., van Lunzen, J., Rouzioux, C., Miller,
M., Vella, S., Schmitz, J. E., and Ahlers, J. (2013). Barriers to a cure for HIV: new ways to target
and eradicate HIV-1 reservoirs. Lancet. 381(9883):2109–2117.
[7] Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müssig, A., Allers, K., Schneider, T., Hofmann,
J., Kücherer, C., Blau, O., Blau, I. W., Hofmann, W. K., and Thiel, E. (2009). Long-term control of
HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360(7):692–698.
[8] Allers, K., Hutter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E., and Schneider, T.
(2011). Evidence for the cure of HIV infection by CCR5 32/ 32 stem cell transplantation. Blood.
117(10):2791–2799.
[9] Henrich, T. J. and Kuritzkes, D. R. (2012). HIV-1 entry inhibitors: recent development and clinical
use. Curr. Opin. Virol. 1–7.
[10] Kent, S. J., Reece, J. C., Petravic, J., Martyushev, A., Kramski, M., De Rose, R., Cooper, D. A.,
Kelleher, A. D., Emery, S., Cameron, P. U., Lewin, S. R., and Davenport, M. P. (2013). The search
for an HIV cure: tackling latent infection. Lancet Infect. Dis. 13(7):614–621.
[11] World Health Organization and UNAIDS (2011). World Health Organization: Global HIV/AIDS
response. Geneva: World Health Organization.
[12] Voet, A. (2010). Development of small molecule protein-protein interaction inhibitors targeting
the HIV-1 integrase-LEDGF/p75 complex. PhD thesis.
[13] Frankel, A. D. and Young, J. A. (1998). HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem.
67(1):1–25.
[14] Doms, R. W. and Moore, J. P. (2000). HIV-1 membrane fusion: targets of opportunity. J. Cell Biol.
151(2):F9–14.
[15] Eckert, D. M. and Kim, P. S. (2001). Mechanisms of viral membrane fusion and its inhibition.
Annu. Rev. Biochem. 70:777–810.
[16] Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997). Core structure of gp41 from the HIV
envelope glycoprotein. Cell. 89(2):263–273.
[17] Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998). Evidence that a prominent cavity in
the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A.
95(26):15613–15617.
[18] Forssmann, W. G., The, Y. H., Stoll, M., Adermann, K., Albrecht, U., Tillmann, H. C., Barlos,
K., Busmann, A., Canales-Mayordomo, A., Gimenez-Gallego, G., Hirsch, J., Jimenez-Barbero,
J., Meyer-Olson, D., Munch, J., Perez-Castells, J., Standker, L., Kirchhoff, F., and Schmidt, R. E.
(2010). Short-Term Monotherapy in HIV-Infected Patients with a Virus Entry Inhibitor Against
the gp41 Fusion Peptide. Sci. Transl. Med. 2(63):63re3.
[19] Epand, R. M. (2003). Fusion peptides and the mechanism of viral fusion. Biochim. Biophys. Acta.
1614(1):116–121.
[20] Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S. S., Puri, A., Durell,
S., and Blumenthal, R. (2003). The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta.
1614(1):36–50.
[21] Harrison, S. C. (2008). Viral membrane fusion. Nat. Struct. Mol. Biol. 15(7):690–698.
[22] Buzón, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M. M., and Weissenhorn, W. (2010).
Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External
Regions. PLoS Pathog. 6(5):e1000880.
[23] Lakomek, N.-A., Kaufman, J. D., Stahl, S. J., Louis, J. M., Grishaev, A., Wingfield, P. T., and Bax,
A. (2013). Internal Dynamics of the Homotrimeric HIV-1 Viral Coat Protein gp41 on Multiple
Time Scales. Angew. Chem. Int. Ed. 52(14):3911–3915.
[24] McGillick, B. E., Balius, T. E., Mukherjee, S., and Rizzo, R. C. (2010). Origins of Resistance to the
HIVgp41 Viral Entry Inhibitor T20. Biochemistry. 49(17):3575–3592.
[25] Kamath, S. and Wong, T. C. (2002). Membrane structure of the human immunodeficiency virus
gp41 fusion domain by molecular dynamics simulation. Biophys. J. 83(1):135–143.
REFERENCES 23
[26] Kim, J. H., Hartley, T. L., Curran, A. R., and Engelman, D. M. (2009). Molecular dynamics studies
of the transmembrane domain of gp41 from HIV-1. Biochim. Biophys. Acta. 1788(9):1804–1812.
[27] Tan, J. J., Chen, W. Z., and Wang, C. X. (2006). Investigating interactions between HIV-1 gp41
and inhibitors by molecular dynamics simulation and MM–PBSA/GBSA calculations. J. Mol.
Struc. (Theochem.). 766(2-3):77–82.
[28] Strockbine, B. and Rizzo, R. C. (2007). Binding of antifusion peptides with HIVgp41 from
molecular dynamics simulations: Quantitative correlation with experiment. Proteins. 67(3):630–
642.
[29] Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L.,
Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M.,
and Saag, M. S. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide
inhibitor of gp41-mediated virus entry. Nat. Med. 4(11):1302–1307.
[30] Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., and Bolognesi, D. (2004). Case
history: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Nat. Res. Drug. Discov. 3(3):215–225.
[31] Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman,
A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., Jenkins, T. M., Medhurst, C.,
Sullivan, J. F., Ridgway, C., Abel, S., James, I. T., Youle, M., and van der Ryst, E. (2005). Efficacy
of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with
HIV-1. Nat. Med. 11(11):1170–1172.
[32] Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw,
G. M., and Kappes, J. C. (2002). Emergence of Resistant Human Immunodeficiency Virus Type
1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. Antimicrob. Agents Chemother.
46(6):1896–1905.
[33] Greenberg, M. L. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob.
Chemother. 54(2):333–340.
[34] Baldwin, C. E., Sanders, R. W., Deng, Y., Jurriaans, S., Lange, J. M., Lu, M., and Berkhout, B.
(2004). Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during
Therapy with the T20 Fusion Inhibitor. J. Virol. 78(22):12428–12437.
[35] Eggink, D., Langedijk, J. P. M., Bonvin, A. M. J. J., Deng, Y., Lu, M., Berkhout, B., and Sanders,
R. W. (2009). Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion
Inhibitors. J. Biol. Chem. 284(39):26941–26950.
[36] Miller, M. D. and Hazuda, D. J. (2004). HIV resistance to the fusion inhibitor enfuvirtide:
mechanisms and clinical implications. Drug Resist. Updates. 7(2):89–95.
[37] Berkhout, B., Eggink, D., and Sanders, R. W. (2012). Is there a future for antiviral fusion
inhibitors? Curr. Opin. Virol. 2(1):50–59.
[38] Ray, N., Blackburn, L. A., and Doms, R. W. (2009). HR-2 Mutations in Human Immunodeficiency
Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical
Resistance to Enfuvirtide. J. Virol. 83(7):2989–2995.
[39] Caffrey, M., Cai, M., Kaufman, J., Stahl, S., Wingfield, P., Covell, D., Gronenborn, A., and Clore,
G. (1998). Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. Embo
Journal. 17(16):4572–4584.
[40] Caffrey, M. (2001). Model for the structure of the HIV gp41 ectodomain: insight into the
intermolecular interactions of the gp41 loop. Biochim. Biophys. Acta. 1536(2-3):116–122.
[41] Zhou, G., Wu, D., Hermel, E., Balogh, E., and Gochin, M. (2010). Design, synthesis, and
evaluation of indole compounds as novel inhibitors targeting Gp41. Bioorg. Med. Chem. Lett.
20(5):1500–1503.
[42] Yu, X., Lu, L., Cai, L., Tong, P., Tan, S., Zou, P., Meng, F., Chen, Y. h., and Jiang, S. (2011).
Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to
Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket. J. Virol. 86(1):589–593.
24 HIV: THE ROLE OF GP41 FP AND REV
[43] Ingallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y.-J., Hrin, R., Veneziano, M., Bonelli, F., Ketas,
T. J., Moore, J. P., Miller, M. D., and Pessi, A. (2009). Addition of a cholesterol group to an HIV-1
peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A.
106(14):5801–5806.
[44] Singh, P., Sharma, P., Bisetty, K., Corcho, F. J., and Perez, J. J. (2011). Comparative structural
studies of T-20 analogues using molecular dynamics. Comp. Theor. Chem. 974(1-3):122–132.
[45] Martins Do Canto, A. M. T., Palace Carvalho, A. J., Prates Ramalho, J. P., and Loura, L. M. S. (2008).
T-20 and T-1249 HIV fusion inhibitors’ structure and conformation in solution: a molecular
dynamics study. J. Pept. Sci. 14(4):442–447.
[46] Martins do Canto, A. M. T., Carvalho, A. J. P., Ramalho, J. P. P., and Loura, L. M. S. (2010). Struc-
ture and conformation of HIV fusion inhibitor peptide T-1249 in presence of model membranes:
A molecular dynamics study. J. Mol. Struc. (Theochem.). 946(1-3):119–124.
[47] Martins do Canto, A. M. T., Carvalho, A. J. P., Ramalho, J. P. P., and Loura, L. M. S. (2011).
Molecular dynamics simulations of T-20 HIV fusion inhibitor interacting with model membranes.
Biophys. Chem. 159(2-3):275–286.
[48] Martins do Canto, A. M. T., Palace Carvalho, A. J., Prates Ramalho, J. P., and Loura, L. M. S.
(2012). Molecular Dynamics Simulation of HIV Fusion Inhibitor T-1249: Insights on Peptide-
Lipid Interaction. Comput. Math. Methods. Med. 2012:1–14.
[49] Martins do Canto, A., Carvalho, A., Ramalho, J., and Loura, L. (2013). Effect of Amphipathic HIV
Fusion Inhibitor Peptides on POPC and POPC/Cholesterol Membrane Properties: A Molecular
Simulation Study. Int. J. Mol. Sci. 14(7):14724–14743.
[50] Matos, P. M., Castanho, M. A. R. B., and Santos, N. C. (2010). HIV-1 Fusion Inhibitor Peptides
Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes. PLoS One.
5(3):e9830.
[51] Hartono, Y. D., Lee, A. N., Lee-Huang, S., and Zhang, D. (2011). Computational study of
bindings of HL9, a nonapeptide fragment of human lysozyme, to HIV-1 fusion protein gp41.
Bioorg. Med. Chem. Lett. 21(6):1607–1611.
[52] Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann,
S., Chaipan, C., Biet, T., Peters, T., Meyer, B., Wilhelm, D., Lu, H., Jing, W., Jiang, S., Forssmann,
W.-G., and Kirchhoff, F. (2007). Discovery and Optimization of a Natural HIV-1 Entry Inhibitor
Targeting the gp41 Fusion Peptide. Cell. 129(2):263–275.
[53] Gonzalez, E., Ballana, E., Clotet, B., and Esté, J. A. (2011). Development of resistance to VIR-
353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS.
25(13):1557–1583.
[54] González-Ortega, E., Ballana, E., Badia, R., Clotet, B., and Esté, J. A. (2011). Compensatory
mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antiviral Res. 92(3):479–
483.
[55] Gordon, L. M., Mobley, P. W., Pilpa, R., Sherman, M. A., and Waring, A. J. (2002). Conformational
mapping of the N-terminal peptide of HIV-1 gp41 in membrane environments using (13)C-
enhanced Fourier transform infrared spectroscopy. Biochim. Biophys. Acta. 1559(2):96–120.
[56] Gordon, L. M., Mobley, P. W., Lee, W., Eskandari, S., Kaznessis, Y. N., Sherman, M. A., and
Waring, A. J. (2004). Conformational mapping of the N-terminal peptide of HIV-1 gp41 in
lipid detergent and aqueous environments using 13C-enhanced Fourier transform infrared
spectroscopy. Protein Sci. 13(4):1012–1030.
[57] Jaroniec, C. P., Kaufman, J. D., Stahl, S. J., Viard, M., Blumenthal, R., Wingfield, P. T., and Bax, A.
(2005). Structure and Dynamics of Micelle-Associated Human Immunodeficiency Virus gp41
Fusion Domain. Biochemistry. 44(49):16167–16180.
[58] Li, Y. and Tamm, L. K. (2007). Structure and Plasticity of the Human Immunodeficiency Virus
gp41 Fusion Domain in Lipid Micelles and Bilayers. Biophys. J. 93(3):876–885.
REFERENCES 25
[59] Gomara, M. J., Lorizate, M., Huarte, N., Mingarro, I., Perez-Payá, E., and Nieva, J. L. (2006).
Hexapeptides that interfere with HIV-1 fusion peptide activity in liposomes block GP41-
mediated membrane fusion. FEBS Letters. 580(11):2561–2566.
[60] Herrera, E., Gomara, M. J., Mazzini, S., Ragg, E., and Haro, I. (2009). Synthetic Peptides of
Hepatitis G Virus (GBV-C/HGV) in the Selection of Putative Peptide Inhibitors of the HIV-1
Fusion Peptide. J. Phys. Chem. B. 113(20):7383–7391.
[61] Herrera, E., Tenckhoff, S., Gomara, M. J., Galatola, R., Bleda, M. J., Gil, C., Ercilla, G., Gatell,
J. M., Tillmann, H. L., and Haro, I. (2010). Effect of Synthetic Peptides Belonging to E2 Envelope
Protein of GB Virus C on Human Immunodeficiency Virus Type 1 Infection. J. Med. Chem.
53(16):6054–6063.
[62] Koedel, Y., Eissmann, K., Wend, H., Fleckenstein, B., and Reil, H. (2011). Peptides Derived from
a Distinct Region of GB Virus C Glycoprotein E2 Mediate Strain-Specific HIV-1 Entry Inhibition.
J. Virol. 85(14):7037–7047.
[63] Sánchez-Martín, M. J., Hristova, K., Pujol, M., Gomara, M. J., Haro, I., Asunción Alsina, M., and
Antònia Busquets, M. (2011). Analysis of HIV-1 fusion peptide inhibition by synthetic peptides
from E1 protein of GB virus C. J. Colloid Interface Sci. 360(1):124–131.
[64] Sánchez-Martín, M. J., Busquets, M. A., Girona, V., Haro, I., Alsina, M. A., and Pujol, M. (2011).
Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with
membrane models. Biochim. Biophys. Acta. 1808(9):2178–2188.
[65] Haro, I., Gómara, M. J., Galatola, R., Domènech, O., Prat, J., Girona, V., and Busquets, M. A.
(2011). Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP
HIV-1 activity. Biochim. Biophys. Acta. 1808(6):1567–1573.
[66] Fernández, L., Chan, W. C., Egido, M., Gomara, M. J., and Haro, I. (2012). Synthetic peptides
derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1
co-infection. J. Pept. Sci. 18(5):326–335.
[67] Gallaher, W. R. (1987). Detection of a fusion peptide sequence in the transmembrane protein of
human immunodeficiency virus. Cell. 50(3):327–328.
[68] Delahunty, M. D., Rhee, I., Freed, E. O., and Bonifacino, J. S. (1996). Mutational analysis of the
fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine
residues. Virology. 218(1):94–102.
[69] Torres, O. and Bong, D. (2011). Determinants of Membrane Activity from Mutational Analysis
of the HIV Fusion Peptide. Biochemistry. 50(23):5195–5207.
[70] Freed, E. O., Myers, D. J., and Risser, R. (1990). Characterization of the fusion domain of the
human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl. Acad. Sci. U. S. A.
87(12):4650–4654.
[71] Freed, E. O., Delwart, E. L., Buchschacher, G. L., and Panganiban, A. T. (1992). A mutation in the
human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes
with fusion and infectivity. Proc. Natl. Acad. Sci. U. S. A. 89(1):70–74.
[72] Dimitrov, A. S., Rawat, S. S., Jiang, S., and Blumenthal, R. (2003). Role of the Fusion Peptide
and Membrane-Proximal Domain in HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion.
Biochemistry. 42(48):14150–14158.
[73] Chang, D. K., Cheng, S. F., and Chien, W. J. (1997). The amino-terminal fusion domain peptide
of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle
primarily as a helix with a conserved glycine at the micelle-water interface. J. Virol. 71(9):6593–
6602.
[74] Yang, J., Gabrys, C. M., and Weliky, D. P. (2001). Solid-State Nuclear Magnetic Resonance
Evidence for an Extended β Strand Conformation of the Membrane-Bound HIV-1 Fusion Peptide.
Biochemistry. 40(27):8126–8137.
[75] Yang, J. and Weliky, D. P. (2003). Solid-State Nuclear Magnetic Resonance Evidence for Parallel
and Antiparallel Strand Arrangements in the Membrane-Associated HIV-1 Fusion Peptide.
Biochemistry. 42(40):11879–11890.
26 HIV: THE ROLE OF GP41 FP AND REV
[76] Sackett, K. and Shai, Y. (2003). How structure correlates to function for membrane associated
HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. J. Mol. Biol.
333(1):47–58.
[77] Yang, J., Prorok, M., Castellino, F. J., and Weliky, D. P. (2004). Oligomeric -Structure of the
Membrane-Bound HIV-1 Fusion Peptide Formed from Soluble Monomers. Biophys. J. 87(3):1951–
1963.
[78] Sackett, K. and Shai, Y. (2005). The HIV Fusion Peptide Adopts Intermolecular Parallel -Sheet
Structure in Membranes when Stabilized by the Adjacent N-Terminal Heptad Repeat: A 13C
FTIR Study. J. Mol. Biol. 350(4):790–805.
[79] Qiang, W., Yang, J., and Weliky, D. P. (2007). Solid-State Nuclear Magnetic Resonance Mea-
surements of HIV Fusion Peptide to Lipid Distances Reveal the Intimate Contact of Strand
Peptide with Membranes and the Proximity of the Ala-14Gly-16 Region with Lipid Headgroups.
Biochemistry. 46(17):4997–5008.
[80] Qiang, W., Bodner, M. L., and Weliky, D. P. (2008). Solid-State NMR Spectroscopy of Human
Immunodeficiency Virus Fusion Peptides Associated with Host-Cell-Like Membranes: 2D
Correlation Spectra and Distance Measurements Support a Fully Extended Conformation and
Models for Specific Antiparallel Strand Registries. J. Am. Chem. Soc. 130(16):5459–5471.
[81] Qiang, W., Sun, Y., and Weliky, D. P. (2009). A strong correlation between fusogenicity and
membrane insertion depth of the HIV fusion peptide. Proc. Natl. Acad. Sci. U. S. A. 106(36):15314–
15319.
[82] Schmick, S. D. and Weliky, D. P. (2010). Major Antiparallel and Minor Parallel Sheet Popula-
tions Detected in the Membrane-Associated Human Immunodeficiency Virus Fusion Peptide.
Biochemistry. 49(50):10623–10635.
[83] Reichert, J., Grasnick, D., Afonin, S., Buerck, J., Wadhwani, P., and Ulrich, A. S. (2006). A critical
evaluation of the conformational requirements of fusogenic peptides in membranes. Eur. Biophys.
J. 36(4-5):405–413.
[84] Grasnick, D., Sternberg, U., Strandberg, E., Wadhwani, P., and Ulrich, A. S. (2011). Irregular
structure of the HIV fusion peptide in membranes demonstrated by solid-state NMR and MD
simulations. Eur. Biophys. J. 40(4):529–543.
[85] Martin, I., Schaal, H., Scheid, A., and Ruysschaert, J. M. (1996). Lipid membrane fusion induced
by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its
orientation in the lipid bilayer. J. Virol. 70(1):298–304.
[86] Peisajovich, S. G., Epand, R. F., Pritsker, M., Shai, Y., and Epand, R. M. (2000). The Polar
Region Consecutive to the HIV Fusion Peptide Participates in Membrane Fusion. Biochemistry.
39(7):1826–1833.
[87] Saez-Cirion, A. and Nieva, J. (2002). Conformational transitions of membrane-bound HIV-1
fusion peptide. Biochim. Biophys. Acta. 1564(1):57–65.
[88] Castano, S. and Desbat, B. (2005). Structure and orientation study of fusion peptide FP23 of gp41
from HIV-1 alone or inserted into various lipid membrane models (mono-, bi- and multibi-layers)
by FT-IR spectroscopies and Brewster angle microscopy. Biochim. Biophys. Acta. 1715(2):81–95.
[89] Morris, K. F., Gao, X., and Wong, T. C. (2004). The interactions of the HIV gp41 fusion peptides
with zwitterionic membrane mimics determined by NMR spectroscopy. Biochim. Biophys. Acta.
1667(1):67–81.
[90] Barz, B., Wong, T. C., and Kosztin, I. (2008). Membrane curvature and surface area per lipid
affect the conformation and oligomeric state of HIV-1 fusion peptide: a combined FTIR and MD
simulation study. Biochim. Biophys. Acta. 1778(4):945–953.
[91] Buzón, V., Padrós, E., and Cladera, J. (2005). Interaction of Fusion Peptides from HIV gp41
with Membranes: A Time-Resolved Membrane Binding, Lipid Mixing, and Structural Study.
Biochemistry. 44(40):13354–13364.
REFERENCES 27
[92] Buzón, V. and Cladera, J. (2006). Effect of Cholesterol on the Interaction of the HIV GP41 Fusion
Peptide with Model Membranes. Importance of the Membrane Dipole Potential. Biochemistry.
45(51):15768–15775.
[93] Zheng, Z., Yang, R., Bodner, M. L., and Weliky, D. P. (2006). Conformational Flexibility and Strand
Arrangements of the Membrane-Associated HIV Fusion Peptide Trimer Probed by Solid-State
NMR Spectroscopy. Biochemistry. 45(43):12960–12975.
[94] Sackett, K., Nethercott, M. J., Epand, R. F., Epand, R. M., Kindra, D. R., Shai, Y., and Weliky, D. P.
(2010). Comparative Analysis of Membrane-Associated Fusion Peptide Secondary Structure and
Lipid Mixing Function of HIV gp41 Constructs that Model the Early Pre-Hairpin Intermediate
and Final Hairpin Conformations. J. Mol. Biol. 397(1):301–315.
[95] Tristram-Nagle, S., Chan, R., Kooijman, E., Uppamoochikkal, P., Qiang, W., Weliky, D. P., and
Nagle, J. F. (2010). HIV Fusion Peptide Penetrates, Disorders, and Softens T-Cell Membrane
Mimics. J. Mol. Biol. 402(1):139–153.
[96] Vogel, E. P., Curtis-Fisk, J., Young, K. M., and Weliky, D. P. (2011). Solid-State Nuclear Magnetic
Resonance (NMR) Spectroscopy of Human Immunodeficiency Virus gp41 Protein That Includes
the Fusion Peptide: NMR Detection of Recombinant Fgp41 in Inclusion Bodies in Whole Bacterial
Cells and Structural Characterization of Purified and Membrane-Associated Fgp41. Biochemistry.
50(46):10013–10026.
[97] Lai, A. L., Moorthy, A. E., Li, Y., and Tamm, L. K. (2012). Fusion Activity of HIV gp41 Fusion
Domain Is Related to Its Secondary Structure and Depth of Membrane Insertion in a Cholesterol-
Dependent Fashion. J. Mol. Biol. 418(1-2):3–15.
[98] Gabrys, C. M., Qiang, W., Sun, Y., Xie, L., Schmick, S. D., and Weliky, D. P. (2013). Solid-
State Nuclear Magnetic Resonance Measurements of HIV Fusion Peptide (13)CO to Lipid (31)P
Proximities Support Similar Partially Inserted Membrane Locations of the α Helical and β Sheet
Peptide Structures. J. Phys. Chem. A. 117(39):9848–9859.
[99] Gordon, L. M., Nisthal, A., Lee, A. B., Eskandari, S., Ruchala, P., Jung, C.-L., Waring, A. J.,
and Mobley, P. W. (2008). Structural and functional properties of peptides based on the N-
terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein. Biochim. Biophys. Acta.
1778(10):2127–2137.
[100] Zhan, H. and Lazaridis, T. (2012). Influence of the membrane dipole potential on peptide binding
to lipid bilayers. Biophys. Chem. 161:1–7.
[101] Bradshaw, J. P., Darkes, M. J. M., Harroun, T. A., Katsaras, J., and Epand, R. M. (2000). Oblique
Membrane Insertion of Viral Fusion Peptide Probed by Neutron Diffraction. Biochemistry.
39(22):6581–6585.
[102] Charloteaux, B., Lorin, A., Brasseur, R., and Lins, L. (2009). The "Tilted Peptide Theory" Links
Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides. Protein Pept. Lett.
16(7):718–725.
[103] Charloteaux, B., Lorin, A., Crowet, J. M., Stroobant, V., Lins, L., Thomas, A., and Brasseur, R.
(2006). The N-terminal 12 Residue Long Peptide of HIV gp41 is the Minimal Peptide Sufficient
to Induce Significant T-cell-like Membrane Destabilization in Vitro. J. Mol. Biol. 359(3):597–609.
[104] Cheng, Y., Li, D., Ji, B., Shi, X., and Gao, H. (2010). Structure-based design of carbon nanotubes
as HIV-1 protease inhibitors: atomistic and coarse-grained simulations. J. Mol. Graph. Model.
29(2):171–177.
[105] Lins, L., Decaffmeyer, M., Thomas, A., and Brasseur, R. (2008). Relationships between the
orientation and the structural properties of peptides and their membrane interactions. Biochim.
Biophys. Acta. 1778(7-8):1537–1544.
[106] Taylor, A. and Sansom, M. S. P. (2010). Studies on viral fusion peptides: the distribution of
lipophilic and electrostatic potential over the peptide determines the angle of insertion into a
membrane. Eur. Biophys. J. 39(11):1537–1545.
[107] Shchelokovskyy, P., Tristram-Nagle, S., and Dimova, R. (2011). Effect of the HIV-1 fusion peptide
on the mechanical properties and leaflet coupling of lipid bilayers. New J. Phys. 13(2):025004.
28 HIV: THE ROLE OF GP41 FP AND REV
[108] Bitler, A., Lev, N., Fridmann-Sirkis, Y., Blank, L., Cohen, S. R., and Shai, Y. (2010). Kinetics
of interaction of HIV fusion protein (gp41) with lipid membranes studied by real-time AFM
imaging. Ultramicroscopy. 110(6):694–700.
[109] Ivankin, A., Kuzmenko, I., and Gidalevitz, D. (2012). Cholesterol Mediates Membrane Curvature
during Fusion Events. Phys. Rev. Lett. 108(23):238103.
[110] Venken, T., Voet, A., De Maeyer, M., De Fabritiis, G., and Sadiq, S. K. (2013). Rapid Conforma-
tional Fluctuations of Disordered HIV-1 Fusion Peptide in Solution. J. Chem. Theory Comput.
9(7):2870–2874.
[111] Wong, T. C. (2003). Membrane structure of the human immunodeficiency virus gp41 fusion
peptide by molecular dynamics simulation. II. The glycine mutants. Biochim. Biophys. Acta.
1609(1):45–54.
[112] Kliger, Y., Aharoni, A., Rapaport, D., Jones, P., Blumenthal, R., and Shai, Y. (1997). Fusion
peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes
and inhibit cell-cell fusion - Structure-function study. J. Biol. Chem. 272(21):13496–13505.
[113] Promsri, S., Ullmann, G. M., and Hannongbua, S. (2012). Molecular dynamics simulation of
HIV-1 fusion domain-membrane complexes: Insight into the N-terminal gp41 fusion mechanism.
Biophys. Chem. 170:9–16.
[114] Pollard, V. W. and Malim, M. H. (1998). The HIV-1 rev protein. Annu. Rev. Microbiol. 52:491–532.
[115] Suhasini, M. and Reddy, T. R. (2009). Cellular proteins and HIV-1 Rev function. Curr. HIV Res.
7(1):91–100.
[116] Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E.
(1997). CRM1 is responsible for intracellular transport mediated by the nuclear export signal.
Nature. 390(6657):308–311.
[117] Kubota, S. and Pomerantz, R. J. (1998). A cis-acting peptide signal in human immunodeficiency
virus type I Rev which inhibits nuclear entry of small proteins. Oncogene. 16(14):1851–1861.
[118] Henderson, B. R. and Percipalle, P. (1997). Interactions between HIV Rev and nuclear import
and export factors: the Rev nuclear localisation signal mediates specific binding to human
importin-β. J. Mol. Biol. 274(5):693–707.
[119] Fernandes, J., Jayaraman, B., and Frankel, A. (2012). The HIV-1 rev response element: An RNA
scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex.
RNA Biol. 9(1):4–9.
[120] Daly, T. J., Doten, R. C., Rusche, J. R., and Auer, M. (1995). The amino terminal domain of HIV-1
Rev is required for discrimination of the RRE from nonspecific RNA. J. Mol. Biol. 253(2):243–258.
[121] Sloan, E. A., Kearney, M. F., Gray, L. R., Anastos, K., Daar, E. S., Margolick, J., Maldarelli, F.,
Hammarskjold, M. L., and Rekosh, D. (2013). Limited Nucleotide Changes in the Rev Response
Element (RRE) during HIV-1 Infection Alter Overall Rev-RRE Activity and Rev Multimerization.
J. Virol. 87(20):11173–11186.
[122] Kumar, S., Bose, D., Suryawanshi, H., Sabharwal, H., Mapa, K., and Maiti, S. (2011). Specificity
of RSG-1.2 Peptide Binding to RRE-IIB RNA Element of HIV-1 over Rev Peptide Is Mainly
Enthalpic in Origin. PLoS One. 6(8):e23300.
[123] Wilkinson, T. A., Botuyan, M. V., Kaplan, B. E., Rossi, J. J., and Chen, Y. (2000). Arginine
side-chain dynamics in the HIV-1 Rev-RRE complex. J. Mol. Biol. 303(4):515–529.
[124] Michael, L. A., Chenault, J. A., Miller, B. R., III, Knolhoff, A. M., and Nagan, M. C. (2009). Water,
Shape Recognition, Salt Bridges, and Cation–Pi Interactions Differentiate Peptide Recognition of
the HIV Rev-Responsive Element. J. Mol. Biol. 392(3):774–786.
[125] Casu, F., Duggan, B. M., and Hennig, M. (2013). The Arginine-Rich RNA-Binding Motif of HIV-1
Rev Is Intrinsically Disordered and Folds upon RRE Binding. Biophys. J. 105(4):1004–1017.
[126] Fischer, U., Huber, J., Boelens, W. C., Mattaj, I. W., and Lührmann, R. (1995). The HIV-1 Rev
activation domain is a nuclear export signal that accesses an export pathway used by specific
cellular RNAs. Cell. 82(3):475–483.
REFERENCES 29
[127] Hakata, Y., Yamada, M., Mabuchi, N., and Shida, H. (2002). The Carboxy-Terminal Region
of the Human Immunodeficiency Virus Type 1 Protein Rev Has Multiple Roles in Mediating
CRM1-Related Rev Functions. J. Virol. 76(16):8079–8089.
[128] Güttler, T., Madl, T., Neumann, P., Deichsel, D., Corsini, L., Monecke, T., Ficner, R., Sattler, M.,
and Görlich, D. (2010). NES consensus redefined by structures of PKI-type and Rev-type nuclear
export signals bound to CRM1. Nat. Struct. Mol. Biol. 17(11):1367–1376.
[129] Fang, J., Kubota, S., Yang, B., Zhou, N., Zhang, H., Godbout, R., and Pomerantz, R. J. (2004). A
DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology. 330(2):471–
480.
[130] Edgcomb, S. P., Carmel, A. B., Naji, S., Ambrus-Aikelin, G., Reyes, J. R., Saphire, A. C. S., Gerace,
L., and Williamson, J. R. (2012). DDX1 Is an RNA-Dependent ATPase Involved in HIV-1 Rev
Function and Virus Replication. J. Mol. Biol. 415(1):61–74.
[131] Robertson-Anderson, R. M., Wang, J., Edgcomb, S. P., Carmel, A. B., Williamson, J. R., and
Millar, D. P. (2011). Single-Molecule Studies Reveal that DEAD Box Protein DDX1 Promotes
Oligomerization of HIV-1 Rev on the Rev Response Element. J. Mol. Biol. 410(5):959–971.
[132] Yedavalli, V. S. R. K., Neuveut, C., Chi, Y.-H., Kleiman, L., and Jeang, K.-T. (2004). Requirement
of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell. 119(3):381–392.
[133] Zhou, X., Luo, J., Mills, L., Wu, S., Pan, T., Geng, G., Zhang, J., Luo, H., Liu, C., and Zhang, H.
(2013). DDX5 facilitates HIV-1 replication as a cellular co-factor of Rev. PLoS One. 8(5):e65040.
[134] Yasuda-Inoue, M., Kuroki, M., and Ariumi, Y. (2013). Distinct DDX DEAD-box RNA helicases
cooperate to modulate the HIV-1 Rev function. Biochem. Biophys. Res. Commun. 434(4):803–808.
[135] Daly, T. J., Cook, K. S., Gray, G. S., Maione, T. E., and Rusche, J. R. (1989). Specific binding of HIV-1
recombinant Rev protein to the Rev-responsive element in vitro. Nature. 342(6251):816–819.
[136] Daly, T. J., Doten, R. C., Rennert, P., Auer, M., Jaksche, H., Donner, A., Fisk, G., and Rusche, J. R.
(1993). Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to
the Rev responsive element. Biochemistry. 32(39):10497–10505.
[137] Mann, D. A., Mikaélian, I., Zemmel, R. W., Green, S. M., Lowe, A. D., Kimura, T., Singh, M.,
Butler, P. J., Gait, M. J., and Karn, J. (1994). A molecular rheostat. Co-operative rev binding to
stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene
expression. J. Mol. Biol. 241(2):193–207.
[138] Daugherty, M. D., Booth, D. S., Jayaraman, B., Cheng, Y., and Frankel, A. D. (2010). HIV Rev
response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric
complexes. Proc. Natl. Acad. Sci. U. S. A. 107(28):12481–12486.
[139] DiMattia, M. A., Watts, N. R., Stahl, S. J., Rader, C., Wingfield, P. T., Stuart, D. I., Steven, A. C.,
and Grimes, J. M. (2010). Implications of the HIV-1 Rev dimer structure at 3.2 Å resolution for
multimeric binding to the Rev response element. Proc. Natl. Acad. Sci. U. S. A. 107(13):5810–5814.
[140] Daugherty, M. D., Liu, B., and Frankel, A. D. (2010). Structural basis for cooperative RNA
binding and export complex assembly by HIV Rev. Nat. Struct. Mol. Biol. 17(11):1337–1342.
[141] Jain, C. and Belasco, J. G. (2001). Structural model for the cooperative assembly of HIV-1 Rev
multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol. Cell.
7(3):603–614.
[142] Daugherty, M. D., D’Orso, I., and Frankel, A. D. (2008). A Solution to Limited Genomic Capacity:
Using Adaptable Binding Surfaces to Assemble the Functional HIV Rev Oligomer on RNA. Mol.
Cell. 31(6):824–834.
[143] Edgcomb, S. P., Aschrafi, A., Kompfner, E., Williamson, J. R., Gerace, L., and Hennig, M. (2008).
Protein structure and oligomerization are important for the formation of export-competent HIV-1
Rev-RRE complexes. Protein Sci. 17(3):420–430.
[144] Auer, M., Gremlich, H. U., Seifert, J. M., Daly, T. J., Parslow, T. G., Casari, G., and Gstach, H.
(1994). Helix-loop-helix motif in HIV-1 Rev. Biochemistry. 33(10):2988–2996.
[145] Pond, S. J. K., Ridgeway, W. K., Robertson, R., Wang, J., and Millar, D. P. (2009). HIV-1 Rev protein
assembles on viral RNA one molecule at a time. Proc. Natl. Acad. Sci. U. S. A. 106(5):1404–1408.
30 HIV: THE ROLE OF GP41 FP AND REV
[146] Daelemans, D., Costes, S. V., Cho, E. H., Erwin-Cohen, R. A., Lockett, S., and Pavlakis, G. N.
(2004). In vivo HIV-1 Rev multimerization in the nucleolus and cytoplasm identified by fluores-
cence resonance energy transfer. J. Biol. Chem. 279(48):50167–50175.
[147] Pallesen, J., Dong, M., Besenbacher, F., and Kjems, J. (2009). Structure of the HIV-1 Rev response
element alone and in complex with regulator of virion (Rev) studied by atomic force microscopy.
FEBS Journal. 276(15):4223–4232.
[148] Živkovic´, J., Janssen, L., Alvarado, F., Speller, S., and Heus, H. A. (2012). Force spectroscopy of
Rev-peptide–RRE interaction from HIV-1. Soft Matter. 8(7):2103–2109.
[149] Havlin, R. H., Blanco, F. J., and Tycko, R. (2007). Constraints on Protein Structure in HIV-1 Rev
and RevRNA Supramolecular Assemblies from Two-Dimensional Solid State Nuclear Magnetic
Resonance. Biochemistry. 46(11):3586–3593.
[150] Hammarskjold, M.-L. and Rekosh, D. (2011). A Long-Awaited Structure Is Rev-ealed. Viruses.
3(12):484–492.
[151] Malim, M. H. and Cullen, B. R. (1991). HIV-1 structural gene expression requires the binding of
multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell. 65(2):241–248.
[152] Malim, M. H., Böhnlein, S., Hauber, J., and Cullen, B. R. (1989). Functional dissection of the HIV-1
Rev trans-activator–derivation of a trans-dominant repressor of Rev function. Cell. 58(1):205–214.
[153] Chapman, R. L., Stanley, T. B., Hazen, R., and Garvey, E. P. (2002). Small molecule modulators
of HIV Rev/Rev response element interaction identified by random screening. Antiviral Res.
54(3):149–162.
[154] Mills, N. L., Daugherty, M. D., Frankel, A. D., and Guy, R. K. (2006). Anα-Helical Peptidomimetic
Inhibitor of the HIV-1 RevRRE Interaction. J. Am. Chem. Soc. 128(11):3496–3497.
[155] Shuck-Lee, D., Chen, F. F., Willard, R., Raman, S., Ptak, R., Hammarskjold, M. L., and Rekosh, D.
(2008). Heterocyclic Compounds That Inhibit Rev-RRE Function and Human Immunodeficiency
Virus Type 1 Replication. Antimicrob. Agents Chemother. 52(9):3169–3179.
[156] Wolff, B., Sanglier, J.-J., and Wang, Y. (1997). Leptomycin B is an inhibitor of nuclear export:
inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1
(HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4(2):139–147.
[157] Daelemans, D., Afonina, E., Nilsson, J., Werner, G., Kjems, J., De Clercq, E., Pavlakis, G. N., and
Vandamme, A.-M. (2002). A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated
nuclear export. Proc. Natl. Acad. Sci. U. S. A. 99(22):14440–14445.
[158] Van Neck, T., Pannecouque, C., Vanstreels, E., Stevens, M., Dehaen, W., and Daelemans, D.
(2008). Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates:
Structure–activity relationship and mechanism of action. Bioorg. Med. Chem. 16(21):9487–9497.
[159] Shuck-Lee, D., Chang, H., Sloan, E. A., Hammarskjold, M. L., and Rekosh, D. (2011). Single-
Nucleotide Changes in the HIV Rev-Response Element Mediate Resistance to Compounds That
Inhibit Rev Function. J. Virol. 85(8):3940–3949.
[160] Vercruysse, T., Pardon, E., Vanstreels, E., Steyaert, J., and Daelemans, D. (2010). An Intrabody
Based on a Llama Single-domain Antibody Targeting the N-terminal α-Helical Multimerization
Domain of HIV-1 Rev Prevents Viral Production. J. Biol. Chem. 285(28):21768–21780.
[161] Vercruysse, T., Pawar, S., De Borggraeve, W., Pardon, E., Pavlakis, G. N., Pannecouque, C.,
Steyaert, J., Balzarini, J., and Daelemans, D. (2011). Measuring cooperative Rev protein-protein
interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biol.
8(2):316–324.
[162] Vercruysse, T., Boons, E., Venken, T., Vanstreels, E., Voet, A., Steyaert, J., De Maeyer, M., and
Daelemans, D. (2013). Mapping the Binding Interface between an HIV-1 Inhibiting Intrabody
and the Viral Protein Rev. PLoS One. 8(4):e60259.
Chapter 2
Molecular Dynamics simulations
"I feel so close to you right
now, it’s a force field"
Feel so Close - Calvin Harris
2.1 Introduction
Biomolecules can be seen as the machinery required by nature to survive, com-
municate and reproduce. Proteins are a very diverse class of macromolecules
that perform numerous roles in living cells, such as regulation (e.g. in signalling
pathways to transmit responses through the body), structure (e.g. collagen, which
offers rigidity to fibrous tissues), transport of small molecules (e.g. water molecules
by aquaporins) or catalyse reactions (e.g. the breakdown of metabolites), to name
a few. Other biomolecules such as carbohydrates are essential as an energy source
for cells (e.g. glycogen in muscle cells) or they play a role in the immune system
(e.g. recognition of pathogens), while lipids are essential to give shape and com-
partmentalise different organelles from each other. Finally, nucleotides contain the
genetic information essential for replication of the cell.
In biophysical research, a wide variety of techniques is available to study the role
of these biomolecules. For example, X-ray crystallography can provide a highly
detailed picture of the atomic positions of a biomolecular structure. However, a
picture is often not sufficient. In those cases, a better option would be to construct
a dynamic movie of an entire process. To use a real-life example, just as a picture
of a running horse tells little about its pace (think of the movies of running
horses made by Eadweard Muybridge in the 19th century [1]), a single protein
conformation tells little about its dynamics (see Figure 2.1 for an illustration). To
use another example: if we want to grasp how a ligand binds to a protein, we are
not only interested in the final bound state but also in the entire binding event.
Atoms and molecules collide with each other very frequently in the crowded
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Figure 2.1: An illustration of the relevance of dynamics. Top: Sallie Gardner at a Gallop [1]. Eadward
Muybridge conducted this photographic experiment in 1872 by taking several photographs of a
galloping horse to find out if all feet where completely off the ground while trotting. This was, at that
time, an unsolved mystery, as the human eye cannot distinguish the rapid movements of the horse. By
converting the individual pictures into a movie, the horse was indeed captured with all feet off the
ground during gallop. Bottom: gp41 FP in solution. In comparison, scientific arguments are often not
explained by a single figure as well, as sometimes a series of pictures is necessary to fully understand
and explain biomolecular questions. The depicted snapshots are gp41 FP conformations in solution
based on PDB code 1ERF and where taken in 1.2 ns in 100 ps intervals, showing partial breakdown of
the α-helical conformation in a relatively short time.
environment of the living cell. Proteins, for example, are inherently flexible and
the protein dynamics strongly influence the function of the protein itself. A
detailed understanding of these interactions can explain the behaviour of larger
macromolecules, or as R. Feynman has stated in a now famous quote: "Everything
that living things do can be understood in terms of the jigglings and wigglings of atoms"
[2, 3]. A detailed movie of molecular interactions will help us to understand
the biological processes in living cells, also in those cases when mistakes lead to
diseases. For example, when two viral proteins interact with each other and this
interaction is essential for the replication of the virus, molecular modelling can
aid to (a) investigate the dynamic nature of the interaction, and (b) find a way to
inhibit this protein-protein interaction, thereby inhibiting the replication of the
virus as well.
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Figure 2.2: Comparison of techniques to study biological processes and entities in different time
scales (x-axis) and of different sizes (y-axis). To optimise experimental methods, often an increase in
resolution is required. In contrast, MD simulations struggle to "decrease" the resolution, that is, to
study larger biomolecular structures at longer time scales. Hence, a combination of experimental and
modelling techniques is usually required to solve biomolecular questions. Figure adapted from Dror et
al. [4]
To allow a dynamical microscopic view of the biomolecules from living cells,
techniques can be employed like NMR, electron cryo-microscopy and fluorescence
based methods such as FRET. While those methods provide a valuable under-
standing of macromolecular structures, they are often limited by both spatial and
temporal resolution [4]. In other words, biophysical techniques are not always
capable of studying small systems or fast processes at a highly detailed atomic
level. Attempts are being made to overcome the limitations, though these usually
require more expensive scientific machinery. As such, molecular dynamics (MD)
simulations can aid to trace the motions of biomolecules at an atomic scale (see
Figure 2.2 for a comparison with experimental techniques).
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Figure 2.3: Demonstration of ensemble deception. Experimental techniques often study ensembles
in bulk, but the measured results can hide potentially interesting distinct microstates. Just as taking a
picture with a long exposure time can blur the motions of the individual cars on a highway, so can the
motions of individual proteins be hidden in ensemble measurements, which can potentially lead to
faulty conclusions. Note that while averaging over distinct populations can be deceiving, conversely
MD simulations can be inaccurate as well when only a limited amount of conformational space is
sampled. Picture reproduced with permission of © Steven Duerinckx www.darkink.be [5].
In a MD simulation, the positions and velocities of atoms are calculated using
classical Newtonian physics to predict the motions of biomolecular systems. To
define the forces of all the atoms in a system, an empirical force field is used
based on parameter fitting of quantum chemical and/or experimental data. While
electrons are explicitly modelled in quantum mechanics, atoms are represented as
rigid spheres connected by unbreakable bonds in a force field.
Nowadays, when starting from a reliable experimental structure or model and
considering the limitations of the chosen force field, MD simulations are con-
sidered as a "virtual microscope". In addition, the behaviour of a single protein
can be tracked, which is not always feasible with experimental techniques where
often an ensemble of molecules is studied in bulk. Those ensemble methods can
mask infrequent but possibly important molecular processes or interactions of a
protein. As such, utilising single molecule techniques like MD allows exposure of
dynamical events that are often averaged in ensemble measurements (see Figure
2.3 for an illustration of this principle).
MD simulation is a highly multidisciplinary technique, combining aspects from
physics, mathematics and informatics to solve biology and chemistry questions
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Figure 2.4: Disciplines in MD simulations. In MD simulations, many different fields are combined to
solve biomolecular questions.
(see Figure 2.4). Numerous MD packages like GROMACS (GROningen Machine
for Chemical Simulations) [6], AMBER (Assisted Model Building with Energy
Refinement) [7], CHARMM (Chemistry at HARvard Molecular Mechanics) [8],
and NAMD (Not just Another Molecular Dynamics program) [9] are becoming
increasingly popular [10]. In parallel, a number of protein optimised force fields
such as the AMBER and CHARMM force fields (not to be confused with the
package name) have been developed.
A wide number of review articles have been published outlining the general
principles of MD simulations [11–16], its applications in drug design [17–22], the
folding of proteins [17, 23–26] and current challenges [27–29], like assessing longer
time scales [4, 30–32]. In addition, researchers are becoming aware that protein
flexibility needs to be taken into account for structure based drug design [33, 34],
for example in virtual screening protocols [35–39].
Below, we will first outline the general principles of MD simulations and its
implementations. Next, we list a number of challenges and limitations of the
method.
2.2 Theoretical principles of Molecular Mechanics
In theory, the well-known Schrödinger’s equation can be solved using quantum
mechanical calculations to predict the properties of a given system ab initio. Un-
fortunately, applying those calculations on large proteins is impossible to track
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the time scales scientists are interested in. This is even impossible for very small
systems, so a number of approximations are implemented in standard MD simula-
tions (and molecular mechanics in general).
First, the Born-Oppenheimer approximation assumes that nuclei are infinitely
heavier than electrons. By decoupling motions of electrons and nuclei, the calcula-
tions are simplified significantly. In MD, the electronic motions are not considered
explicitly and they depend on the position of the atoms in the system, so each
atom is considered as a point mass.
Second, it is assumed that nucleic motions can behave classically according to
Newton’s second law, so quantum effects are not taken into account explicitly.
To obtain the sum of all forces, a third approximation is used, namely the applica-
tion of an empirical force field, which we will explain more in detail below.
2.2.1 Force fields
In molecular mechanics, Newtonian laws are used instead of the Schrödinger’s
equation to describe a system. This yields a sufficiently reliable approximation of
the total energy in a system at a much lower computational cost. The force field is
the core of a MD simulation and determines the behaviour of the system of interest.
Consequently, a vast number of force field have been developed specifically for
the simulation of proteins. However, the systems’ potential energy is not sufficient
as such, but a combination of potential energy functions with an appropriate
parameter set is required. In short, the force field is basically the collection of
empirical potential functions that describe the interactions between all the atoms
in the system. In other words, the sum of all the individual energy contributions
in and between atoms constitutes the total potential energy U . Potential functions
are bonded (i.e. internal interactions between atoms through covalent bonds, Eb)
or non-bonded (i.e. external interactions by atoms that are not bonded, Enb):
U = Eb + Enb (2.1)
Eb = Ebond + Eangle + Edihedral (2.2)
Enb = Evdw + Ecoul (2.3)
In AMBER [40], a force field frequently used in this thesis, the bonded and non-
bonded terms consist of:
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Ebond =
∑
bonds
kr(r − req) (2.4)
Eangle =
∑
angles
kθ(θ − θeq) (2.5)
Edihedral =
∑
dihedrals
kφ(1 + cos(nφ− γ)) (2.6)
Evdw =
∑
i<j
( Aij
Rij
12 −
Bij
Rij
6 ) (2.7)
Ecoul =
∑
i<j
qiqj
Rij
(2.8)
A ball-and-spring-like model represents the molecules in a force field, where
atoms are treated as charged point masses connected by bonds. In the force field
described above, the energy terms between covalently bonded atoms are defined
by bond stretching Ebond, an angle bending strain Eangle and a dihedral term
Edihedral for four steric atoms. Non-covalently bonded terms consist of a van der
Waals term Evdw, which defines atom-atom repulsion and dispersion interactions,
and an electrostatic term Ecoul, defined by Coulomb’s law.
Bonded terms
Chemical bonds and atomic angles are treated by simple harmonic springs, while
dihedral or torsional rotations are defined by a sinusoidal term that corresponds
to energy differences between eclipsed and staggered conformations. The bond
term Ebond is used to account for deformations in the bond length. Here, kr is the
force constant, r is the current bond length and req the bond length at equilibrium
between two atoms. Similarly, the angle term consists of an angle force constant
kθ, a current angle θ and an ideal angle θeq formed by three atoms. The four-atom
dihedral potential contains an improper force constant kφ with periodicity n, a
phase shift γ and the current torsional angle φ. All the parameters result in a
"fixed" list of atoms, that is, bonds are predefined and cannot be broken during
the simulation.
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Non-bonded terms
For the non-bonded terms, repulsion and dispersion interactions are described
by the van der Waals term Evdw with the Lennard-Jones (LJ) 6-12 potential as a
function of the distance between two interacting atoms rij . A repulsive force exists
at short atom-atom distances (defined by Aij), while attractive London dispersion
forces occur at longer distances (defined by Bij). The constants Aij and Bij are
determined experimentally and are specific for each atom pair. The electrostatic
termEcoul is treated by Coulomb’s law and describes the interaction force between
two static point charges. Here, qi and qj are the (usually quantum chemically
derived) partial charges and  is the permittivity of the medium.
The number of pairwise non-bonded interactions scales quadratically with the
number of atoms in the system. Therefore, the amount of non-bonded pairs
in the simulation is computed from a neighbour list. That is a list of all the
non-bonded atoms within a certain radius. The list is updated regularly after a
specified amount of time steps in the MD simulation (typically 10 ps). For the LJ
interaction, the radius is often chosen between 1.0 and 1.4 nm. The long-range
electrostatic interactions are notoriously the computationally most expensive part
of a MD simulation step. Unfortunately, an abrupt cut-off generates artefacts in
the simulation system as the Coulombic potential decays slowly at long distances.
However, we cannot simply ignore these processes, as long-range electrostatics
are essential for the structural stability of proteins, the folding of proteins [41] and
in ligand binding events. Therefore, the particle mesh Ewald (PME) summation
scheme has been developed to handle long-range electrostatic interactions more
efficiently [42, 43]. The Ewald method partitions the potential into a short- and
long-range part and sums these separately. The short part is calculated in real
space while a Fourier transformed space is used to treat the long-range interactions.
A more detailed implementation is found in the GROMACS manual [44].
Parameterisation
Force field parameters are derived either from fitting to experimental data or from
quantum mechanical calculations such as ab initio or semi-empirical methods.
There is no unique way to implement a force field as exemplified by a wide range
of different force fields developed by a variety of groups. The most common force
fields for biomolecular simulations are AMBER, CHARMM, OPLS (Optimised
Potentials for Liquid Simulations) and GROMOS (GROningen MOlecular Sim-
ulation). In a force field, the specific force parameters and ideal values must be
parameterised with great care, as even small deviations may influence the entire
protein dynamics. As an illustration, the small hydrophobin protein contains 70
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amino acids, consisting of 982 atoms interacting with each other [45]. Due to the
large amount of possible interactions, solving these equations is a computationally
intensive task. Even in such a relatively small protein, there are 993 bonds, 1821
angles, 2835 dihedrals and 2629 pairwise interactions to be calculated in every
single time step. Thus, a static picture of a protein can be deceiving as the molecule
will in reality behave more like a giant ball of oscillating springs. It is with MD
simulations that we try to solve this giant scientific puzzle in a step-by-step
approach.
2.2.2 Integration
In a MD simulation, the time evolution of a system comprising N particles (with
i = 1 ... N) is written as:
Fi = miai (2.9)
Here, the force Fi acting on a particle i is defined by its massmi and its acceleration
ai, which is the second derivative of the atomic position ri with time t, while
velocity vi is the first derivative:
Fi = mi
δvi
δt
= mi
δ2ri
δt2
(2.10)
The potential energy in the system U is a function of the coordinates of the particles
xi in the system:
Fi = −δU
δri
(2.11)
The force calculated here is simply the negative derivative of the potential energy.
Essentially, the potential energy U defines how the system evolves in time. For
this reason, we need a set of initial coordinates (xi) and assigned velocities (vi)
to start a MD simulation at time i. Next, the Newton second law is applied
at every time step (t = t + ∆t) to obtain the motions of individual atoms in a
system. By incrementally increasing the time with a fixed time step, a series
of atomic conformations is generated iteratively in time, which we designate
a "system trajectory". As such, MD is a deterministic technique, meaning that
Newton’s equations are integrated reversibly in time. The direction in time is
merely arbitrary; in theory it is possible to swap the sign of the atom velocities,
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thereby going "back" in time [12]. Note that ∆t is determined by the fastest
occurring process in the system. In the case of atomistic simulations, this is the
vibration of hydrogen atom in range of one femtosecond (10−15 s). The short time
step is required to minimise inaccuracies in the cumulative integration of each
force field equation.
There are several ways to integrate equation 2.9 numerically. One of the earliest
methods is the velocity Verlet algorithm [46, 47]. In this method, a modified set of
coordinates r at a new time (t+∆t) is calculated from a previous set of coordinates
and accelerations at time t.
v(t+ 12∆t) = v(t) +
∆t
2mF (t) (2.12)
r(t+ ∆t) = r(t) + ∆tv(t+ 12∆t) (2.13)
In GROMACS [6], the standard integrator is the so-called leap-frog algorithm,
which is basically a modification of the original Verlet algorithm. The integration
steps are computed by:
v(t+ 12∆t) = v(t−
1
2 t) +
∆t
m
F (t) (2.14)
r(t+ ∆t) = r(t) + ∆tv(t+ 12∆t) (2.15)
Hence, the velocities v(t + 12∆t) are based on the velocities at time t −
1
2∆t,
while the positions r(t + ∆t) are derived from the previous position r(t) with
intermediate velocity v(t+ 12∆t). Or in other words: the velocities "skip" or leap
over the positions during the integrations and vice versa [48].
It is essential that the integrator is as accurate as possible, as the system can
become unstable if accumulated numerical errors propagate in time. Although
both velocity Verlet and leap-frog can generate identical trajectories, the leap-frog
integrator is considered to be computationally more stable.
A number of algorithms have been designed to speed up the MD simulation
integration. The time step of 1 fs is increased to 2 fs by constraining the bond
lengths in the system. That constraint "freezes" the bond lengths and angles after
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integration of the forces in the system and is justified because temporary bond
stretching vibrations are usually not coupled to global protein dynamics and
function. In GROMACS, the LINCS algorithm (Linear Constraint Solver) is used
as default to fix bond lengths and angles after the integration step, producing a
four-time MD simulation speed up [49].
In ACEMD [50], another MD package used in this thesis, the M-SHAKE algorithm
[51, 52] is applied for bond constraints and RATTLE for velocity constraints [53].
In addition, a hydrogen mass repartitioning scheme increases the time step to 4 fs,
thereby increasing the integrator efficiency [50].
2.2.3 Periodic Boundary Conditions
As all particles interact with each other, there will obviously be artefacts at the
boundaries of the simulation box. A "trick" called periodic boundary conditions (PBC)
is therefore applied. PBC construct an infinite system by copying the simulation
cell in all directions. By using this method, the system virtually has no boundaries,
so e.g. a water molecule that exits the left side of the box reappears on the right
side. As a result, the total amount of atoms (N) in the system remains constant in
the main unit cell.
Different box types exist such as cubes, rhombic dodecahedrons and truncated
octahedrons. Preferably, the size of the box should be as small as possible to limit
the total amount of solvent atoms in the system, which consequently reduces the
computational simulation cost. Importantly, the box size may not be too small, as
periodic images can sense each other through long-range interactions. Typically,
those interactions are much lower between 1.0 and 1.4 nm, it is therefore advised
to create a box size with a minimum distance of 0.5 to 0.7 nm between each protein
atom and the periodic box edges. The influence of the box shape on the dynamic
properties of a protein in a MD simulation has been assessed previously [54].
2.2.4 Ensemble
An ensemble is a macroscopic collection consisting of different microscopic states
of a system. Typically, a MD simulation is conducted using a chosen thermody-
namic ensemble, i.e. a combination of a constant number of atoms (N), energy
(E), pressure (P), volume (V) and temperature (T). Usually, a selection of three
parameters defines the thermodynamic ensemble of a system. The most straight-
forward case is simply solving the equations mentioned above, which yields the
microcanonical NVE ensemble with a fixed amount of particles (N), fixed volume
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(V) and fixed total energy (E). That corresponds to an isolated system, as the total
energy remains constant.
A better approximation of the experimental measurements is the canonical NVT
ensemble, which applies an average constant temperature by using a specific
algorithm called thermostat. That algorithm derives the temperature in the system
from the atomic velocities, where each particle in the system is coupled to an
external heat bath with a given temperature. The thermostat constantly adds or
removes energy from the system by adjusting the velocities of each atom, which
accordingly keeps the average temperature in the simulation box constant. For
example, the Berendsen thermostat will generate a correct average temperature,
but unfortunately it does not generate temperature distributions corresponding to
a true statistical mechanical ensemble. As a result, the velocity rescaling thermostat
is now commonly used in the GROMACS package, which accurately represents a
canonical ensemble [55]. Other implementations are the Langevin [56] and Nose-
Hoover thermostat [57, 58]. The differences between the thermostat algorithms
are small: although temperature fluctuations are affected, the average temperature
is almost identical in each case.
Alternatively, an isobaric-isothermal NPT ensemble can be applied using a barostat
to keep the average pressure constant. Just like a simulation box is linked to
a heat bath with a thermostat, so is there coupling to a pressure bath with a
barostat. In contrast to NVT, NPT allows the volume to fluctuate by modifying the
dimensions of the periodic box and coordinates in each time step, which creates
an average reference pressure in the system. The NPT ensemble is essential to
stabilise for example lipid bilayers with or without embedded membrane proteins
and it is therefore frequently used to compare simulation data with experimentally
measured properties.
Importantly, comparison with ensemble measured properties relies on the ergodic
hypothesis, which states that all possible microstates can represent macroscopic
properties if the complete phase space is sampled in the simulation trajectory.
Hence, time averaged properties from MD simulation can be compared to experi-
mental data. However, when sampling is insufficient, the system is considered
nonergodic, meaning that only a subset of the phase space has been sampled.
In a simulation trajectory, the system evolves into distinct microstates in time,
but conformations can get trapped in local energy minima. Averaging over a
number of snapshots in a simulation trajectory is therefore not representative for a
thermodynamic property when conformational sampling is insufficient in time.
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2.2.5 Solvent models
While we have now described the force field definitions of biomolecules, evidently
the environment of immersed biomolecules needs to be characterised accurately
as well. To this end, many different solvent models have been developed over the
years to study the important effects of water molecules in binding pockets or the
transport of water molecules through aquaporins [59]. The most commonly used
water models are the explicit TIP3P and SPC, while more advanced models such
as SPC/E, TIP4P and TIP5P provide higher accuracy (e.g. inclusion of the water
dipole moment). In addition, implicit solvent models have been developed that
use a continuum solvation description. By replacing the explicit representation of
water molecules with an infinite continuum containing the dielectric properties of
water, the amount of particles in a system is drastically reduced (see for example
a study of the HIV protease by Hornak et al. [60]), thereby reducing computa-
tional costs and extending the accessible time scales. Solvation models such as
Poisson-Boltzmann (PB) and generalised Born (GB) treat the solvent as a dielectric
continuum, where mean interactions are modelled instead. We will explain these
two methods more in detail in section 3.4.1.
2.2.6 Common protocol
While each simulation protocol will differ depending on the content of the sys-
tem and the questions posed in advance, we will illustrate how to set up a MD
simulation for a standard protein. Protein structure files called PDB files can be
downloaded from the RCSB Protein Data Bank [61], where a large amount of struc-
tures determined by either X-ray crystallography, NMR or electron microscopy is
available. In case of a crystal structure, hydrogens are only present in rare ultra
resolution structures, so usually hydrogen atoms need to be added. In rare cases,
all residues are present, but generally not all residues in the protein have been
resolved or lack certain side chain atoms. Another issue is the determination of
the correct protonation state of polar residues such as histidine [62, 63]. Also,
glutamine and asparagine side chains often need to be flipped 180 degrees, as
crystallography is not able to distinguish diffraction patterns from nitrogen and
oxygen. In the cases where the protein structure has incomplete termini, it is
advised to neutralise these ends by addition of an acetyl group (ACE) to the N-
terminus or an N-methyl amide (NME) to the C-terminus. If the structure of a
protein is unknown, it is possible to create a homology model if a suitable template
structure can be found.
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In summary, it is essential to verify the integrity of the protein structure before
starting the simulation, as even small errors can propagate in time producing
artefacts, thereby jeopardising the reliability of the simulation. MD is a determin-
istic technique, thus the output depends highly on the provided input structure.
Also, even though for example geometric errors can be rather small, the force
field is usually not able to "fix" this, as the structure might get trapped in local
minima [64]. A notable example is the formation of a so-called "wedding ring", for
example during the placement of residue side chains during homology modelling.
As illustrated in Figure 2.5, the aromatic rings of hydrophobic protein residues
are intertwined. Because bonds are unbreakable in molecular mechanics, the force
field will never ever be able to correct this conformation and the starting structure
simply has to be remodelled.
Figure 2.5: Example of an unfortunate modelling error. Two tryptophan residues adopt an intimate
conformation due to incorrect placement of the side chain residues. Because bonds are unbreakable in
a force field, a minimisation step is unable to solve this error.
After the selection of the starting structure, a molecular topology is defined from
the force field parameters. Bonds, angles, dihedrals and atom pairs are contained in
a parameter file, which cannot be changed during the course of the MD simulation.
Standard force field parameters are available for common molecules in the system.
However, for non-classical ligands or residues, parameters need to be determined
by the user [65, 66] or need to be converted from other force fields, for example
using the Acpype program [67].
After generation of the protein topology, the protein is placed in a virtual box
with edges at a safe distance (usually around 1 nm) to avoid PBC artefacts (see
section 2.2.1). The system is filled with solvent molecules and replacement of
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random solvent molecules by counterions neutralises the charge of the protein. Al-
ternatively, a predefined salt concentration can be specified to mimic experimental
buffer conditions. Usually, the next step is to perform a short energy minimisation
using steepest descent or conjugate gradient to resolve clashes in the system. Once
the system potential energy has been minimised, an equilibration run is started.
Initial velocities are assigned to all atoms in the system. A position restraint force
is applied to the protein atoms to relax the solvent molecules, thereby filling any
solvent-accessible cavities in the protein structure. Depending on the size and
the stability of the protein, multiple minimisation and equilibration runs have
to be performed. Once the potential energy of the system has reached a stable
minimum, the restraints are released from the protein atoms and the so-called
production run is initiated. The protein dynamics can now be followed in time.
For decent sampling the simulation should be at least in the nanosecond range,
depending on the size of the protein and the questions to be answered.
2.3 Limitations and challenges
MD simulations suffer from a number of restrictions, which are outlined more in
detail below. The limitations can be summarised as: i) which representation of
the system is appropriate to resemble experimental conditions, ii) the force field is
inherently "imperfect", and iii) spatiotemporal restrictions hinder full sampling.
2.3.1 Levels of approximation
Every system that is studied in research is afflicted by certain inaccuracy. Evidently,
the highest theoretical accuracy is preferred, but as with experimental studies,
the cost of computational time has to be taken into account as well. Regarding
MD simulations, a consensus should be found between cost and outcome of
the simulations. To describe the motions of particles in a predefined system,
one can resort to quantum physical methods, but imposing these calculations
on macromolecular structures is not always feasible. In addition, depending on
the posed questions, the outcome of those calculations would not necessarily
result in a more accurate result. In other words, exploring the conformational
landscape of a biomolecule can be compared to looking at a cartographic map,
showing different tracks between the conformational states. Such a map can show
every possible track, however, showing too much detail can be superfluous and
confusing, as the main roads can be sufficient to reach a specific location.
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With MD simulations, sometimes a more precise characterisation of the system
is needed. For example, QM/MM systems treat a part of the system (usually a
sphere, for example the binding site of a protein) by quantum mechanics while the
remaining of the system (outside of the sphere) is treated with a faster molecular
mechanics scheme. Considering the map analogy, the MM can be regarded as the
overview of the map, while the QM part resembles an enlarged part of the map
such as a city centre. The method can be used to study enzymatic reactions for
example, where the active site is treated with QM to model bond formation and
breaking, while the remaining of the protein is modelled by static-bonded MM.
Usually, most MD simulations are simulated using an all-atom representation, that
is, all atoms are modelled explicitly as individual points, including all hydrogens
atoms. There is a large number of force fields available using this representation,
such as the AMBER, CHARMM and OPLS/AA force fields. In addition, so-called
united-atom representations do not model apolar hydrogens explicitly. In that case,
those apolar hydrogens are joined with carbon atoms to allow less atoms in the
systems, thereby allowing faster calculations and thus longer accessible time scales.
The GROMOS force fields are examples of this class, with parameters available for
proteins, lipids and ribonucleotides. A course-grained representation reduces the
amount of atoms in the system even further by fusing similar atoms together into
beads as single interaction points. Course-graining is useful because the number
of particles is decreased significantly in the simulation system. The degrees of
freedom are reduced considerably and as a consequence the computational cost of
the simulation is minimised. Though this simplification no longer allows tracking
of individual atoms, course-graining can thus be beneficial when large complexes
or processes at long time scales are of interest. For example, the Martini force
field [68, 69] can be used on large protein complexes, such as modelling of the
immature HIV virion [70]. In addition, the force field is frequently used for analysis
of membrane systems, such as gating of ion channels [71], membrane pores [72],
insertion of peptides [73, 74] and larger membrane proteins [75]. Sometimes, the
system is first simulated using course-grained potentials, but is subsequently
converted into an all-atom representation to study the biomolecular behaviour of
the system more in detail [76–78]. A number of reviews discusses the applications
of course grained MD simulations more in detail [79–81] and parameters are
frequently being improved [82].
Finally, some words should be spent on the development of so-called polarisable
force fields. All-atom force fields treat atoms as fixed particles, while in reality
electron clouds are constantly deforming depending on their environment. Al-
though computationally more expensive, the development of such polarisable
force field is currently ongoing, including all-atom [83, 84] and course grained [85]
optimised parameters.
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2.3.2 Force field accuracy
The precision of molecular modelling simulations relies considerably on the quality
of the underlying force field parameters that describe the total potential energy in
a system. Mixing force fields from different roots is highly inaccurate, though there
are some exceptions to this rule [86, 87]. Hence, the force field choice and selection
of parameters found in the literature is one of the most important preparations for
a computational chemist conducting MD simulations.
Due to the recent increase in computational power and development of advanced
algorithms, the simulation of much longer time scales uncovered force field inaccu-
racies, such as force fields that are either "too α-helical" [60, 88, 89] (i.e. overstabilise
α-helices in proteins compared to experiments) or contain dihedral parameter
errors [64]. Hence, many force fields are optimised continuously by a meticu-
lous refinement of the parameters through quantum mechanical calculations and
careful comparison with experimental measurements. The force fields used in
this thesis are OPLS/AA and AMBER ff99SB, which are both all-atom force fields
with a similar functional form. The latter was obtained by adjustment of the
backbone dihedral terms to reduce the overstabilisation of α-helical conformations
[60] and has been put forward as the force field of choice for simulations in
the microsecond time scale [90]. The ff99SB force field has been further refined
into AMBER ff99SB-ILDN, which contains adjustments for the side chain tor-
sional parameters of isoleucine, leucine, aspartate and asparagine residues (hence
the suffix "ILDN"). Those residues displayed significantly different rotameric
distributions compared to statistics in the PDB and were accordingly corrected
with new quantum mechanical calculations [91]. While this force field contains
optimised parameters for side chain potentials, additional energy modifications
of the backbone torsions were recently introduced to generate more balanced α-
helical propensities in MD simulations [92], resulting in the AMBER ff99SB*-ILDN
force field [93]. In parallel, the CHARMM force field received similar backbone
dihedral corrections, yielding CHARMM22* [93], and modifications to the side
chain torsional parameters, designated CHARMM36 [94]. Similar corrections were
recently made to the GROMOS parameter set as well [95].
Because there are many force fields available, which one should we select? Because
each force field is inherently an approximation, the answer to this question de-
pends of course on the scientific questions posed in advance. To this end, a number
of systematic comparison studies have been performed to simplify answering that
question. Some focus specifically on the folding [93, 96, 97] and denaturation [98]
of proteins and/or use experimental validation by comparing with hydration free
energies [99, 100] and with NMR spectroscopy data [90, 101, 102]. In addition,
comparative force field studies have been performed for specific cases, such as the
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reliability of nucleic acid force fields [103], the formation of hydrogen bonds [104],
secondary structure tendencies [105–108] including residue specific propensities
[109] and interactions between amino acid side chains [110]. Of course, simply
investigating force field parameters can be misleading, as proteins are always
immersed in a medium. Consequently, a number of noteworthy studies inves-
tigate the reliability of implicit [111–113] and explicit [114, 115] solvent models,
protein-water interactions [116, 117] and lipid force fields [118–120]. In addition
to force field parameters, the reader should also remember that algorithm imple-
mentations, electrostatic schemes like PME, box sizes and equilibration protocols
can differ between all the above mentioned publications, which irrefutably impact
experimental validation as well. Also, modelling failures are sometimes not
caused by force field deficiencies, but rather by insufficient sampling of the protein
conformational space. We will explain this "sampling" problem more in detail in
the next section.
2.3.3 Sampling
MD simulations, just like experimental biophysical methods, are affected by spa-
tiotemporal limitations. For experimental methods one tries to increase the res-
olution to investigate smaller or faster processes, while the resolution of MD
simulations is already high, but the simulation of larger systems and/or longer
processes requires a much higher computational cost. Hence, the limitations of MD
simulations in space and time are reversed compared to experimental methods (as
illustrated in Figure 2.2). Sampling problems in MD are related to the difficulty
in spanning these large time scales. While force field inaccuracies are commonly
held responsible, it has recently become more and more clear that inappropriate
sampling can explain observed deviations from experiments [27].
How can we increase the sampling of biomolecules to longer time scales? Nowa-
days, a MD simulation of a small protein can be calculated for several nanoseconds
on current desktop and laptop computers. But solving the equations of motions in
a system is a complicated task, which involves solving the many different force
field terms sequentially. The computational demand of MD simulations increases
exponentially with the system size due to the pairwise non-bonded terms. As
a result, sufficient conformational sampling of the energy landscape for larger
complexes requires longer time scales. Choosing an appropriate representation
as mentioned above can already reduce the spatiotemporal limitations. However,
simulations in the range of microseconds and more and systems containing more
than 100 000 atoms are currently only feasibly with high performance comput-
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ing (HPC) infrastructure.1 It is only recently that technological advances have
increased the limit of biomolecular systems accessible by MD simulations, thereby
allowing a broader overlap regarding the spatiotemporal resolution compared
to experimental techniques. Clusters have been designed with unique chips and
architecture optimised for MD simulations such as MD-GRAPE [121] and Anton
[122]. Also, the advent of distributed computing such as folding@home [123, 124]
and GPUGRID [125] allows the generation of many separate MD simulation
trajectories.2 Here, volunteers who have installed distributed computing software
on their system dedicate idle CPU and/or GPU time to solve scientific questions in
biochemistry, such as the folding of proteins or the binding of ligands to receptors.
In additions, a large number of software developments such as parallelisation of
the MD code and implementation of faster algorithms have increased the time
limit accessible by MD simulations.
That of course raises the question: is the thermodynamic ensemble in the simulated
system sampled sufficiently? For this, statistical analysis can be applied to ensure
whether a thermodynamic ensemble is converged in time, i.e. if all relevant states
have been probed adequately [126]. In addition, the construction of Markov
state models (MSM) [127] allows a direct evaluation of the degree of sampling
in a system by resolving measurable statistical properties from the simulation
ensemble. It is expected that methods based on statistical relevance will become
increasingly important in the field of biomolecular simulations.
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Chapter 3
Binding free energy calculations
"In An Isolated System; The
Entropy Can Only Increase"
The 2nd Law - Muse
3.1 Introduction
Without thorough analysis, a MD simulation is merely a suggestive and expensive
movie. We will illustrate an important analysis applied to MD used throughout
this thesis: the quantitative estimation of the binding free energy between two
interacting particles. Investigation of the binding between molecules is one of
the most fundamental aspects in biophysical research, as molecular recognition
is essential in practically all biological processes. Extracting binding free ener-
gies from molecular simulations is thus potentially interesting to understand
underlying processes at the atomic scale. The affinity of biological systems can
be estimated when thermodynamic measurements in experiments are unfeasible.
In addition, measuring binding free energy values with an appropriate precision
could significantly reduce the need of those wet lab experiments, which are often
expensive, difficult and time-consuming.
For these reasons, there is a lot of interest from the pharmaceutical industry to
accurately predict biological activities using in silico methods. Because drug devel-
opment is a highly time-absorbing task (requires usually more than 10 years) and
expensive (costs approach one billion dollar per drug on the market), computer-
aided drug design (CADD) can be applied to speed up the process. For example,
binding free energies of potential drugs in interaction with the target of interest can
be evaluated. Previously, traditional screening of drug molecules did not rely on
any protein target information. Currently however, pharmaceutical companies are
incorporating rational design strategies in their drug discovery pipelines to com-
plement or even replace traditional screening techniques. To this end, it is crucial
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to obtain trustworthy predictive models of the binding affinity between potential
hit molecules and their respective targets, to discard low potency compounds and
inquire optimisation strategies.
Typically, computational methods are used in multiple stages of the drug discovery
pipeline. In the early stages, virtual screening methods can be applied to identify
initial "hits", that is, a small molecule that binds effectively to the target of interest
and is a good candidate to optimise further into an effective drug by modifying
molecular properties. In these stages, extensive virtual molecular databases can
be screened, which requires fast computational filtering techniques. The time
spent to evaluate a single compound must be short but may affect the reliability
of the applied scoring function. However, once interesting hits have been found,
designated as "lead" molecules, the accurate prediction of binding affinities be-
comes more important than speed. To optimise the initial hits and its properties
using sequential chemical remodelling, effective ranking of good and weak affinity
molecules is needed. These affinity scores can subsequently be correlated with
the structural characteristics of the molecules, for example in structure-activity
relationship (SAR) studies.
The first computational binding free energy methods were developed in the late
1980s and initially resulted in high expectations. It was envisioned that researchers
in the near future would be able to simply push a button on a computer, which
swiftly and accurately would offer a solution of a putative drug. In retrospect,
these exceptions were probably way too high, as the high number of failures
surpassed the number of early successes. Looking back, it is clear that significant
hurdles had to be surmounted due to limitations at that time. Despite recent
progress, there are still many question and challenges to be solved. Many re-
searcher are now developing and optimising algorithms and tools to accurately
describe non-covalent interactions by enhancing sampling techniques and utilising
recent progress in computer hardware.
In the ideal case, the computationally calculated binding affinities would deviate
from the experimental measurements by just 1 to 2 kcal mol−1 [1]. Although
an accurate estimation of binding affinity has been considered a "holy grail" in
computational chemistry for many years [2, 3], we are still far from achieving
this goal with the current set of algorithms. Binding free energy calculations are
challenging due to the large number of interactions that need to be computed.
Moreover, chemical effects such as protonation state and tautomeric conformations
can be important. Other issues are the many degrees of freedom of the molecules
involved, the reduction of conformational entropy upon binding, and the approx-
imations present in the applied force field and solvent models. Consequently,
a binding affinity analysis of a range of compounds should always take these
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challenges and limitations into account, as frequently one of these gives rise to
deviations from experimental affinities. An incorrect ranking of drug molecules
can subsequently result in misguided and unsuccessful drug design strategies.
Generally, three different approaches can be distinguished. First, exact methods
or so-called "alchemical" methods apply statistical mechanics to compute binding
free energy differences between bound and unbound states of a receptor/ligand
pair using a non-physical pathway (hence the term "alchemical"). These meth-
ods are considered the most rigorous and accurate to estimate relative binding
affinities. Unfortunately, the calculations require a considerable amount of con-
formational sampling to obtain thermodynamically converging results, especially
on larger protein/ligand complexes. That makes exact methods computationally
consuming and is worsened even more when highly dissimilar ligands are com-
pared. Examples of that class are thermodynamic integration (TI), free energy
perturbation (FEP) and Bennet’s acceptance ratio (BAR) [3–6]. Second, so-called
pathway methods determine absolute binding free energy values by displace-
ment of a ligand along a reaction coordinate, generating a potential of mean force
(PMF). These pathways can be generated using steered MD (SMD) [7], umbrella
sampling [8–10] or metadynamics [11]. Third, so-called endpoint methods are
considered more approximate and only require simulations of the bound and un-
bound state of the ligands. Hence, the latter technique is more efficient for larger
molecules such as peptide binding or scrutiny of protein-protein interactions.
Molecular mechanics/Poisson-Boltzmann surface area (MM-PBSA), molecular
mechanics/generalised-Born surface area (MM-GBSA) and linear interaction en-
ergy (LIE) are examples of that class [5, 6, 12, 13].
Due to the relatively large size of the ligands and proteins investigated in this
manuscript, exact and pathway methods are outside the scope of this thesis and
are discussed more in detail in the following review articles [1, 14–16]. A number
of articles discusses the implementation, application and differences between
those binding free energy methods [4, 17, 18]. Below, we will give a summary of
the theory behind non-covalent binding and the approximate binding free energy
methods used in this thesis, including an emphasis of the applications and current
limitations.
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3.2 Theory of non-covalent interactions
3.2.1 Kinetics
Considering two molecules in solution, the reversible binding of both molecules
can be expressed as a chemical reaction by:
A+B kon−−−⇀↽ −
koff
AB (3.1)
Here, A is the first free molecule, B is the second free molecule and AB is the
complex of both molecules. These two molecules can be either kind, for example
two proteins of similar size, a protein-peptide interaction or the binding of a
ligand into a protein cavity. The kinetics can be expressed using a first-order
model with kon and koff the rate constant for respectively association of A and
B and dissociation of the AB complex. Upon equilibrium, a combination of A, B
andAB will exist in the system. The equation can be written using the equilibrium
association constant Ka, or conversely the equilibrium dissociation constant Kd:
Ka =
1
Kd
= kon
koff
= [AB]eq[A]eq[B]eq
(3.2)
where [AB]eq , [A]eq and [B]eq are the concentrations at equilibrium of the complex
AB and the constituents A and B. Higher values of Ka thus indicate a larger
attraction between both molecules. Consequently, Ka is a measure of the binding
affinity. However, usually Kd is applied to compare binding affinity values: a
compound with nanomolar affinity (10−9 M) is therefore a stronger binder than a
compound with only micromolar affinity (10−6 M).
3.2.2 Thermodynamics
The association constant Ka can be expressed thermodynamically in terms of the
concentration-independent Gibbs free energy of binding in standard experimental
conditions (i.e. room temperature and 1 atmospheric pressure in a NPT ensemble)
using the van’t Hoff equation:
∆G◦bind = −RTlnKa (3.3)
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Here, R is the ideal gas constant and T is the temperature. For clarity, each ∆Gbind
in this manuscript refers to a binding free energy in standard conditions ∆G◦bind.
Relating the Gibbs free energy with the equilibrium constant shows that higher
Ka values, and hence higher concentrations of complex at equilibrium, result in
more negative ∆G values. A reaction can occur spontaneously with a negative
∆G (known as an exergonic reaction), while reactions with a positive ∆G value
do not proceed spontaneously (known as an endergonic reaction) and require
coupling to a favourable reaction. Or to put in other words: if the free energy of
the complex AB is smaller than the sum of its constituents (A and B), then the
reaction will occur spontaneously until an equilibrium is reached:
∆G◦bind = G◦AB −G◦A −G◦B (3.4)
While the above equation results in an absolute binding free energy difference
for one complex (∆G), it is typical to compute the relative binding free energy
difference between different complexes (∆∆G). For example, ligands can attach
to a receptor in a wild type and a mutated form. In that case, the relative binding
free energy difference is calculated from the absolute binding free energies of
the wild type and the ligand (∆G◦bind1) and mutated receptors and the ligand
(∆G◦bind2) (as illustrated in Figure 3.1). Conversely, the receptor conformation can
remain similar to compare the affinity of different ligands.
∆∆G◦bind = ∆G◦bind1 −∆G◦bind2 (3.5)
= ∆G◦wt −∆G◦mutant (3.6)
Binding reactions have kcal mol−1 as unit. It must be emphasised that even small
changes in free energy may lead to substantial effects in binding constant values.
A convenient rule of thumb is that a tenfold increase in the binding constant Ka
corresponds to an increase in binding affinity of only 1.4 kcal mol−1. Note that
the rate of the reaction does not depend on favourable thermodynamics, but is
regulated by the kinetic rate constants described above (equation 3.2).
A thermodynamic profile of a binding reaction indicates the predominant forces
that drive binding between molecules. The binding free energy value ∆G can be
decomposed in changes in enthalpy (∆H) and changes in entropy (∆S):
∆Gbind = ∆H − T∆S (3.7)
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Figure 3.1: Illustration of a binding free energy calculation of a protein-protein interaction. ∆∆G◦
is the relative binding free energy between the absolute binding free energy of the wild type pro-
tein complex (∆G◦wt) and the absolute binding free energy where one of the proteins is mutated
(∆G◦mutant).
Characterisation of a binding reaction thus depends on the determination of
the enthalpy and entropy components at a specified reference temperature and
pressure. Every system seeks to achieve a minimum in free energy, therefore the
enthalpy changes should be large and negative, while entropy changes should
be large and positive. We will discuss the meaning of each thermodynamic term
more in detail below.
3.2.3 Enthalpy
Enthalpy is defined as the thermodynamic quantity equivalent to the total heat
content of a system.
H = U + pV (3.8)
withU the internal energy, p the pressure and V the volume of the system. Favourable
enthalpy changes upon binding arise from stronger interactions between the bind-
ing molecules relative to interactions with solvent molecules.
∆Htot = ∆Hcoul + ∆Hvdw + ∆Hsolv1 (3.9)
1Those terms contribute to free energies (G), where entropic effects are also taken into account.
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These interactions are van der Waals interactions (∆Hvdw) and electrostatic inter-
actions like hydrogen bond formations (∆Hcoul). If the enthalpy is negative and
thus favourable, then the interactions between the binding molecules are stronger
than the interactions with the solvent molecules (∆Hsolv). Otherwise, the enthalpy
term will be positive and unfavourable.
We must emphasise that a quantitative amount of hydrogen bonds is not sufficient
to calculate the hydrogen bond energy in ∆Hcoul. The qualitative strength of each
bond depends on the optimal distance, angle and charge of the donor-acceptor
pair compared to inhibitor-solvent interactions [19]. Hydrogen bonds should
thus be aimed at already structured regions of the protein. Also, the formation of
multiple hydrogen bonds can decrease the mobility of an inhibitor in the binding
pocket, resulting in a smaller conformational entropy (see below), which indirectly
improves the binding affinity between both molecules even further. Thus, the
enthalpy is considered as a specific term due to directionality and proper location
of hydrogen bond acceptors and donors between protein and binding partner.
Finding selective drugs is therefore defined mostly by the enthalpy term and not
entropy.
The solvation term, ∆Hsolv , is unfavourable for the enthalpy if interactions of the
molecule with the solvent are stronger than with the binding partner. Addition
of polar groups to introduce additional hydrogen bonds with the protein target
does not always enhance the binding affinity of an inhibitor due to a desolvation
penalty. This penalty states that positive and therefore disadvantageous enthalpies
arise from transfer of polar groups from the solvent to the (usually hydrophobic)
protein binding pocket. Thus, strong interactions of the molecule with the target
are usually required to compensate for the unfavourable desolvation penalty of
the polar groups.
3.2.4 Entropy
Entropy is considered as a measure of disorder of a system. The first law of
thermodynamics assumes that the total energy of an isolated system is always
constant. In addition, the second law of thermodynamics states that the total
entropy of a system and its surroundings will always increase for a spontaneous
process until a thermodynamic equilibrium is reached:
∆S
∆T ≥ 0 (3.10)
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In binding reactions, entropy plays an important role for reaching the equilibrium
state. A number of terms contribute to the total entropy:
∆Stot = ∆Ssolv + ∆Sconf (3.11)
Entropy changes between biomolecules arise from two contributions, the con-
formational entropy (∆Sconf ) associated with the loss of conformational degrees
of freedom upon binding of both reaction partners, and the solvation entropy
(∆Ssolv) related to the burial of hydrophobic groups from the solvent.
The conformational or configurational entropy ∆Sconf can be explained as fol-
lows. A flexible linear ligand will adopt an ensemble of conformationally flexible
molecules in solution and will therefore greatly reduce its conformational entropy
upon binding. Consequently, a high number of rotational and translational degrees
of freedom is unfavourable for binding. In contrast, constrained molecules with
relatively few rotatable bonds will only adopt a limited amount of conformations
and will consequently only have a marginal conformational entropy penalty upon
binding. Hence, a possible drug optimisation strategy is the introduction of
conformational restraints in the binding molecule such that the conformational
space of the free and bound states is more alike. Note that residues in the protein
target become restricted in their mobility as well upon binding, which is also
entropically disadvantageous.
While the conformational entropy is usually unfavourable, the desolvation entropy
∆Ssolv on the other hand is one of the most favourable contributors to binding.
A number of water molecules are expelled from the protein binding site upon
binding of a ligand. This desolvation process increases the degrees of freedom
in the system, which consequently increases the entropy term by becoming more
positive and thus more beneficial to binding. The binding molecule properties
contribute to the desolvation entropy term as well because many hydrophobic
forces become buried from an aqueous environment upon binding. This process,
designated as the hydrophobic effect, is also an essential driving force of the
folding of proteins. Here, hydrophobic residues become buried by an entropically
favourable process.
In drug design, the desolvation entropy term is correlated with the hydrophobicity
of the compound. To increase the potency of a potential drug molecule, it is
therefore common to increase the hydrophobicity by attachment of apolar groups
or replacement of polar into apolar functionalities. However, the hydrophobic
character cannot increase without limit, because the molecule will become insolu-
ble and therefore useless as a drug molecule at a certain hydrophobicity level. In
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addition, some hydrophobic groups can become overexposed to the solvent even
when binding to a narrow binding pocket, leading to an unfavourable solvation
entropy.
Finally, we must highlight that, in contrast to enthalpy, entropy terms are non-
specific due to the lack of specificity of hydrophobic forces. Hence, maximal
affinity are usually only obtained when both the enthalpy and entropy changes
are optimised simultaneously.
3.2.5 Enthalpy-entropy compensation
In contrast to the enthalpy term, the entropy component has been proven to be
much easier to optimise. Enthalpy is more difficult to modulate because individual
molecular interactions between drug and target like hydrogen bonds need to
be known precisely. These unexpected changes are often difficult to interpret
and to alleviate [20–22]. Because a number of terms are responsible to obtain a
final binding affinity (as described above), entropy and enthalpy are intrinsically
coupled. As a result, a notorious problem in drug optimisation strategies is
that modifications to improve one term can be mitigated by an increase of other
unfavourable terms. This process, called enthalpy-entropy compensation, is an
infamous issue in drug optimisation studies [23–25]. Two drug molecules with
different enthalpy and entropy profiles can have similar binding affinities. In fact,
compounds that exhibit extremely high affinity can possess both beneficial entropy
and enthalpy contributions. As a result, the total binding free energy, including
the entropy, is preferably included to rank the potency of inhibitors. Except when
the entropic or enthalpic nature of a series of compounds is already known in
advance, studies ignoring one of these components can give misleading results,
thereby disrupting a drug design optimisation trial [23, 24, 26].
3.3 Experimental methods
Note that absolute total free energies (G) cannot be measured directly and there-
fore only absolute differences (∆G) between states are obtained from experiments.
Association constants can be measured with many experimental techniques such
as fluorescence spectroscopy, ultracentrifugation, binding assays, isothermal titra-
tion calorimetry (ITC), surface plasmon resonance (SPR) and consequently the
calculation of the reaction binding free energy of a reaction. In addition, the
binding enthalpy can be estimated using spectroscopic techniques by performing
experiments at different temperatures using the van’t Hoff equation (equation 3.3).
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However, these van’t Hoff enthalpies are sometimes difficult to obtain and suscep-
tible to experimental errors and artefacts compared to calorimetric enthalpies.
We will explain here shortly the principles and advantages of ITC. It is a useful
technique to simultaneously obtain the stoichiometry, association constant, the
enthalpy and entropy of two distinct molecules upon binding [27–29]. In ITC,
a solution of dissolved molecules is injected incrementally into a reaction cell
containing the binding partner. Each injection generates an amount of heat and the
binding enthalpy is subsequently calculated from the amount of power required
to maintain a constant temperature difference between the reaction cell and a
reference cell. Interestingly, ITC is the only method to measure both enthalpy
and entropy contributions coincidently, so that complexes with similar binding
free energy values though different enthalpy and entropy contributions can be
distinguished. In addition, ITC does not depend on immobilisation of one of the
binding components, in contrast to SPR, but derives affinities from biomolecules
in solutions.
SPR is an other effective method to determine binding free energies experimentally.
With SPR biosensors, a molecule of interest is immobilised on a metal sensor
surface. The binding partner of the immobilised molecule is subsequently injected
onto the surface. The SPR instrument will measure electromagnetic wave changes
due to binding of the soluble molecules with the immobilised target molecule
[30, 31]. The advantage of SPR is that both kinetic and thermodynamic parameters
can be extracted from a single experiment.
3.4 Approximate binding free energy methods
Molecular mechanics/Poisson-Boltzmann surface area (MM-PBSA) [13, 32, 33]
and molecular mechanics/generalised-Born surface area (MM-GBSA) [33–35] are
two similar binding free energy methods. Binding affinities can be estimated from
sufficiently sampled simulation trajectories, where snapshots (i.e. conformations
at specified time frames) from the molecules of interest are extracted in regular
intervals. Affinities can thus be calculated from a single simulation run. That
makes MM-PBSA and MM-GBSA popular methods for ranking of drugs.
These approximate methods are considered "endpoint" methods because they
are restricted to conformations before and after binding, and therefore do not
depend on intermediate states like exact methods. In addition, the application
of a thermodynamic cycle and a continuum representation of the solvent further
reduces the computational cost. Because both methods only differ in their solvent
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representation, we will refer to these methods as the MM-PB/GBSA method in
the discussion below.
The thermodynamic cycle and the continuum solvent models are computational
"tricks" to facilitate the calculation of a binding affinity. Most energy interactions in
a solvent immersed protein-ligand complex are caused by solvent-solvent interac-
tions, which obscure the binding affinities between protein and ligand. Calculating
an accurate binding free energy would require sufficiently long simulations to
reach converged energy levels due to the noise caused by small variations of the
solvent molecules. To this end, water and ions are stripped from the structures
after the all-atom simulation, and MM-PB/GBSA applies a thermodynamic cycle
to alleviate the solvent convergence issue. In this cycle, the solute is moved from a
vacuum to a continuum solvent environment. By replacing an explicit water model
with an implicit representation, the degrees of freedom in the solvent are reduced
significantly. This simplifies the estimation of solvent binding free energies. As a
result, although solvation free energy is sometimes unintentionally misspelled as
"salvation" free energy (see for example Mobley et al. [4, 36], Tan et al. [37], Chen et
al. [38], Moreira et al. [39] and Suenaga et al. [40]), MM-PB/GBSA can be regarded
as a "salvation" in the field of binding free energy methods by accelerating the
electrostatic calculations considerably. In aggregate, MM-PB/GBSA is several
orders of magnitude faster than exact methods like FEP and TI.
3.4.1 Implementation
MM-PB/GBSA is one of the most well-known binding free energy methods. It
estimates binding free energies by combining classical molecular mechanics, con-
tinuum solvent methods and conformational entropies. Comparable to equation
3.4, the absolute binding free energy ∆Gbind is derived from the free energy of
the complex (GAB) minus the receptor (GA) and ligand (GB) free energies. Free
energy is a state function and therefore identical free energy differences can be
calculated from different routes between states. This principle is applied in the
thermodynamic cycle shown in Figure 3.2, where the binding free energy of each
molecule is determined by a combination of enthalpic and entropic contributions.
The average free energy of a state in each environment is approximated by:
Gtot = GMM +Gsolv − TS (3.12)
Gsub−tot = GMM +Gsolv (3.13)
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Figure 3.2: A thermodynamic cycle applied in a typical MM-PB/GBSA setup.
Here, the total free energy Gtot is calculated by summation of the molecular
mechanics free energy (GMM ), solvation free energy (Gsolv) and configurational
entropy (−TS). The entropy term −TS is usually neglected in a standard MM-
PB/GBSA approach. In that case, not a total binding free energy (Gtot) but rather a
partial subtotal binding free energy (Gsub−tot) is estimated. Such an approximation
is warranted when the conformational entropy is negligible, for example when ge-
ometrically constrained ligands are compared or the conformations of the ligands
do not differ from each other significantly.
The meaning of each term in equation 3.12 is explained below.
Molecular Mechanics
The molecular mechanics term in MM-PB/GBSA, GMM , is simply calculated from
the internal energy (Gb), van der Waals (Gvdw) and electrostatic interactions (Gcoul)
in a standard force field using no non-bonded cut-offs (see equation 2.1):
GMM = Gb +Gvdw +Gcoul (3.14)
Because GMM is usually determined in the gas or vacuum phase, that term is
referred to as the gas phase (Ggas) or vacuum free energy (Gvac). In principle,
GMM can also be replaced with quantum mechanics (GQM ) if a higher precision
is wanted, for example in the active site of a protein [41].
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The internal bonded energy Gb is ignored when complex, receptor and ligand
conformations are extracted from the same simulation trajectory. We will discuss
the considerations of that approach more in detail in section 3.4.3.
Solvent models: Poisson-Boltzmann and generalised Born
The solvation free energy Gsolv is more difficult and time-consuming to calculate
and is determined by transferring each system (free ligand, free receptor and
complex) separately from the gas phase into the solution phase (as depicted in
Figure 3.2). It is composed of polar (GPB or GGB) and apolar components (GSA):
Gsolv = GPB/GB +GSA (3.15)
The polar term is usually referred to as the electrostatic or polarisation energy
component of the solvation free energy. We will explain the meaning of this term
more in detail in this section. In principle, electrostatics can be solved using the
Coulomb’s law (equation 2.8). Unfortunately, this law does not consider changes
in dielectrics when molecules are transferred between different environments. As
a consequence, Coulomb electrostatics are unsuitable in this context. Therefore,
the polar solvation energy should be calculated by a continuum method instead,
such as Poisson-Boltzmann (GPB) or generalised Born (GGB). The basic principles
of electrostatics in proteins are summarised in a number of review articles [42–47],
including emphasis on implicit solvent models [48–52] like PB [53–56] and GB
[57, 58].
In MM-PBSA, the polar solvation term is obtained from a numerical solution of
the PB equation. This is a partial differential equation of the molecular electrostatic
potential, which depends on the function and position of atomic charges, the
dielectric constant in relation to the position of the charge, and the ionic strength
of the medium. It yields the polarisation energy, i.e. the energy difference of
transferring a molecule from the gas phase to an aqueous phase (with different
dielectric constants in both phases).
The calculation can be understood by first outlining the rigorous Poisson’s equa-
tion of a dielectric medium:
∇[(r)∇φ(r)] = −4piρ(r) (3.16)
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Here,  is the space-dependent dielectric constant or relative permittivity of the
medium, φ is the electrostatic potential, r is the position vector, ρ(r) is the charge
density in the medium and∇ is the differential operator using Cartesian coordi-
nates.
The dielectric constant is a term that describes the polarisability of a medium,
for example by applying an electric field on a system. In continuum models, the
protein is considered as a continuum medium with low polarisability (p = 1− 4,
in vacuum, though even values of 20 have been reported) enclosed by the solvent
with a continuum medium of high polarisability (w = 78− 80, which is typical
for water). Water has a high dielectric constant because the dipole moments of
the water molecules will rapidly orient parallel to each other under the influence
of the field. In contrast, a much weaker dipole moment is present in proteins
despite the presence of charged and polar side chains depending on the amino
acid composition. The polarisability of a protein is therefore mainly restricted
to electronic redistributions, which result in a much lower dielectric constant
than water. It is important to note that the protein’s dielectric constant p, often
termed the internal dielectric constant, is not a universal constant but is basically
a parameter that depends on the specific model used [59].
If the charge distribution is written in terms of a set of fixed point charges, then
solving the Poisson equation fundamentally results in the law of Coulomb (see
equation 2.8). To account for the mobile ionic strength in the medium and by
assuming that these ions are dispersed according to a Boltzmann distribution, a
Boltzmann factor can be added to the Poisson equation, yielding the so-called
nonlinear Poisson-Boltzmann formula:
∇[(r)∇φ(r)] = −4piρ(r) + (r)κ2sinh(φ(r)) (3.17)
where κ2 is the Debye-Hückel screening constant representing the ionic strength
of the solution. The equation can be linearised to reduce the complexity and thus
to facilitate the calculation:
∇[(r)∇φ(r)] = −4piρ(r) + κ2φ(r) (3.18)
The linearised and approximated Poisson-Boltzmann equation is sufficient for
most applications and can be solved analytically by mapping a system on a three-
dimensional cubic grid. The parameter values required for solving the PB equation,
such as the charge density, dielectric constant and ionic strength, are assigned to
each lattice point (representing biomolecule or solvent). A fine grid is necessary
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to obtain accurate electrostatic values but also increases the computational cost,
hence a trade-off should be found between lattice grid size and reliability of
the calculation. Ultimately, the PB equation yields the electric field around a
macromolecule, which is important for attraction/repulsion of ligands in many
protein recognition processes. Furthermore, it can be used to estimate solvation
free energies, as outlined here.
The solvation process is mimicked by transferring the molecules of interest from
a dielectric continuum of low polarisability to a dielectric medium of high po-
larisability. Hence, the polar solvation free energy should be solved twice. Two
dielectric constants yield two different electrostatic potentials; the difference be-
tween those potentials is designated by the reaction field energy:
φreac = φsolv − φgas (3.19)
From that equation, the polar component of the solvation free energy can be
written as:
∆GPB =
1
2
∑
i
qiφreac(ri) (3.20)
where qi is the charge assigned to each grid point i. This equation is implemented
in the AMBER package to determine solvation free energies and in consequence
binding free energies between two biomolecules. In addition, it can be calculated
with stand-alone packages like DelPHI [60] and APBS [61].
A simplification of continuum treatment is the generalised Born (GB) method.
GB is based on the principle that the dielectric screening of interactions between
point charges is correlated with the amount of interaction of the charge with
neighbouring water molecules. Due to that simplification, GB is considerably
faster than PB [49], though is still able to capture as much as possible the physics
of the Poisson equation. The electrostatic contributions to the solvation free energy
as written in equation 3.20 can be approximated with the Born formula for a single
particle with charge q and radius a as:
∆GBorn = − q
2
2a (1−
1
solv
) (3.21)
The generalised Born model can subsequently be obtained by "generalising" the
Born formula over a system of many atoms of arbitrary shape. Or in other words:
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multiple partial charges with respective radii are "fused" together and treated as a
set of spheres:
∆GGB = −12(1−
1
solv
)
N∑
i,j
qiqj
f(rij , aij)
(3.22)
with aij the Born solvation radii of the atoms and f(rij , aij) a Gaussian function
that generates the "effective Born radius" by characterising the degree of burial of
the molecule. The latter term reflects the distance between the point charge and
the edge of the solvent and depends not only on aij but also on corresponding
radii and positions of neighbouring atoms. Accurate estimation of the effective
Born radius is essential to assign boundary conditions and therefore explains most
differences between the developed GB models.
The GB contribution is often termed as the solvent-induced reaction field energy,
because it corresponds to the favourable energy generated by the solvent in
response to a charge. Due to its theoretical foundation, PB methods are considered
as the benchmark and often the accuracy of GB methods is assessed by comparison
with PB calculations. Most GB models show close agreement with corresponding
PB calculations [62–64].2
Surface Area
The apolar solvation term GSA is derived from the solvent-accessible surface area
(SASA) of each molecule [65]:
GSA = γSASA+ b (3.23)
Here, γ is an empirical surface tension constant, while b is an additional empirical
parameter, both derived from experimental solvation energies. In this manuscript,
we applied the ICOSA technique for the SASA determination [66]. The SASA of
complex, receptor and ligand are measured using a probe radius (usually between
1 to 1.5 Å) that determines the boundary surface between molecule and solvent.
The term will fluctuate in time and can be averaged from the conformations of an
equilibrated MD trajectory.
The apolar term GSA can be understood in terms of the hydrophobic effect, an
entropically driven process. The more hydrophobic residues are buried upon
2We show in chapter 4 that the accuracy differences between MM-PBSA and MM-GBSA are
negligible for peptide-peptide interactions.
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binding (implying larger SASA values), the more favourable the apolar solvation
free energy. Consequently, GSA approximates the desolvation entropy ∆Ssolv
from equation 3.11. The proportionality of GSA to SASA is however limited to a
certain extent as it ignores subtle shape differences between molecules.
Configurational entropy
Configurational entropy, a measure of the relative disorder in a system, requires
global sampling of the conformational landscape and is therefore considered as
one of the most difficult terms to estimate. Nevertheless, configurational entropy
effects can contribute considerably to binding energy values [67]. There are multi-
ple ways to approximate that entropy using simulations, albeit rather qualitatively.
The method applied in this thesis is the quasi-harmonic approximation of the abso-
lute entropy, which assumes that the fluctuations in a system can be approximated
by a multivariate Gaussian probability distribution.
The true entropy of a system can be approximated from a collection of indepen-
dent harmonic oscillators i of corresponding frequencies ωi using the following
probability distribution:
Sho = kB
3n−6∑
i
λ
eλ − 1 − ln(1− e
−λ) (3.24)
where the eigenvalues λi are obtained from corresponding quasi-harmonic fre-
quencies ωi:
λi =
1
2pi
√
kBT
ωi
(3.25)
These frequencies are calculated from diagonalisation of the covariance matrix
(σik) of the mass-weighted atomic coordinate fluctuations:
σik =
√
mimk〈(xi − 〈xi〉)(xk − 〈xk〉)〉 (3.26)
with m and x respectively the masses and coordinates of the atoms in the system
after least square fitting of all MD trajectory snapshots to the protein atoms.
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The vibrational entropies are calculated in both bound (AB) and unbounded (A,B)
conformations to yield the configurational entropy changes upon binding:
− T∆S = −T (SAB − SA − SB) (3.27)
Alternatively, a normal mode (NM) analysis can be conducted. This method
derives the entropy from the second derivative of the potential energy from a single
minimised conformation. A drawback of this approach is that artefacts can arise
during the minimisation step, which is a prerequisite of conducting NM analysis.
The approach is also restricted to a local region of the configurational space and
is therefore not applicable to solvated molecules with high mobility. In contrast,
quasi-harmonic analysis attempts to characterise the global configurational space
of a molecular system by sampling multiple potential wells [68], yet also bears a
number of disadvantages. Obtaining convergence is intrinsically complicated due
to anharmonicity in the phase space. The eigenvectors of a peptide system have
been shown to converge rather slowly in one microsecond of simulation time [69].
Reliable entropy estimates are more difficult to obtain for protein systems [70, 71].
In fact, it has been suggested that convergence could not be achieved for larger
proteins even on a millisecond time scale [72], which implies that estimations can
only provide an indication of the true entropy of larger systems.
Summary
For clarity, we will summarise the different contributions of the MM-PB/GBSA
method to the calculated binding free energy values below:
Gtot = GMM +Gsolv − TS (3.28)
= GMM +GPB/GB +GSA − TS (3.29)
= Gb +Gvdw +Gcoul +GPB/GB +GSA − TS (3.30)
with Gele−tot = Gcoul +GPB/GB (3.31)
and Ghyd−tot = Gvdw +GSA (3.32)
Often, the total electrostatic energy of a molecule (Gele−tot) is derived from the sum
of the internal electrostatic energy (Gcoul) and electrostatic solvation free energy
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(GPB/GB). In addition, the total hydrophobic binding force can be obtained from
the van der Waals energy (Gvdw) and apolar solvation free energy (GSA).
3.4.2 Applications
A number of excellent reviews discusses the methodology and applications of
MM-PB/GBSA methods in detail [13, 49, 51, 56, 73]. We will outline a selection of
notable examples and applications of MM-PB/GBSA in scientific research below.
Overview of research applications
Due to its lower computational cost compared to "alchemical" binding free en-
ergy methods, the MM-PB/GBSA method has become increasingly popular in
protein studies and drug design workflows. One of the first applications of MM-
PB/GBSA was a stability study by Srinivasan et al. [32], who calculated the
binding affinities of two helices in DNA and RNA duplexes. It was found that
the B-form of DNA is clearly more favourable than the A-form, in correlation
with previous experimental observations. The methodology was later extended
to protein-peptide [33], protein-protein [70, 74] and protein-ligand binding inter-
actions [75, 76].3 In the latter approach, MM-PB/GBSA is now commonly used
in conjunction with docking and MD simulations to estimate binding affinities of
a series of inhibitory compounds [77, 78]. As such, the method is implemented
to investigate the activity of known molecules. The method is also applicable
in prospective virtual screening protocols to identify potential drug candidates.
Good and weak inhibitors can be distinguished based on interaction energies with
the target protein. It has been demonstrated that MM-PB/GBSA considerably
outperforms current scoring functions in popular docking software packages [79].
MM-PB/GBSA can thus be implemented as a post-docking filter to allow a more
rigorous and accurate ranking of a selection of docked molecules [80, 81]. MM-
PB/GBSA is however significantly more demanding than basic scoring function
and is therefore frequently integrated in HPC systems to accelerate the binding
affinity calculations [82–84]. A recent example of an MM-PB/GBSA integrated
filtering approach is the discovery of promising small-molecule anticancer drugs
by Shima et al. [85].
While MM-PB/GBSA can be useful to seek prospective novel inhibitors, it can
also be applied to tackle drug efficacy complications like the emergence of drug
resistance. Wang et al. [86] instigated one of the first computation studies to explain
3In chapter 4, we apply binding free energy calculations on a peptide-peptide interaction using a
modified MM-PB/GBSA setup.
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the molecular basis of drug resistance of viral inhibitors against HIV-1 protease.
An agreeable level of correlation with experiments was found, despite a neglect
of the configurational entropy contribution. The correlation with experiments
was improved in later studies by including the entropy term [87]. The lessons
applied from drug resistance studies can subsequently be applied in current drug
design strategies to predict resistance mutations in proteins. Safi and Lilien [88]
for example have combined MM-PB/GBSA with Dead-End Elimination [89] to
identify mutations that potentially diminish drug binding.
The latest advances in both hardware and software have also allowed MM-PB/GBSA
investigation of much larger complexes, such as integral membrane proteins [90],
transporter proteins [91] and multimeric protein complexes [92, 93]. Conforma-
tional transitions can be explored based on the computed energy levels [94], for
example due to aggregation [95] or folding of proteins [96]. A novel approach is
the integration of MM-PB/GBSA in protein design strategies to distinguish highly
stable designer complexes from weaker ones [97, 98].
Energy decomposition of the binding affinity
An advantage of MM-PB/GBSA is that the energy terms can be decomposed into
the most important contributions to the overall binding affinity. Hence, it can
be elucidated whether binding between specific molecules is for example driven
by van der Waals interactions or merely by electrostatic effects. In addition, a
distinction between enthalpy and entropy components can be made, which can aid
the alleviation of enthalpy-entropy compensation issues (as described in section
3.2.5). MM-PB/GBSA can thus be very useful to reveal the dominant forces and
characteristics of a binding interaction.
Residue decomposition of the binding affinity
Another feature is that protein residues can be decomposed in terms of their
contribution to the overall affinity, identifying the hot spot residues in the binding
interface [66]. This is a useful application as it allows a straightforward comparison
of the amino acid binding contribution with experimental site-directed mutagene-
sis studies. Molecular mechanics, solvation free energy and even configurational
entropy contributions can be derived on a per residue level [99].4 Note that the
decomposition property can only be calculated by MM-GBSA because it is based
on a fully pair-wise potential, in contrast to MM-PBSA.
4In chapter 6, we perform a decomposition per residue of the binding interactions, where a
configurational entropy contribution is included.
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Computational alanine scanning
A similar approach to decomposition per residue is computational alanine scan-
ning [100, 101]. This methodology, where amino acids of the protein-protein
complex are mutated to alanine, identifies hot spot residues in the binding interface
[99, 102]. For example, the relative binding free energy difference of the wild type
and mutated protein are calculated. The results from the approach are compared
directly with experimental alanine scans, if available [103]. A disadvantage of the
technique is that mutations to alanine are not always directly linked to affinity;
mutations can directly destabilise the binding region, even when no close contact
with the binding partner is present. A decrease in affinity might therefore be
misleading if conformational rearrangements are neglected. However, alanine
scanning delivers similar results as binding free energy decomposition per residue
if the conformational changes are minimal [104]. Both methods are therefore
usually applied in a complementary fashion to compensate their drawbacks.
3.4.3 Limitations, challenges and considerations
While MM-PB/GBSA has been applied accurately in a broad variety of biomolecu-
lar studies [13, 73], it must be emphasised that a number of unsuccessful results
[105, 106] revealed unfortunate limitations and pitfalls of the method.
Length of the simulation
It has been shown that longer simulations do not necessarily result in better
correlations with experimental results [64]. This might simply be a convergence
issue, as in principle the most populated states have to be sampled sufficiently to
obtain accurate free energy values. Converging energy values is difficult because
fluctuations in both the ligand and the binding site need to be considered. The use
of an inconsistent force field where errors are propagated in longer simulations
would be another explanation. We must note that many initial MM-PB/GBSA
studies were performed with less accurate force fields (as discussed previously
in section 2.3.2), while the reliability of recent force fields have been improved
to a certain extent [107]. Furthermore, protein-ligand studies depend on a subtle
interplay between the ligand conformations and the rotameric states of the binding
site residues. Regarding force field accuracy, particularly the derivation of ligand
parameters can sometimes be questionable [108], while mixing force fields from
different roots may produce inaccurate energies in the simulation system [109].
Obviously, other ligand parameters such as protonation and tautomerisation state
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must be carefully assessed before relying on a MM-PB/GBSA affinity prediction
[110, 111]. The configuration of the protein may not be neglected as well, as it has
been demonstrated that errors in modelled protein structures can affect binding
affinity predictions significantly [106].
Simulation protocol
MM-PB/GBSA is commonly applied by extracting structures in regular intervals
(designated as snapshots) from an average ensemble generated by MD or MC
simulations. Although the binding free energy can in principle be calculated
from just a single structure, this strategy is inherently flawed as free energies are
by definition represented by all populations in the configurational space. Even
small conformational perturbations can result in significantly different binding
free energy values. In addition, it is not uncommon that multiple binding modes
can become apparent.
An important consideration is that the complex (AB), receptor (A) and ligand (B)
conformations should in principle be extracted from three independent simulation
trajectories. Alternatively, the conformations can be derived from just one MD
simulation of the complex AB, with individual receptor and ligand conformations
basically stripped from the same trajectory. This latter approach is actually applied
widely because it simplifies the calculation time considerably. In addition, binding
free energies calculations reach convergence much faster than the three-trajectory
approach. Internal energy contributions between complex, receptor and ligand
are cancelled (Gb in equation 3.14), which reduces noise in the energy levels. This
assumption unfortunately implies that the conformations of the molecules may
not change considerably upon binding. Consequently, using a one-simulation
MM-PB/GBSA protocol is not ideal if induced fit effects or other rearrangements
are expected. For example, the single trajectory approach is not recommended for
estimating configurational entropies [64], which highly depend on the conforma-
tional space of the complex, receptor and ligand conformations. As such, there is a
lot of debate in the literature whether the single [105] or three-simulation approach
[71, 103] is preferred. Alternatively, convergence of the one-simulation approach
can be increased by determination of an average binding free energy over multiple
copies of the same simulation system [103, 112]. An important rule of thumb is
therefore that the calculated binding free energy values can be reproduced from
multiple independent simulation trajectories.5
5In chapter 4 and 6, we perform each simulation in triplicate to verify the reproducibility of the
calculated affinities.
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The choice of the internal dielectric constant
Another issue of MM-PB/GBSA is the misconception between the protein’s dielec-
tric constant as a modelling parameter to determine polar solvation free energies
(p) and the dielectric constant in physical microscopic ensembles (¯) [46, 59, 113].
While the choice of the external dielectric constant is basically determined by
the solvent medium (such as water: w = 80), the choice of the internal dielectric
constant is less clear due to heterogeneity of the protein structure. The internal
dielectric constant parameter is in fact a misguiding term, as in reality the relative
permittivity will depend on the specific region within the protein and is therefore
never "constant". Hence, there is basically no universal dielectric constant that
can be applied on all protein systems. In principle, the dielectric constant value
should depend on the degree of molecular flexibility and the specific region
within a protein. In fact, it can be argued that, depending on the amino acid
composition, treating the protein as a dielectric continuum could be too deceptive.
For example, a higher protein dielectric constant value can be warranted when
computing protein-ligand binding free energies because surface exposed amino
acid residues are fairly flexible compared to the interior of the protein. Similarly,
the mobility of water molecules in protein binding pockets will be much smaller
than in bulk solvent, thereby limiting the polarisability of the binding site cavity.
A mixture of amino acid side chains and solvent molecules will guide the binding
site electrostatics calculation and therefore a representative dielectric constant
treating both protein and solvent characteristics should be applied. Consequently,
MM-PB/GBSA methods may lead to different results depending on the choice of
the internal dielectric constant, as shown by a protein-protein interaction study
by Dong et al. [114]. Follow-up studies also demonstrated that the optimal choice
appears to be system dependent and does not only depend on the receptor protein
but also on the ligands of interest [64, 81, 115].
A number of strategies have been suggested to improve the accuracy of the protein
dielectric constant. For example, charged residues are the primary driving force
of the protein’s dielectric constant, thus a higher dielectric constant can be found
near polar residues compared to hydrophobic groups [116, 117]. Charged residues
can induce a stronger electronic polarisation near the protein surface. To this end,
Archontis et al. [118] applied a two-step pathway for a charged ligand binding
event, using a low p-value for static insertion and an increased p-value for
relaxation of the environment. Similarly, multiple dielectric constants have been
applied to study electron transfer [119]. The principle of variable p-values has
also been implemented by Moreira et al. [39] on an alanine scanning mutagenesis
calculation. The size of the p-values was adapted to the type of the mutated
amino acid, which resulted in an improved correlation with experimental alanine
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scans.6 Another notable example is the simulation of lipid membranes, where
multiple p-values are justified as well. The hydrophobicity of the interior of the
membrane results in a decreased polarisable relaxation compared to the solvent.
Therefore, Tanizaki et al. [120] constructed a heterogeneous dielectric GB model,
where the p-value are adapted according to the location perpendicular to the lipid
bilayer. This layered dielectric constant approach was subsequently extended to
integral membrane embedded proteins [121]. Finally, it can be suggested that MM-
PB/GBSA calculations on amphiphilic proteins, which contain both hydrophilic
and lipophilic parts, would benefit from such an apparent dielectric constant
profile. An improved representation of the physical dielectric constant can thus be
obtained by splitting the amphiphilic protein in multiple continuums with distinct
p-values. Li et al. [113] have developed a smooth protein dielectric function to
account for such polarisability relaxation effects.
A critical concern is that MM-PB/GBSA estimations using implicit solvent can
differ significantly from explicit solvent measurements [122]. Implicit solvent
might be too crude in specific cases, thus inclusion of explicit water molecules
may be required [17, 123]. This is necessary when specific water molecules play
an important role in the protein dynamics and function. To reduce the compu-
tational cost, the amount of solvent molecules is limited by only considering an
explicit hydration shell around the ligand binding site [124] or by truncating the
protein system altogether [125]. In addition, attempts have been made to include
polarisability in exact binding free energy methods to improve consistency with
experimental results [126].
The importance of entropy
Small errors in the prediction of the entropy and enthalpy components can sig-
nificantly impact the total binding free energy difference. The configurational
entropy term is often overestimated and frequently blamed as the culprit in MM-
PB/GBSA failures. Unfortunately, evaluating these entropic contributions can be
cumbersome as the corresponding errors are often larger than the other binding
free energy terms [127, 128]. In fact, the term is sometimes excluded voluntarily
due to large standard deviation values, unrealistic entropy contributions or the
excessively high computational cost depending on the system size and entropy
estimation method. In contrast, neglecting entropic contributions has been con-
firmed to deliver less accurate relative binding free energies in a number of cases
6A similar strategy to improve the estimation of peptide-peptide binding free energies is applied
in chapter 4.
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[87, 104, 129, 130].7 Although there are numerous attempts to improve the reliabil-
ity of the entropic computations, for example with quasi-harmonic approximation
[69, 131] and NM analysis adjustments [132, 133], the configurational entropy
remains a difficult term to estimate.
Comparison with other methods
MM-PB/GBSA contains a considerable amount of approximations and therefore
improvement of one of the individual terms will not necessarily improve the
reliability of the total binding free energy estimates. To improve the binding
free energy methods, a number of studies compare different endpoint methods
with each other [62–64, 106, 115, 134, 135], with other more exact approaches
such as pathway [136] and exact methods [137–140], or with all three approaches
altogether [141]. While many of these review articles focus merely on differences
between the methods, each method has its advantages and drawbacks such as the
use of approximations (in endpoint methods) or the occurrence of sampling issues
(in pathway and exact methods). Hence, it must be stressed that binding free
energy methods are preferrably optimised by direct correlation with experimental
binding affinities.
Conclusion
Finally, we must underline that MM-PBSA and MM-GBSA are generally used
to rank the binding affinities between a series of interactions rather than give
accurate predictions of the absolute binding free energies. Relative binding free
energy calculations are generally more efficient due to cancellation of errors by
subtracting the absolute energy values. However, even these relative differences
can sometimes deviate from experimental values due to overestimation of the
energy terms. This effect is usually less concerning when not accurate binding free
energy values but rather distinction between good and weakly binding molecules
is needed, for example in a typical drug design workflow.
7We demonstrate in chapter 4 that ignoring the configurational entropy contribution for the
estimation of peptide-peptide free energies is not recommended.
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Part III
Results
Chapter 4 | Optimisation of VIRIP
In this chapter, we suggest and successfully obtain a number of improved VIRIP
derivatives by implementing a peptide-peptide optimised MM-PBSA virtual screen-
ing approach. The development and efficacy of the improved method is explained.
In addition, the interaction of VIRIP with its target, gp41 FP, is discussed in detail
and we outline a number of future directions.
The contents of this chapter have been published in:
Venken, T., Krnavek, D., Münch, J., Kirchhoff, F., Henklein, P., De Maeyer, M., and Voet,
A. (2011). An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41
fusion peptide inhibitor. Proteins. 79(11):3221–3235
Chapter 5 | The flexibility of HIV-1 FP in solution
Although the results from the previous chapter are promising, the lack of structural
information of the target hinders additional optimisations. Therefore, we applied
multiscale MD simulations to explore the conformational ensemble of the gp41
FP in solution. We discuss the measured secondary structure properties in detail
and implement a secondary structure clustering method. A number of future
prospects is outlined in detail.
The contents of this chapter have been published in:
Venken, T., Voet, A., De Maeyer, M., De Fabritiis, G., and Sadiq, S. K. (2013). Rapid
Conformational Fluctuations of Disordered HIV-1 Fusion Peptide in Solution. J. Chem.
Theory Comput. 9(7):2870–2874
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Chapter 6 | Scrutiny of the Rev multimerisation
In the last result chapter, we study the multimerisation of the HIV-1 Rev protein
using a computational methodology. The binding affinities between individual
Rev monomers are explained in detail and a number of hot spot residues are
identified and compared to experimental results. The results of this chapter form
the basis for virtual screening of specific Rev multimerisation inhibitors.
The contents of this chapter have been published in:
Venken, T., Daelemans, D., De Maeyer, M., and Voet, A. (2012). Computational investigation
of the HIV-1 Rev multimerization using molecular dynamics simulations and binding free
energy calculations. Proteins. 80(6):1633–1646
Chapter 4
Optimisation of VIRIP
"I Want To Decompose"
Whistling - The Hickey Underworld
This chapter is an adapted reprint of the article:
Venken, T., Krnavek, D., Münch, J., Kirchhoff, F., Henklein, P., De Maeyer, M., and Voet, A. (2011). An optimized
MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor. Proteins. 79(11):3221–3235.
The original introduction and materials and methods section have been shortened to avoid
repetition with previous thesis chapters. I performed all the simulations, binding free
energy calculations and most of the analyses. Suggested peptides were tested in the lab
of prof. dr. F. Kirchhoff and prof. dr. J. Münch (Materials and methods can be found
in the full paper). I wrote the paper with adjustments and additions of the co-authors.
4.1 Summary
VIRus Inhibitory Peptide (VIRIP), a 20 amino acid peptide, binds to the FP of
HIV-1 gp41 and blocks viral entry. VIRIP derivatives with improved antiviral
activity have been developed, and one of those derivatives has recently proven
effective and safe in a phase I/II clinical trial. Here, MD simulations were executed
in combination with MM-PBSA free energy calculations to explore the binding
interaction between VIRIP derivatives and gp41 FP. A promising correlation be-
tween antiviral activity and simulated binding free energy was established thanks
to restriction of the flexibility of the peptides, inclusion of configurational entropy
calculations, and the use of multiple internal dielectric constants for the MM-PBSA
calculations depending on the amino acid sequence. Based on these results, a
virtual screening experiment was carried out to design VIRIP variants with further
improved antiretroviral activity. A selection of peptides was tested for inhibitory
activity and several VIRIP derivatives were identified with significantly enhanced
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activity compared to the reference peptides. The results demonstrate that compu-
tational modelling strategies using an adapted MM-PBSA methodology improve
the accuracy of binding free energy calculations of peptide complexes compared to
the classic MM-PBSA protocol. As such, this virtual screening approach generated
HIV-1 gp41 FP inhibitors with improved antiviral activity that could be useful for
future clinical applications.
4.2 Introduction
As outlined previously in section 1.4.2, VIRIP and its derivatives offer an alterna-
tive antiretroviral strategy by inhibiting the anchoring event of the gp41 FP. The
published NMR structure of the optimised VIR-165 derivative in complex with the
FP [1] provides a paradigm for in silico optimisation. Here, we report an improved
methodology using MD simulations and the MM-PBSA approach to investigate
peptidic interactions. The method consists of the implementation of restraints,
inclusion of configurational entropy calculations, and the use of multiple internal
dielectric constants depending on the sequence of the peptide. To our knowledge,
this is the first time that a peptide-peptide interaction has been analysed using
the MM-PBSA method. The improved procedure forms the basis for the design of
enhanced gp41 FP inhibitors to interfere with the HIV-1 entry process. In fact, a
significant correlation between antiviral activity and simulated binding free energy
was found, allowing the design of VIRIP derivatives with improved antiretroviral
activity based on virtual screening.
4.3 Materials and methods
4.3.1 System preparation
Coordinates for all VIRIP derivatives were based on the NMR structure of VIR-165
(Protein Databank code: 2JNR) [1]. Amino acid point mutations were created using
the Brugel package [2] by retaining the dihedral angles of the side chain followed
by 1000 steps of conjugated gradient energy minimisation using a CHARMM-
based force field [3].
MD simulations were performed with the GROMACS package, version 4.0.7 [4]
using the OPLS/AA force field [5]. Each complex was placed in a trigonal box and
filled with TIP3P water molecules [6]. Distances between the complex and the edge
of the box were at least 0.85 nm. When required, chloride or sodium counterions
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were added to neutralise the charges of the complex. Following conjugate gradient
energy minimisation, each complex was equilibrated during 100 ps at constant
pressure (NPT ensemble). During this equilibration phase, both peptides were
fixed with harmonic position restraints on all heavy protein atoms with a force of
1000 kJ mol−1 nm−2. The water molecules were allowed to adapt to the complex,
thus filling possible cavities and eliminating clashes. Next, three separate full
production MD simulations of 10 ns each were executed on all complexes. In
these simulations, three different conditions were applied: no restraints, "weak"
restraints (a combination of dihedral restraints of the backbone atoms and position
restraints only on the Cα atoms with a force of 100 kJ mol−1 nm−2), and "strong"
restraints (position restraints only on the Cα atoms with a force of 1000 kJ mol−1
nm−2). For comparative reasons, an equilibration and production MD simulation
was performed on the VIR-165:FP complex using NOE distance restraints similar
to the MD setup for the original NMR determination [1].
During the simulations, periodic boundary conditions and the Berendsen thermo-
stat at 298 K and barostat at 1 bar were applied [7]. Temperature and pressure
were maintained with coupling constants τT = 0.1 ps and τp = 1 ps. Atom bonds
were constrained using the LINCS algorithm [8] with a 2 ps integration step. Elec-
trostatic interactions were calculated using the particle mesh Ewald summation
method [9]. For the short-range van der Waals interactions, a cut-off distance of
1.4 nm was applied. Each system contained roughly 8500 atoms.
4.3.2 Binding free energy calculations
An average ensemble of structures was generated with MD simulations in explicit
solvent as described above. Five hundred snapshots were extracted during the
last 5 ns of the production MD trajectory (i.e., at 10 ps intervals), while removing
solvent and counterions. Next, MM-PBSA calculations were performed using the
AMBER 8 package [10] using this ensemble of structures. The MM-PBSA approach
was used to determine the binding free energy of VIRIP and FP, while MM-GBSA
using the Onufriev model [11] was used for binding free energy decomposition
of the binding interaction. The implementation as reviewed in section 3.4.1 was
used for both methods. Regarding the configuration entropy calculations, the
structures used to construct the covariance fluctuation matrices of receptor, ligand,
and peptidic complex were all extracted from the same MD trajectory of the
peptide complex, identical to the MM-PBSA calculations. As such, rotational or
translational changes upon binding are not taken into account. Thus, entropy
calculations are restricted to the dynamics between FP and VIRIP in the bound
state, where large entropic costs indicate that the dynamics of both peptides are
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highly associated. The entropy estimations were calculated during the whole
10 ns of the production MD run using all frames. As entropy is a time-dependent
parameter, 10 ns were chosen to obtain as much convergence as possible.
4.3.3 Methodology of the binding free energy calculations
The MM-PBSA method depends on the conformation of the studied molecules.
Since structural changes have a large effect on the overall energetic profile, too
much flexibility will increase the uncertainty of the binding free energy values
and configurational entropy predictions. The high flexibility of the VIR-165:FP
complex was confirmed from initial MD simulations (see Figure 4.1). To over-
come this inherent flexibility, it is possible to apply restraints to prevent a strong
deviation from the starting structure. NOE distance restraints were used for the
initial determination of the NMR-structure of the VIR-165:FP complex [1]. The
implementation of these NOE distance restraints was utilised for the VIR-165:FP
complex, but is not applicable for the mutated VIRIP derivatives. Therefore,
it was investigated whether alternative methods can be applied to simulate all
VIRIP derivatives. As such, other restraining methods were explored: (i) position
restraints, (ii) dihedral restraints, and (iii) a combination of position and dihedral
restraints. Different restraining strengths were tested: (i) "strong" restraints of 1000
kJ mol−1 nm−2 on each Cα atom and (ii) "weak" restraints of 100 kJ mol−1 nm−2
on each Cα atom. A gradual decrease of the backbone RMSD profile is observed
when increasing the restraining force (Figure 4.1A).
In the end, a combination of dihedral restraints on the backbone atoms and position
restraints on the Cα atoms proved to be ideal. For these restraints, position restraint
forces of 100 kJ mol−1 nm−2 on each Cα atom and dihedral restraint forces of 100
kJ mol−1 rad−2 on φ and ψ angles of the backbone were applied, thereby finding a
balance between flexibility and extreme deviation from the starting structure. Of
note, side chain atoms remained unrestrained during all production simulation
steps, allowing interfacial adaptation between both peptides and the calculation
of the side chain configurational entropy contribution. As a remark, the backbone
RMSD of the VIR-165:FP complex using the "weak" restraints agrees with the
RMSD of the same complex using NOE distance restraints (Figure 4.1B). Thus,
combination of "weak" dihedral and position restraints reproduces the original
NMR structure, allowing the usage of these restraint settings. A representation of
the effect of the different restraints conditions on VIR-165 and gp41 FP is shown in
Figure 4.3A.
A second adaptation in the methodology is the inclusion of configurational entropy
calculations, which are often neglected due to efficiency reasons and possible inac-
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Figure 4.1: Structural analysis of the MD simulations. (A) Root mean square deviation (RMSD)
profile of the VIR-165:FP complex when increasing position restraint strength (given in kJ −1 nm−2)
on Cα atoms and dihedral restraint strength (given in kJ mol−1 rad−2) on φ and ψ angles of the
backbone. (B) RMSD of the backbone atoms of VIR-165 and (C) radius of gyration of the VIR-165:FP
complex during 10-ns MD simulations. Results for four different conditions (unrestrained, NOE
distance restraints, weak restraints, and strong restraints) are shown.
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Figure 4.2: Examination of configurational entropy estimates. (A) Example of the convergence of
the entropy part of the binding free energy of VIR-165 with gp41 FP. The configurational entropy
was estimated with a quasi-harmonic approximation during a 10-ns MD simulation. (B) Effect of
configurational entropy difference between complex, FP, and VIR-165 using restraint strength on all
atoms or on the backbone atoms. Entropy estimates were performed on all atoms (designated as "all")
or on only the side chain atoms (designated as "ss").
curacies [12–14]. However, the flexible nature of the VIR-165:FP peptide complex
requests the inclusion of configurational entropy. An initial 1-ns MD simulation
resulted in entropy estimates over 50 kcal mol−1, but longer simulations (>10 ns)
of the VIR-165:FP complex resulted in convergence of the entropical contribution
(Figure 4.2A). This has already been observed in simulations on the PDZ domains
[12], demonstrating the necessity of long simulations to obtain convergence of
the entropic contribution using the quasi-harmonic analysis method. Although
entropy estimates did not converge entirely after 10 ns, it is clear from Figure 4.2A
that the −T∆S value is almost converged, and thereby can provide an estimate
of the binding entropy difference. Furthermore, this research is focused mainly
on a relative comparison of derivatives and less on an absolute reproduction of
entropic contributions.
The restraints are implemented only on the backbone atoms of the peptides, while
side chain atoms are unrestrained and thus able to explore the conformational
space extensively. As such, the entropy estimations in the restraint conditions are
mainly a representation of the amino acid side chain motions, while the backbone
only contributes partially due to the restricted mobility. Nevertheless, a major
consequence of the restraint implementation is the direct effect on the flexibility of
the system. Applying restraints influences the configurational entropy predictions
MATERIALS AND METHODS 97
one wishes to evaluate. Therefore, additional calculations were performed to
verify the effects of the restraint settings on the entropy estimations. In Figure 4.2B,
the effect of different restraint settings on the configurational entropy estimations
was explored. Two types of restraints settings were used, restraining all atoms
in the system or restraining only the Cα atoms and dihedral backbone angles.
Entropy calculations were performed on all atoms or only the side chain atoms.
Restraint forces range from very weak (1 kJ −1 nm−2, which corresponds to an
almost unrestrained condition) to very strong (10,000 kJ −1 nm−2, corresponding
to only minimal flexibility in the peptide complex). As is visible, the restraint
settings show that the side chain entropy difference between VIR-165:FP and its
constituents correlates closely with the entire protein entropy difference, indicating
that the backbone barely contributes, as was expected. In addition, increasing
the restraint force on all atoms results in an exponential decrease of the entropy
difference. This difference increases after reaching a restraint force of 1000 kJ −1
nm−2. In contrast, restraining only the backbone conformation results in a much
weaker dependency on the restraint settings. In fact, the entropy difference no
longer reduces significantly upon increasing the restraint force beyond 100 kJ −1
nm−2. This shows that exclusively restraining the backbone atoms results only in
a limited loss of thermodynamic information compared to restraining the entire
protein conformation. However, some information is lost, so the configurational
entropy contribution calculated here should be considered as a virtual screening
value instead as an absolute thermodynamic value.
A third adaptation is the use of multiple dielectric constants for the protein de-
pendent on the sequence of each VIRIP derivative. As described in chapter 3,
the dielectric constant of a protein is not a universal parameter, and commonly
different values are used ranging from 1 to 4 (and even higher) depending on the
methodology or models used [15–17]. It has been shown before that the use of
different dielectric constants can drastically enhance the reliability of ∆∆G values
using MM-PBSA. This approach, however, has solely been applied in alanine
scanning simulations, and a procedure based on the same principle for other
mutations must consequently be implemented. Different degrees of relaxation are
present in a protein upon mutation of an amino acid to an alanine. Ramos and co-
workers used the following internal dielectric constants: two for apolar residues
(Val, Leu, Ile, Phe, Met, and Trp), three for polar residues (Asn, Gln, Cys, Tyr, Ser,
and Thr) and four for charged residues (Asp, Glu, Lys, Arg, and His) [17]. They
obtained an excellent agreement between their calculated relative binding free
energy values and the experimental results. In the present study, multiple amino
acids are mutated and an average dielectric constant was calculated when multiple
mutations were present. Ala, Pro, and Gly mutations were added to the category
with value p = 2. When no alanine substitution was present, the dielectric differ-
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ence between two amino acids based on their dielectric categories was subtracted
by the following rule: newvalue = oldvalue − (originalresidue − mutatedresidue).
As such, mutation of a residue from a lower category results in an increase of
the internal dielectric constant, while mutation of a residue from a higher cate-
gory decreases the internal dielectric constant, analogous to the alanine scanning
methodology [17]. This procedure has the advantage that multiple amino acid
substitutions can be investigated and that the analysis should not be restricted to
alanine scans. This implementation is justified in our case because of the small
size of the VIRIP derivatives, since small amino acid sequence changes can have
a substantial effect on the electric environment at the interface, and thus on the
accuracy of the binding free energy estimations.
4.3.4 Virtual screening
Conservative mutations of specific residues were proposed to construct additional
VIRIP derivatives, for example, replacement of hydrophobic residues like Val
by a larger Leu residue. Some mutations were based on biochemical intuition
after structural investigation of the NMR structure of VIR-165, for example, VIR-
165_F12L_A13F. In addition, information from the computational alanine scanning
and binding free energy decomposition (as explained above) was used to suggest
mutations. Certain positions were not altered, for example, the cysteine bridge
in VIR-165 and most prolines, as these mutations could have a drastic effect on
the conformation of the peptide. Polar and charged residues were left unchanged
(e.g. Lys16); or changed to a homologue residue. Initially, only single mutations
were proposed. In total, 81 in silico single mutations were tested: 35 based on
VIR-165 and 46 based on VIR-175. From these results, 40 additional double and
triple mutants were suggested based on VIR-165. All mutations were constructed
with the Brugel package [2] and simulations were carried out as described above.
For reasons of accuracy, all calculations were run in triplicate using a random seed
for each MD-simulation.
4.4 Results and discussion
4.4.1 Initial analysis of the VIR-165:FP peptide complex struc-
ture
Estimating the binding free energy and thereby accurately distinguishing strong
from weak-binding flexible peptides is not as straightforward as for large pro-
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tein–ligand and protein–protein complexes. Extensive secondary structure ele-
ments in large proteins help to stabilise the overall structure. In contrast, the
structural prediction of the conformation of small peptides is significantly more
difficult, since a peptide can adopt a whole spectrum of conformations. Thus,
there is a need to adapt the simulation settings in order to develop a more reli-
able predictive model. Such a model should calculate the binding free energy
of each VIRIP derivative with the gp41 FP with significant precision. To verify
the flexibility of the peptide complex, a structural analysis of the VIR-165:FP
interaction was performed. Based on the visual inspection of the NMR structure
of VIR-165 in complex with the gp41 FP, it can be deduced that both short peptides
have no clear secondary structure. Only a disulphide bridge in certain optimised
VIRIP derivatives introduces some rigidity. This assumption was confirmed by a
secondary structure prediction program [18], showing that VIR-165 has an average
coil probability of 80%. The gp41 FP has more secondary structure, with an average
a-helix probability of 40%, mostly spanning residues Gly5 to Leu12, while the
average coil probability is 53%. In addition, initial MD simulations showed high
flexibility of the peptide complex in unrestrained conditions, although no drastic
unfolding occurs. This was verified by calculating the RMSD of the backbone
atoms of VIR-165 (Figure 4.1B) and the radius of gyration of the peptide complex
(Figure 4.1C). Interestingly, the NMR determination of the VIR-165:FP structure
relied on NOE distance restraints, and in principle these could have been applied
in our simulations. However, these restraints are only applicable in the VIR-
165:FP complex and not in derivatives. Therefore, we explored different settings
of dihedral restraints and position restraints of the backbone atoms, while keeping
the side chain atoms unrestrained.
4.4.2 Restrained MM-PBSA simulations including entropy cal-
culations
A set of VIRIP derivatives comprising only natural amino acids was selected from
a previous study [1] to validate the MM-PBSA setup as explained above. Most
tested VIRIP derivatives contain a disulphide bridge between Cys6-Cys11, as
in, for example, VIR-165 [1]. Derivatives without a disulphide bridge were also
selected. However, derivatives with disulphide bridges at other positions were
not included since NMR structures of these peptides are not available, and hence
a precise conformation is not known. Using these criteria, 29 derivatives were
selected for further analysis (see Table 4.1). For each VIRIP derivative, restrained
simulations were conducted in order to reduce the flexibility during the MD
simulations with inclusion of configurational entropy calculations. The simulated
100 OPTIMISATION OF VIRIP
binding free energy values were compared to experimental IC50 values, which
were converted to relative free energy values using the following relationship [19]:
∆∆G = RTln(IC50mut/IC50wt) (4.1)
where R is the ideal gas constant and T is the temperature in K. The antiviral
activity as measured by the IC50 of the tested derivatives ranges from 0.18 µM to
inactive ( 100 µM) [1].
Three different restraining strengths were tested for all 29 VIRIP derivatives (unre-
strained, weakly, and strongly restrained). The effect of these restraint conditions
on the RMSD of the backbone atoms of VIR-165 is shown in Figure 4.1B, while
a visual representation of the VIR-165:FP complex flexibility is presented in Fig-
ure 4.3A. As can be seen in Figure 4.3B, low correlation was found between the
experimental and theoretical values when unrestrained conditions were applied.
Apparently, this condition results in too many degrees of freedom to allow a
reliable determination of the binding free energy. In addition, configurational
entropy calculations did not converge due to relatively high peptide flexibility.
Although configurational entropy predictions were possible when applying strong
restraints, no correlation was found. These settings result in rigidity preventing
strong adaptation to the backbone conformation of the VIRIP derivatives. In
contrast, a promising correlation between experimental and theoretical values is
found in the case of weak restraints (R2 = 0.40). These simulation settings allow a
balance between rigidity and flexibility of the VIRIP derivatives in complex with
FP.
VIRIP acts exterior of the cell and therefore factors such as cellular permeability,
stability, and other interferences of the cellular environment do not influence
the activity [1]. As such, a correlation between the simulated free energy of
binding values and in cellulo antiviral activity is expected and has been found
in the experimental data. Although the implementation of restraints during
the MD simulations was obligatory, this procedure might skew the results for
some derivatives, explaining the good but imperfect correlation. Furthermore,
the force field, limitations of the entropy calculations, and other approximations
inherent to the MM-PBSA methodology (such as the implicit solvent model)
cause deviations. As such, to evaluate the predictive power of the MM-PBSA
method, receiver operator characteristic (ROC) curves were plotted [20]. A ROC
curve corresponds to the enrichment of the method and forms an association
between sensitivity (defined by the true positive rate) and specificity (defined
by the false positive rate). ROC analysis revealed a promising predictivity for
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Figure 4.3: Correlation and predictivity using different restraint conditions on 29 selected VIRIP
derivatives. (A) Representation of three different restraint conditions on VIR-165 (green) and gp41
FP (cyan), ranging from unrestrained (left), weak restraints (middle), and strong restraints (right). In
each case, 10 superimposed snapshots of a 10-ns MD simulation are shown. The backbone is shown in
ribbon and side chain atoms are represented by wireframe. (B) Correlation (top graphs) and predictivity
(bottom graphs showing ROC curves). A correlation is shown of experimental ∆∆G (converted from
IC50 values) and theoretical ∆∆G (calculated with AMBER using a dielectric constant of p = 2). A
line is drawn to visualise the fit. WT-VIRIP was used as reference with theoretical and experimental
∆∆G set to zero. ROC curves are shown at the bottom to demonstrate the prediction of theoretical
∆∆G in each restraint condition. Each graph shows the true positive rate (y-axis) versus the false
positive rate (x-axis). The black line indicates the "random selection trend". (C) Same as Figure 4.1B, but
theoretical ∆∆G calculated with AMBER using different internal dielectric constant values depending
on the peptide sequence (see Table 4.1).
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Table 4.1: List of VIRIP derivatives for comparison with IC50 data.
Derivative Sequencea p
b IC50 ± SEMc
VIR-344 LEAIPCSIPPCVFFGKPFVF 5 0.28 ± 0.02
VIR-165 LEAIPCSIPPCFAFNKPFVF 3 0.27 ± 0.04
VIR-345 LEAIPCSIPPCFLFGKPFVF 5 0.39 ± 0.13
VIR-162 LEAIPCSIPPCVGFGKPFVF 5 0.73 ± 0.13
VIR-23 LEAIPMSIPPEVAFNKPFVF 4 4.73 ± 0.61
VIR-148 LEAIPCSIPPCVAFNKPFVF 3 0.18 ± 0.08
VIR-163 LEAIPCSIPPCVLFNKPFVF 3 0.84 ± 0.08
VIR-164 LEAIPCSIPPCVFFNKPFVF 3 0.93 ± 0.05
VIR-175 LEAIPMSIPPEFLFGKPFVF 6 1.34 ± 0.42
VIR-42 LEAIPMSIPPEVAFAKPFVF 6 3.45 ± 0.44
VIR-102 LEAIPMSIPPEVFFNKPFVF 4 0.66 ± 0.06
VIR-18 LEAIPMSAPPEVKFNKPFVF 2 23.46 ± 0.28
WT-VIRIP LEAIPMSIPPEVKFNKPFVF 2 14.79 ± 2.56
VIR-12 LEAIPASIPPEVKFNKPFVF 3 13.00 ± 1.04
VIR-21 LEAIPMSIPPAVKFNKPFVF 4 11.00 ± 4.75
VIR-22 LEAIPMSIPPEAKFNKPFVF 2 10.64 ± 2.23
VIR-24 LEAIPMSIPPEVKANKPFVF 2 4.62 ± 1.32
VIR-25 LEAIPMSIPPEVKFAKPFVF 4 17.41 ± 3.66
VIR-26 LEAIPMSIPPEVKFNAPFVF 4 10.81 ± 0.68
VIR-13 LEAIAMSIPPEVKFNKPFVF 2 23.50 ± 5.19
VIR-14 LEAIPMSIAPEVKFNKPFVF 2 16.33 ± 4.34
VIR-15 LEAIPMSIPAEVKFNKPFVF 2 9.72 ± 1.66
VIR-27 LEAIPMSIPPEVKFNKAFVF 2 12.72 ± 10.17
VIR-19 AEAIPMSIPPEVKFNKPFVF 2 >100
VIR-20 LAAIPMSIPPEVKFNKPFVF 3 >100
VIR-39 LEAAPMSIPPEVKFNKPFVF 2 >100
VIR-28 LEAIPMSIPPEVKFNKPAVF 2 >100
VIR-29 LEAIPMSIPPEVKFNKPFAF 2 >100
VIR-30 LEAIPMSIPPEVKFNKPFVA 2 >100
(a) Amino acids mutated compared to wild type are underlined. The wild type sequence and VIR-165
as starting NMR structure are shown in bold. (b) p is the internal dielectric constant used for the
MM-PBSA calculations. (c) IC50 values are given in µM and were determined previously by Münch et
al. [1].
weakly restrained simulations, while a random trend is observed for unrestrained
or strongly restrained simulations (Figure 4.3B).
4.4.3 MM-PBSA simulations: inclusion of multiple internal di-
electric constants
The initial results were promising, but the correlation and predictivity could be
further improved. Therefore, a third adaptation in addition to restraints and
entropy calculations was introduced: the implementation of multiple internal
dielectric constant values as a function of the peptide sequence.
Using the procedure outlined in the Materials and Methods section, an improved
correlation between the theoretical and experimental ∆∆G values using weak
restraints was found. Overall, an R2 value of 0.71 was obtained. As shown in
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Figure 4.3C, a clear separation is now achieved between strong and weak binding
derivatives. The difference between high and low binding free energy is significant,
despite large standard deviations intrinsic to the MM-PBSA methodology. In
comparison, the correlation is also present in the initial simulations (where p =
2) in Figure 4.3B, but much weaker. In addition, the correlation is improved in
the unrestrained and strong restraint conditions (compare Figure 4.3B,C), though
these differences are not significant.
Similar conclusions can be made using ROC-analysis. The sensitivity is improved
upon using multiple dielectric constants (Figure 4.3C), since the curve rises in-
stantly to a sensitivity of 0.91. In addition, an area under the curve (AUC) value
of 0.96 was obtained, which is considered an excellent predictivity. However,
the enrichment is certainly not satisfactory when calculating binding free energy
using only one internal dielectric constant. As can be observed from Figure 4.3B,
the ROC curve has a high AUC value when using weak restraints, though this is
mainly attributed by the specificity (x-axis) and not by the sensitivity (y-axis).
Our results demonstrate that the best predictivity is obtained when all individual
components of the binding free energy are calculated. The enrichment disappears
when only the molecular mechanics free energy GMM or the solvation free energy
Gsolv is determined. In fact, a random trend is only seen when comparing each
individual term of the MM-PBSA method with the experimental binding free
energy (see Figure 4.4). GMM has the best predictivity, which is probably a result
of the hydrophobic interactions in the complex. A combination of these individual
terms (∆Gsub−tot), however, results in an improved prediction of theoretical ∆∆G
values. Nevertheless, if ROC curves for binding free energy with configurational
entropy included (Gtot) and excluded (Gsub−tot) are compared, it is obvious that
the enrichment is improved even further when the entropy term is taken into
account.
Interestingly, a predictive trend between experimental binding free energy and
configurational entropy is observed, although the entropy is predicted as un-
favourable in all cases. This is not unexpected, as the entropy components of the
complex and the individual peptides were calculated from a single MD trajectory.
Therefore, the entropy of the complex is by definition smaller than the sum of
its constituents, resulting in an unfavourable entropy contribution upon binding.
Furthermore, the configurational entropy values calculated here mainly represent
the motions of the side chain atoms, as the backbone atoms were restrained
using weak or strong restraints. In fact, the average entropy contribution using
weak restraints is 4.48 ± 2.16 kcal mol−1, while a highly similar value of 4.42
± 1.41 kcal mol−1 was obtained using strong restraints. Thus, it seems that the
implementation of restraints does not influence the calculation of the entropic
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Figure 4.4: ROC curves for individual binding free energy components. Weak restraints and
multiple internal dielectric constants depending on peptide sequence were applied. Each graph
shows the true positive rate (y-axis) versus the false positive rate (x-axis). The black line in-
dicates the "random selection trend". (a) The subtotal binding free energy (excluding entropy):
∆Gsub−tot = ∆GMM + ∆GPB + ∆GSA (b) The total binding free energy (including entropy):
∆Gtot = ∆Gsub−tot − T∆S.
contributions significantly. Since restraints on the backbone were employed, the
configurational entropy contribution should be considered as a virtual screening
value instead of an absolute thermodynamic value.
It can be observed from the calculations that the entropy contribution to the total
binding free energy is rather small compared to the other individual terms. For
example, most optimised VIRIP derivatives have an entropy contribution smaller
than 3 kcal mol−1. In fact, it has been postulated previously that the optimised
VIRIP derivatives have relatively low entropy contributions for binding to FP
[1, 21]. In contrast, larger entropic penalties of more than 6 kcal mol−1 were
calculated for unoptimised VIRIP derivatives. Thus, although the calculated
configurational entropy contributions do not significantly improve the predictivity
of the setup due to the small magnitude of the entropy values, a relation with the
sequence of the peptides was found and its inclusion results in the best enrichment.
Possibly, a higher correlation and predictivity could be obtained if translational
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and rotational entropy contributions are calculated as well, but these could be
difficult to calculate for flexible peptides like VIRIP and FP.
4.4.4 Investigation of the VIR-165:FP binding interaction
The construction of a reliable setup for the quantitative study of peptide com-
plexes allows the investigation of the binding interaction of VIR-165:FP in detail.
Therefore, an in silico computational alanine scan was performed on VIR-165. This
procedure allows the identification of essential residues in the binding site, and
is based on the assumption that single alanine mutations do not considerably
alter the conformation of the peptide complex. As shown in Figure 4.5B, most
alanine mutations of VIR-165 are unfavourable. This is a consistent result, since
VIR-165 is already an optimised structure compared to wild type VIRIP [1]. Some
derivatives show an increased binding free energy, such as L1A and V19A, but the
difference is only marginal. Alanine mutations of residues Ile8 and Phe12 have
the largest disturbing effect, suggesting that these could be important residues for
the binding interaction with FP.
Interestingly, the contribution of each individual amino acid to the binding free
energy can be investigated as well, excluding the configurational entropy. The
MM-GBSA approach implemented in the AMBER package [10] was used for these
calculations, as MM-PBSA cannot be used to decompose the different energy terms.
This does not pose a problem as the correlation between MM-PBSA and MM-
GBSA values was 0.987 using the testset of 29 VIRIP derivatives (data not shown).
From the binding free energy decomposition calculations (Figure 4.5C), it can be
deduced that the C-terminal residues of VIR-165 contribute the most to the binding
interaction with gp41 FP, where hydrophobic phenylalanine (Phe12, Phe14, Phe18,
and Phe20) and a polar asparagine residue (Asn15) are the strongest binding
contributors. On the contrary, most N-terminal residues contribute unfavourably
to the binding affinity. The largest energy values in the gp41 FP result from
a combination of hydrophobic residues (Gly10, Phe11, and Leu12) and polar
residues (Ser17 and Thr18). As expected, these residues are positioned closely to
the C-terminal residues of VIR-165, as is visible in Figure 4.5A. It is also noteworthy
from this figure that the interplay between VIR-165 and FP is a combination of
central residues with a strong contribution (shown as red sticks) and residues
positioned outward with a weaker contribution (shown as yellow sticks).
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Figure 4.5: Investigation of the binding interaction between VIR-165 and gp41 FP. (A) Stereo view
of the most important residues of VIR-165 (green) to gp41 FP (cyan) for the binding with ribbon
representation and transparent surface. Residues with a binding free energy decomposition below
-3 kcal mol−1 are shown as red sticks, less important residues between -1 and -3 kcal mol−1 are
shown as yellow sticks, other residues are shown as lines coloured by element. Main chain atoms and
hydrogen atoms were removed for clarity, except for Gly10 of FP that would be invisible otherwise. (B)
Computational alanine scan on VIR-165 with calculated free energy difference (∆∆Gtot) in kcal mol−1.
Negative values contribute favourably to the binding, while positive values contribute unfavourably.
The sequence of VIR-165 is shown at the bottom. The colour of the bars corresponds to the binding free
energy decomposition values of 4.5C. (C) MM-GBSA binding free energy decomposition (∆∆Gsub−tot)
by residue of VIR-165 and gp41 FP with calculated free energy difference in kcal mol−1. Negative
values contribute favourably to the binding, while positive values contribute unfavourably. The
sequences of VIR-165 and gp41 FP are shown at the bottom. Residues with a large binding free energy
contribution (below -3 kcal mol−1) are shown as red bars, while less important residues (between -1
and -3 kcal mol−1) are shown as yellow bars.
4.4.5 Virtual screening
As demonstrated above, the simulation setup yielded promising correlations
between theoretical and experimental binding free energies. The structural infor-
mation and the predictive model were applied in a virtual screening experiment to
test the efficacy of the improved MM-PBSA method. Furthermore, this experiment
enables the creation of optimised VIRIP derivatives with increased anti-HIV-1
activity. Virtual screening was performed by constructing point mutations in
the VIR-165 sequence. A second starting sequence was VIR-175, which lacks the
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Figure 4.6: Virtual screening results. Top: 121 VIRIP derivatives were suggested and ranked by their
binding affinity with FP. Bottom: Entropy contribution of each derivative. Due to the importance of
the entropy component, we only selected VIRIP derivatives with an entropy threshold below 4 kcal
mol−1.
disulphide bridge. Although VIR-175 is less active than VIR-165 in cellulo [1],
it was selected for its therapeutic relevance as it resembles to the most potent
molecule currently tested in the clinic, that is, the VIR-576 dimer [1]. The combi-
nation of virtual screening on both strong and weak binding derivatives allows
the investigation of the predictivity of the MM-PBSA method in a broad affinity
spectrum.
In total, 121 mutations were proposed for in silico investigation (see Figure 4.6).
Twenty derivatives based on VIR-165 and 23 derivatives based on VIR-175 showed
improved binding free energy compared to their originating sequences. The
majority of the VIR-165 mutations have beneficial binding free energy, while
derivatives of VIR-175 have the lowest affinity. All VIR-165 derivatives have
disulphide bridges and these additional connections reduce the flexibility of the
peptide. As a result, fewer configurations reduce the absolute value of the entropy
of each derivative (−TS), but the configurational entropy difference upon binding
(−T∆S) is improved because the dynamics of each derivative and the FP are
coupled in each simulation. It is interesting to note that the VIR-165 derivatives
have the most favourable entropy difference upon binding, as observed by the cal-
culations. These simulations corroborate our initial finding that VIRIP derivatives
with disulphide bridges have improved configurational entropy contributions for
gp41 FP binding. In addition, replacement of large hydrophobic residues such as
phenylalanine and isoleucine is usually unfavourable.
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Based on the in silico results, 20 specific derivatives were chosen for extensive
in cellulo analysis: 17 peptides based on VIR-165 and three on VIR-175 were
synthesised. Derivatives with beneficial binding free energy were selected. In
addition, an entropy limit was imposed on derivatives of VIR-165 because of the
importance of this term. It was found that most optimised VIRIP derivatives have
configurational entropy contributions lower than 3 kcal mol−1. A higher limit of 4
kcal mol−1 was used to test this hypothesis and to include VIR-165 derivatives
with promising binding free energy values, despite a high entropic penalty. In
addition, the reliability of the predictive model was further investigated by also
testing a selection of derivatives with decreased in silico affinity.
The results of the virtual screening approach are shown in Table 4.2. The in cellulo
results were obtained by determining the antiviral activity of each VIRIP derivative
in HIV-1 inhibition assays as described [1]. The IC50 values shown in Table 4.2
were calculated from one representative measurement with X4-tropic HIV-1 NL4-3
and were confirmed in three other independent experiments. No inactive com-
pounds were found in all measurements, thus no substitutions were detrimental
for the binding strength. In a separate measurement, cells were infected with
R5-tropic HIV-1 virus and the relative inhibitory value differences are comparable
in most cases, which is not unexpected as the inhibitory efficacy of VIRIP has
been shown to be coreceptor independent [1]. As shown in Figure 4.7, derivatives
with significantly enhanced antiviral potency were found. Compared to the IC50
of the original sequence using X4-tropic virus, 11 derivatives showed more un-
favourable IC50 values, two derivatives showed similar inhibitory values, while
seven derivatives showed improved efficiency. Some mutations, for example, VIR-
165_F12W and VIR-165_F12L_A13F, improved their inhibitory strength by more
than twofold compared to the reference VIR-165. Mutations at positions 12 and 13
are very beneficial, as shown by the improved IC50 values of VIR-165_F12L_A13F,
VIR-165_A13F and VIR-165_F12W. Interestingly, when a computational alanine
scan is executed on VIR-165, the mutation of Phe12 has a large disturbing effect
(Figure 4.5A). In addition, Phe12 is very important for the binding interaction
as shown by binding free energy decomposition of the VIR-165:FP complex (Fig-
ure 4.5B). From the in silico and in cellulo results, it can be concluded that increasing
the hydrophobic content in this area is highly advantageous. Other hydrophobic
residue substitutions, that is, VIR-165_F14W and VIR-165_I8Y_F12V_A13F, were
also favourable. Intriguing derivatives are VIR-175_M6L and VIR-165_S7Q, which
have increased affinity although their mutated residues do not directly contact the
FP. These substitutions could have a stabilising influence on vicinal amino acids
or could stabilise the overall conformation of the peptide. For example, the larger
Gln7 residue in VIR-165_S7Q is directed toward Leu1, and this shielding could
enhance the hydrophobic interactions of the latter residue with gp41 FP.
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Table 4.2: Virtual screening on selected variants of VIR-165 and VIR-175c
Variant ∆Gcoul ∆Gvdw ∆GSA ∆GPB ∆Gsub−tot −T∆Sa ∆Gtot ± STDV a IC50X4d IC50R5d
VIR-165_V19T -9.61 -51.12 -7.60 23.68 -44.65 3.30 -41.35 ± 3.15 0.83 0.51
VIR-165_I8Q -14.64 -50.12 -7.04 27.52 -44.28 3.26 -41.02 ± 3.35 1.03 0.80
VIR-165_I4Y -13.02 -48.64 -7.09 26.19 -42.57 3.05 -39.52 ± 0.80 1.10 0.30
VIR-165_I4L -11.58 -49.22 -7.06 25.42 -42.43 3.01 -39.43 ± 0.87 0.62 2.03
VIR-165_I8L -7.99 -49.54 -7.11 22.67 -41.97 3.17 -38.80 ± 1.44 0.35 0.83
VIR-165_A13F -9.20 -46.55 -6.52 21.36 -40.92 2.72 -38.19 ± 2.07 0.22 0.46
VIR-165_F18L -10.11 -45.84 -6.84 21.80 -40.99 3.11 -37.88 ± 2.92 0.48 0.40
VIR-165_F14W -9.42 -44.68 -6.66 21.99 -38.77 1.49 -37.28 ± 1.03 0.33 2.51
VIR-165_I4F -6.88 -46.76 -6.72 21.10 -39.26 2.05 -37.21 ± 2.70 0.40 0.26
VIR-165_F18Y -10.07 -46.86 -6.52 23.36 -40.09 2.93 -37.17 ± 1.13 0.62 0.48
VIR-165_F12W -10.21 -45.18 -6.64 22.01 -40.02 2.93 -37.08 ± 1.24 0.18 1.95
VIR-165_S7Q -10.01 -46.78 -6.73 23.63 -39.88 2.90 -36.98 ± 1.50 0.15 0.51
VIR-165_F12L_A13F -9.78 -43.78 -6.46 20.93 -39.10 3.34 -35.76 ± 1.19 0.13 0.41
VIR-165_F12V_A13F_P10A -12.92 -48.38 -7.07 23.05 -45.32 4.59 -40.73 ± 0.31 0.61 nc
VIR-165_F12V_A13F_F20Y -8.30 -45.87 -6.66 21.76 -39.08 2.81 -36.28 ± 2.86 0.72 1.29
VIR-165_I8Y_F12V_A13F -10.36 -44.18 -6.46 21.62 -39.37 3.31 -36.06 ± 3.14 0.25 0.48
VIR-165_S7N_F12V_A13F -9.75 -42.93 -6.55 22.09 -37.14 1.96 -35.18 ± 1.48 0.24 0.21
VIR-175_I4Q -16.38 -49.82 -7.84 32.69 -41.35 5.00 -36.35 ± 1.15 1.61 0.62
VIR-175_M6L -16.36 -48.36 -7.27 32.60 -39.39 4.27 -35.12 ± 1.72 0.37 0.20
VIR-175_E2Q -3.45 -48.93 -7.01 18.33 -41.05 6.31 -34.74 ± 0.46 0.77 0.69
VIR-165 -8.94 -46.92 -6.69 23.15 -39.39 2.47 -36.92 ± 1.92 0.34 0.59
VIR-175 -14.98 -47.52 -7.42 30.91 -39.00 6.35 -32.66 ± 3.36 0.47 0.20
(a) Bold numbers represent favorable entropy values (<3 kcal mol−1) or low standard deviations (<2 kcal mol−1).
(b) nc, not calculated. (c) Binding free energy values given in kcal mol−1, IC50-values given inµM. (d) IC50-values
were determined from both X4- and R5-tropic HIV-1.
Mutations located at the N- and C-terminal part of the VIRIP derivatives were
in most cases unfavourable, despite a beneficial in silico affinity as predicted by
the MM-PBSA method. Evidently, kinetic effects (i.e. docking of both peptides to
each other prior to actual binding and folding events) are not estimated by the
MM-PBSA approach, which could explain the disagreement between the in silico
and in cellulo values of N- and C-terminal mutations. Although some derivatives
based on VIR-165 and VIR-175 with mutations located in the N- and C-terminal
part were less active than their references, in cellulo alanine scans of the N-terminal
or C-terminal residues of wild type VIRIP render the peptide completely inactive
[1]. Another important factor is that MM-PBSA is capable of clearly distinguishing
active from non-active molecules, that is, predicting the expected trend of the
binding free energies, but it performs poorly when derivatives with similar activ-
ity are tested [22]. For example, some derivatives that have more unfavourable
binding free energies than VIR-165 displayed enhanced activity in cellulo (e.g.,
VIR-165_I8Y_F12V_A13F and VIR-165_F12L_A13F), even though the differences
in binding free energies are within range of the standard deviation. In addition,
derivatives that are less active than predicted have larger standard deviations
regarding the simulated binding free energy (larger than 3 kcal mol−1 difference,
e.g., VIR-165_V19T and VIR-165_I8Q) and the in cellulo effect is consequently more
difficult to predict in silico. These specific derivatives also have larger configura-
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Figure 4.7: Dose–response curves of improved VIRIP derivatives. TZM-bl reporter cells were in-
fected with X4-tropic HIV-1 NL4-3. Improved derivatives of VIR-165 are shown in blue, double and
triple mutants in teal and improved derivatives of VIR-175 in red. As a remark, VIR-576, shown
in black, seems the least active but is a dimer compared to the other derivatives, therefore its IC50
value (19 µM [1]) is more favorable than visible from this graph. The results were confirmed in four
independent experiments.
tional entropy contributions (larger than 3 kcal mol−1), but the entropic penalty is
still underestimated in these calculations. Thus, although these derivatives have
beneficial binding free energy values, the higher entropy contributions explain
why these derivatives are less active, highlighting the importance of including
configurational entropy calculations for peptide–peptide interactions. In hindsight,
an entropy limit lower than 4 kcal mol−1 for the selection of VIRIP derivatives
should have been imposed, also because derivatives with low simulated entropical
contributions are in cellulo more active than the original sequence. Although other
factors in cellulo may influence the reliability of the IC50 values, the improved
MM-PBSA model has shown to predict several VIRIP derivatives with enhanced
affinity in cellulo.
Our results show that it is feasible to use computational modelling on peptide
complexes to predict mutations that increase in cellulo inhibitory activity. The most
potent designed derivates have doubled their activity compared to the reference
VIR-165. As shown in Figure 4.7, some derivatives have similar or improved
potency compared to the derivative currently tested in the clinic, namely, VIR-576
(IC50 = 19 µM)[1]. From our calculations, it can be concluded that peptide opti-
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misation will be dependent on reduction of the configurational entropic penalty.
Future experiments will include non-natural amino acids to reduce the peptide
flexibility and to improve the binding affinity even further. These improved
derivatives may initiate small molecule design based on the key features of VIRIP
with an analogous mode of action. The improved VIRIP derivative VIR-576 has
recently been proven to be safe and effective in a phase I/II clinical trial, but is
not suitable for broad application because it requires high doses and it needs to
be injected [21]. Peptidomimetics or small molecules with analogous mode of
action that are orally available would overcome these limitations. The improved
derivatives described in this chapter are a first step toward optimised FP inhibitors
for future clinical applications.
4.5 Conclusion
MM-PBSA has previously been used for the investigation of small molecule and
protein–protein interactions, but we have shown that MM-PBSA can be modified
to approximate the binding free energy between peptides. Here, the improved
method was applied to investigate the binding interaction of the HIV-1 inhibitor
VIRIP with its viral target, the gp41 FP. The best correlation with experimental
HIV-1 inhibitory efficiency is obtained when all individual components of the
binding free energy are calculated, including the configurational entropy term.
Furthermore, the implementation of restraints during the MD simulations was
necessary to allow a reliable determination of the binding free energy and to con-
verge the configurational entropy calculations. In addition, an MM-PBSA based
virtual screening approach was conducted on two optimised VIRIP derivatives. A
selection was tested for antiviral activity and multiple improved derivatives have
been identified. Thus, our methodology can form a basis for the development of
new peptidic drugs or small molecules with higher affinity.
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Chapter 5
The flexibility of HIV-1 FP in solution
"Everything Must Converge In
Time"
Nick Cave and the Bad Seeds
This chapter is an adapted reprint of the article:
Venken, T., Voet, A., De Maeyer, M., De Fabritiis, G., and Sadiq, S. K. (2013). Rapid Conformational Fluctuations of
Disordered HIV-1 Fusion Peptide in Solution. J. Chem. Theory Comput. 9(7):2870–2874
The original introduction has been shortened to avoid repetition with previous thesis
chapters. This article is the result of a combined modelling effort, where dr. K. Sadiq and
I contributed equally. We created and conducted the research and wrote the article to-
gether, which has been adjusted with helpful suggestions and corrections of the co-authors.
5.1 Summary
The conformationally flexible HIV-1 FP is indispensable for viral infection of host
cells, due to its ability to insert into and tightly couple with phospholipid mem-
branes. There are conflicting reports on the membrane-associated structure of FP
and solution structure information is limited, yet such a structure is the target for
a novel class of antiretroviral inhibitors. An ensemble of explicit solvent molecular
dynamics simulations were initiated from a disordered HIV-1 FP (aggregate time of
∼30 µs). These simulations revealed that while the vast majority of conformations
predominantly lack secondary structure, both spontaneous formation and rapid
interconversion of local secondary structure elements occurs, highlighting the
structural plasticity of the peptide. Therefore, even at this rapid time scale, FP
constitutes a diverse and flexible conformational ensemble in solution. Secondary
structure clustering reveals that the most prominent ordered elements are α- and
3-10-helical subsets of membrane-bound conformations, while trace populations
within 2 Å RMSD of all complete membrane-bound conformations are found to
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pre-exist in the solution ensemble. Since inhibitor bound conformations of FP are
only rarely found, FP inhibitors could function by modulating the conformational
ensemble and binding to non-fusogenic FP structures. A thermodynamic charac-
terisation of the most prominent ordered non-fusogenic structures could facilitate
the future design of improved FP inhibitors.
5.2 Introduction
Most attempts to characterise the FP have been in membrane-bound form (Figures
1.4A-E) [1–5], of which several have been shown stable in membrane simulations
[5–9]. Despite this, characterisation of HIV-1 FP in solution may be of crucial
importance in understanding the fusogenic process. Furthermore, the recently
discovered VIRIP and its optimised derivatives (e.g. VIR-165 and VIR-576) block
viral entry by binding to a disordered conformation of FP (Figure 1.4F) [10, 11].
Thus, structural characterisation of the conformational ensemble of FP in solution
is of great pharmacological importance if a priori predictions of solution structure
can be made.
In this chapter, we aim to gain insight into the propensity to form secondary
structure elements as well as to qualitatively establish whether any significant
structural plasticity of HIV-1 FP is exhibited in solution. Therefore, we used a
classical molecular simulation methodology, which we outline more in detail
below. We find that none of the membrane bound structures is stable in solution
and that FP undertakes rapid fluctuations including α-helix and β-sheet secondary
structure elements, i.e. dynamics compatible with a disordered protein.
5.3 Materials and Methods
5.3.1 Model construction & simulation details
All-atom explicit solvent molecular dynamics simulations using ACEMD [12] on
local computer resources were performed starting from each of the conformations
A-F shown in Figure 1.4 up to a production time of 300 ns. α-helical conformations
A-D were extracted from PDBs 1ERF [1], 1P5A [2], 2ARI [3] and 2PJV [4] respec-
tively, taking the first 23 amino acids of FP from the first structure in each PDB.
β-sheet containing conformation E was an adaptation of the fusion peptide based
on PDB 3D58 [5], shared by the laboratory of Robert C. Rizzo. Conformation F
was extracted from 2JNR [10].
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Furthermore, a larger ensemble of simulations (94×300 ns) were performed on the
GPUGRID infrastructure [13], starting from a completely unstructured peptide
chain, with the highest prevalence HIV-1 FP sequence, AVGIGALFLGFLGAAGST-
MGARS, denoted FP23. This structure was built using VMD [14].
The systems were solvated with TIP3P water [15] molecules and neutralised at
an ionic concentration of 150 mM NaCl using the leap module of the AMBER
10 software package [16]. All minimisation, equilibration and production sim-
ulations were performed using ACEMD [12]. The recently improved AMBER
forcefield, ff99SB-ILDN, was used to describe all parameters [17]. Conjugate gradi-
ent minimisation was performed for 1000 steps, followed by 1 ns of unconstrained
equilibration in the NPT ensemble with a timestep of 4 fs. The temperature was
maintained at 300 K using a Langevin thermostat [18] with a damping coefficient
of 0.1 and the pressure at 1 bar using a Berendsen barostat [19] with a pressure
relaxation time of 800 ps−1. The SHAKE algorithm [20] was employed on all
atoms covalently bonded to a hydrogen atom. The long range Coulomb interac-
tion was handled using a GPU implementation [21] of the particle mesh Ewald
summation method (PME) [22]. A non-bonded cut-off distance of 9 Å was used
with a switching distance of 7.5 Å for the VdW interactions.
For the unstructured peptide, the primary phase of equilibration caused collapse
of the extended linear chain into a coiled structure thus allowing the construction
of a smaller system. The ultimate structure from the primary equilibration was
extracted and subsequently resolvated with TIP3P water molecules and ionically
neutralised at a concentration of 150 mM NaCl and subjected to a secondary phase
of equilibration. Conjugate gradient minimisation was reapplied for 1000 steps
and the system requilibrated under identical NPT conditions as before, but with
a 2 fs timestep and with a constraining potential of 1 kcal/molA2 on all protein
heavy atoms. Unrestrained equilibration was then performed for 10 ns changing
the timestep to 4 fs in the NPT ensemble and for a further 10 ns in the NVT ensem-
ble. Different initial structures, obtained from the last phase of the equilibration,
were used to seed 100 production simulations, each with randomised velocities
describing a Maxwell-Boltzmann distribution. All production simulations were
performed in the canonical NVT ensemble on the GPUGRID infrastructure [13]. As
several trajectories were not returned by the server and some were more advanced
than others at the time of analysis, a subset of 94×300 ns was used for the analysis.
5.3.2 DSSP analysis
The DSSP method (define secondary structure of proteins) [23] was used to char-
acterise the secondary structure for each snapshot in each trajectory. The do_dssp
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plug-in tool in GROMACS (version 4.5.3) [24] was used to implement DSSP. The
following secondary structure elements are defined: α-helix, β-sheet, coil, β-bridge,
bend, turn, pi-helix and 3-10-helix for each amino acid.
5.3.3 Secondary structural features of membrane-bound struc-
tures
The structural features of conformations A-F are defined as: A (α-helix: residues
3-15), B (α/pi-helix: residues 4-15), C (α-helix: residues 4-18), D (α-helix: residues
4-9 and 11-14), E (β-hairpin: 2-5 and 9-12 and α-helix: residues 15-22) and F
(bend/turn/coil: all residues). These definitions were used to calculate RMSDs of
Cα atoms with respect to the initial conformations with prior fitting to the same
secondary structural features, in each case.
5.4 Results
5.4.1 Solvent MD simulations of experimental membrane struc-
tures
Figure 5.1 shows the time evolution of the DSSP state during the 20 ns equili-
bration and subsequent 300 ns simulation of each of the conformations A-F of
FP. All simulations of FP in solvent from each of the conformations A-F show
rapid decay of their respective secondary structure features into unstructured
conformations within the 20 ns period of equilibration and specifically as soon
as constraints are removed. Furthermore, lack of ordered features persists for all
systems across 300 ns of simulation, except interestingly for system F. This system
reconstituted secondary structural features (specifically a small β-hairpin) after
100 ns of simulation in a similar sequence region to the initial conformation of
model structure E and which persisted for the duration of the simulation.
Cα atom RMSD calculations with respect to the initial secondary structural features
of each structure (dark grey lines) are consistent with the DSSP calculations, show-
ing small RMSD values (< 1 Å) up to removal of constraints followed by rapid
increase (4Å< RMSD < 10Å) upon further equilibration and simulation for all
systems. Our results thus show that the respective experimental membrane-bound
and VIR-165-bound monomeric apo-form structures are unstable in solution,
yet highlight that secondary structural elements may be spontaneously formed,
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Figure 5.1: Unfolding of the membrane conformations. Time evolution of the DSSP state (color
legend) and RMSD of Cα atoms of secondary structure regions (dark grey line) is shown during 20 ns
equilibration and 300 ns subsequent simulation for HIV-1 FP23 in solution, starting from each of the
experimental and modelled membrane-bound structures (A-E) and the VIR-165-bound structure in
apo-form (F). Rapid unfolding occurs for each structure as soon as constraints are removed, 11 ns into
the equilibration (dashed black line).
Figure 5.2: RMSD distribution of the conformational ensemble of FP. The Cα atom RMSD with re-
spect to corresponding experimental/model FP structures (A-F) was measured from the conformations
in the simulation ensemble.
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thus further indicating that HIV-1 FP has substantial conformational plasticity in
solution.
5.4.2 Ensemble solvent MD simulations
We investigated whether any of the structural features found in structures A-F can
pre-exist in solution, by performing simulations (94×300 ns) from multiple initial
unstructured conformations of FP23.
RMSD distribution
We determined the Cα atom RMSD distribution of the entire ensemble with respect
to each of the specific secondary structural features corresponding to the experi-
mental conformations (Figure 5.2). Most conformations in our solution ensemble
deviate strongly from the FP23 structures found in membrane-like environments
(Figure 5.2A-E) with peak RMSDs of between 5 to 6 Å compared to secondary
structural features. Nevertheless, a small percentage of structures within the
ensemble were found within 2 Å RMSD of conformations A-D (A: 0.21%, B: 0.05%,
C: 0.01%, D: 0.49%) while conformation E was not present. Interestingly, when
comparing RMSD relative to either the α- (residues 15-22) or β- (residues 2-5 and
9-12) components of structure E separately, 0.21% and 6.38% of conformations
were within this RMSD threshold respectively (RMSD distribution for E shown in
Figure 5.2 corresponds comparison with the β-sheet only). The mean deviation
from structure F (VIR-165 bound apo-form of FP) was ∼7 Å and no conformations
were present below a 2 Å RMSD threshold, the minimum being at 3 Å and only
0.01% were within 3.5 Å RMSD. This is not surprising as conformation F has no
significant secondary structural features (only bends and turns), so RMSD was
calculated with respect to all Cα atoms within the chain.
DSSP proximity distribution
Calculating the proximity distribution in DSSP state space resulted in a similar
trend, displaying the rare occurence of structures matching the experimental
structures. Proximity of any two snapshots in DSSP space was calculated by
computing the number of amino-acid changes required to convert one DSSP
structure into the other. A change of DSSP state for a single amino acid into
any other DSSP state was considered a distance of 1 in the DSSP space. Of the
experimental structures of membrane bound FP (Figure 5.3:A-D), the solution
ensemble most closely proximates the α-helical conformations A and B, with a
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Figure 5.3: Normalised proximity distribution in DSSP state space for the ensemble with respect to
various experimental/model FP structures. The structures are outlined in Figure 1.4:A-F, respectively.
Corresponding DSSP states or ‘flags’, of these reference structures are inset. The red arrow indicates a
single instance in the data set which exactly matches the VIR-165 bound structure of FP.
Figure 5.4: Normalised proximity distribution in reduced DSSP state space for the ensemble with
respect to various experimental/model FP structures. The structures are outlined in Figure 1.4:A-F,
respectively. Corresponding DSSP states or ‘flags’, of these reference structures are inset. In the reduced
representation pi-helices and 3-10-helices are included as α-helices (blue), β-bridges are included as β-
sheets (red) and turns and bends are included as coils (white). This allows only the classical secondary
structural features to be compared.
120 THE FLEXIBILITY OF HIV-1 FP IN SOLUTION
peak variation of 16 amino acids in DSSP space and an additional minor peak
at a variation of 12 (11 identical amino acids). Thus, although the majority of
solution conformations vastly differs from the membrane conformations, some
membrane-like structures infrequently seem to pre-exist in solution.
Reduced DSSP proximity distribution
The proximity distribution of the entire ensemble in reduced DSSP state space
with respect to the six experimental/model structures was calculated (Figure 5.4).
A reduced representation in which pi-helices and 3-10-helices are included as α-
helices (blue), β-bridges are included as β-sheets (red) and turns and bends are
included as coils (white) allows only the classical secondary structural features
to be compared. Compared to the full DSSP distribution, there is a notable shift
of each distribution towards more proximal states. The key secondary structure
features of conformations A (5 instances) and B (14 instances) exist, albeit rarely,
in the solution ensemble. Conformations C-E are not found although there is a
notable shift in the ensemble distribution to more proximal states. In addition,
a small number of coiled structures similar to the VIR-165-bound conformation
were found.
Analysis of conformational changes
Our motivation for using DSSP to gain insight into conformational changes stems
from the insufficient information that other conventional metrics often yield. This
notion is certainly relevant for an extremely flexible system such as the fusion
peptide, and furthermore, when a sufficient number of reference structures do
not exist. For example, the normalised frequency distribution of the radius of
gyration (Figure 5.5A) shows a single peak at about 7.5 Å; no specific structural
information about the different conformational features can be gleaned. Even a
frequency distribution of the RMSD with respect to both an α-helical (structure
A in Figure 1.4) and β-sheeted (structure E in Figure 1.4) structure (Figure 5.5B)
shows a single peak. No member of the ensemble exhibits an RMSD with respect to
these conformations of less than 5 Å; furthermore, there exist many distinct confor-
mations within an RMSD of 7 Å that are equidistant from both α-helix and β-sheet
structures. By contrast, DSSP directly distinguishes the key secondary structural
features. The drawback of DSSP is that such characterisation comes at the cost of
approximating tertiary conformational structure to secondary structural features.
Therefore, DSSP would not be relevant for tertiary structure characterisation of
larger proteins but in the smaller peptide limit, it can provide insight.
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Figure 5.5: Normalised frequency distributions for the ensemble using radius of gyration and
RMSD. (A) The radius of gyration of the solution ensemble. (B) The RMSD distribution for the
ensemble with respect to α-structure A (x-axis) and β-structure E (y-axis) defined in Figure 1.4.
Global secondary structure propensity
The overall propensity to form any given secondary structure element was calcu-
lated both as an average across the entire peptide (termed global DSSP propensity)
and on a per residue basis. Block averages of the secondary structures in DSSP
representation were calculated in 30 ns intervals to verify equilibrium of the global
propensity to form secondary structure elements (Figure 5.6). The global α-helix
propensity is reduced during the first 100 ns while the β-sheet and β-bridge
increases gradually. The global amino acid structural properties are in equilibrium
after 150 ns. The latter 94×150 ns was therefore used for reporting global and per
residue structural propensities.
DSSP analysis shows that FP23 is predominantly unstructured or exhibits locally
stabilised structures such as bends and turns in the solution ensemble (Figure 5.7A).
Coiled conformations have a high frequency (average of 38.1%) which is mainly
manifested in the terminal residues. Moreover, a high concentration of bends
(average of 19.7%) and turns (average of 20.6%) are present in the entire structure.
Extended secondary structure elements are found as well, though at lower per-
centages. A modest amount of 3-10-helices (average of 7.9%) was found in the
FP23 structure, while the propensity of pi-helix is insignificant (average of 0.1%).
In contrast, a small degree of α-helix formation (average of 4.0%) was detected,
mostly between residues Gly5 to Leu12. Interestingly, the higher α-helical content
between residues Gly5 to Leu12 as compared to the other residues has been
suggested previously using a secondary structure prediction program (see chapter
4) and is consistent with the results of an α-helical prediction algorithm [25] (see
Figure 5.8A). There is also a moderate propensity of β-sheet conformations (aver-
age of 5.7%) or isolated β-bridges (average of 3.9%) in solvent as well. Combining
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Figure 5.6: Percentage of average secondary structure of all trajectories. Block averages were calcu-
lated in 30 ns intervals. Structural colour scheme is blue:α-helix, red:β-sheet, white:coil, black:β-bridge,
green:bend, yellow:turn and grey:3-10-helix. The propensity of pi-helix is very low and is therefore
omitted for clarity.
Figure 5.7: Global secondary structure propensities of the FP ensemble. (A) Percentage of secondary
structure averaged over all trajectories and calculated per residue. Structural colour scheme is blue:
α-helix, red: β-sheet, white: coil, black: β-bridge, green: bend, yellow: turn, purple: pi-helix and
grey: 3-10-helix. (B) Selected examples of trajectories with different secondary structure elements in
DSSP representation. Simulation 75: conversion of α-helical to β-sheet conformation. Simulation 16:
trajectory with a high β-sheet content. Simulation 25: trajectory with a combination of β-bridges and
β-sheets. Simulation 30: trajectory with a combination of multiple β-bridges and 3-helices. Simulation
79: trajectory with a high amount of coiled conformations and only a limited amount of secondary
structure. Representative structures during the trajectories are shown besides the DSSP graphs, with
the secondary structure of the FP in DSSP colors.
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all helical (α-helix, 3-10-helix and pi-helix) and β-sheet conformations (β-sheet
and β-bridge) results in a slightly larger tendency to form helices (average of
11.9%) than β-sheet like structures (average of 9.6%). Nevertheless, these fractions
are much lower than the unstructured conformations coil, bend and turn taken
together (average of 78.4%).
A B
Figure 5.8: Prediction of secondary structure properties of FP23. (A) Predicted α-helicity of FP23 per
residue using AGADIR [25]. This algorithm predicts helicity of peptides based on theoretical helix/coil
transitions. (B) Disorder probabilities of FP23 per residue. The PONDR-FIT [26], OnD-CRF [27] and
DisEMBL [28] servers (by Loops/coils definition) were used to verify the disorder characteristics of
FP23.
Experimental comparison
We next compared the secondary structure predictions with previous experiments.
Transmission FTIR measurements of FP23 in deuterated buffer solution indicated
a mixture of molecular aggregates of intermolecular β-sheet structures and un-
ordered plus helical conformations [29]. FTIR measurements of FP23 in phosphate
buffer showed α-helix, β-sheet, β-bridge and coil estimations of respectively 20.1%,
40.4%, 19.5% and 20% [30]. Electron paramagnetic resonance (EPR) spectra of
nitroxide spin labels attached to N-terminal and C-terminal residues showed a
high rotation rate, underlining the flexibility of the coiled conformations of FP
in solution [31]. These reduced significantly when probing lipid environments.
Coiled conformations in aqueous solvent have been found for other fusion pep-
tides as well, such as the influenza FP [32]. In addition, a secondary structure
prediction study performed previously in chapter 4 showed α-helix, β-sheet and
coil probabilities of respectively 40%, 7% and 53%. Furthermore, several protein
disorder prediction methods indicate that the peptide could be disordered (see
Figure 5.8B). Although the disorder probability is calculated differently for each
method, all three methods suggest that FP23 is mainly disordered. The N- and
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C-terminal ends are the most highly disordered, while residues Ile4 to Phe11
display the lowest disorder probability, in qualitative agreement with our results.
The quantitative deviation with our calculations may be for a number of rea-
sons. Firstly, single FP molecules were simulated here while interactions between
multiple FP molecules occur in experiments. For example, interstrand β-sheets
and other interresidual stabilisations are absent in our simulations, which could
explain the higher β-sheet content in the FTIR experiments. We hypothesise that
conformational experiments on single FPs would result in lower β-sheet content
and partially explain the role of FP multimerisation. Secondly, simulations may
be sensitive to the cut-off used to describe various intramolecular interactions
[33]. Furthermore, the AMBER forcefield, ff99SB-ILDN, is known to slightly
underestimate the α-helical content in MD simulations [34]. Use of a more ac-
curate forcefield may thus reduce the observed discrepancy. Finally, while the
secondary structure prediction shows a majority of coil probabilities (53%), a large
amount of α-helix was predicted as well (40%), which is much higher than in our
MD simulations and in the FTIR experiments. Secondary structure prediction
algorithms are usually optimised for larger proteins which also contain tertiary
structures. In contrast, the FP with only 23 amino acids is too small to contain
a tertiary fold, which could influence the reliability of the secondary structure
prediction.
On the other hand, we note that the amount of α-helix measured in experiments
may be exaggerated because these involve ensemble measurements averaged in
time. Sometimes helical structures can be detected in experiments, though these
structures actually could be highly averaged random-flight chains, containing
mostly bends, turns and coils instead [35]. Previous studies on the alanine-based
XAO peptide, a model for the unfolded state of proteins [36], show it to display a
very flexible, fluctuating structure that only seldomly adopts a helical conforma-
tion, quite similar to the behaviour of FP23.
Time evolution analysis
Analysis of the time evolution of secondary structural features across all trajectories
reveals a detailed account of the specific conformational ensemble and structural
interconversions (Figure 5.9). Strong variations exist between different simulations
but also within a single trajectory, clearly demonstrating the inherent structural
plasticity of FP23.
Most simulations reveal a high quantity of unstructured conformations. This
notion is demonstrated by simulation 79 (Figure 5.7B), for example, where mostly
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Figure 5.9: Time evolution of all trajectories in DSSP representation. Each panel represents a tra-
jectory up to 300 ns. Structural color scheme is blue:α-helix, red:β-sheet, white:coil, black:β-bridge,
green:bend, yellow:turn, purple:pi-helix and grey:3-10-helix.
coil, bend and turn are exhibited. The secondary structures also display a persis-
tence time of only a few nanoseconds. In contrast, simulation 16 clearly illustrates
the formation of a stable C-terminal β-sheet structure, which persists for around
250 ns, though unfolds again at the end of the simulation.
The formation of stable β-sheets is not restricted to these specific residues as
shorter β-sheets have also been observed, for example, in simulation 75. Isolated
β-bridges were found regularly as well, like in simulation 25. This local structure
lasts for more than 100 ns until it unfolds and then forms a transient β-sheet.
β-bridges can be found in almost all residues except for termini. Simulation 30 for
example contains multiple temporary β-bridges at different time points.
In simulation 75, an α-helix with persistence time of ∼100 ns converts into a β-
sheet structure that lasts to the end of the simulation via transitional 3-10 helix
and β-bridge conformations (Figure 5.7B and Movie M11). This example clearly
demonstrates the high secondary structure plasticity of FP23 in solution, as both
1This movie can be found online at http://pubs.acs.org/doi/suppl/10.1021/
ct300856r/suppl_file/ct300856r_si_002.mpg
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stable α-helix, β-sheet and coiled unfolded structures can occur in just a few
hundred nanoseconds.
Cluster analysis
The ensemble was clustered in DSSP space (Figure 5.10A) using a k-means clus-
tering algorithm in the EMMA software package [37]. A number of cluster sizes
were explored with 50 being found to provide a good qualitative balance between
differentiating visible features and conformational variance in the ensemble. Clus-
ters contained amino acid regions of both persistent and widely varying (‘noisy’)
DSSP structure, although each cluster was predominantly disordered. Filtering of
the most frequent secondary structure elements in each cluster (frequency>0.8)
and then highlighting those clusters which had low mean RMSDs (<0.75Å) rel-
ative to the average filtered secondary structure element revealed that the most
prevalent and stable conformations in the ensemble are firstly N- and then C-
terminal α-helices or closely related 3-10-helices. N- and C-terminal β-sheets
also exist in conformations but not to the same degree of prevalence or stability
(Figure 5.10B). The most relevant stable elements thus are subsets of the α-helical
forms of membrane-bound fusion peptide.
5.5 Discussion
The conventional paradigm of structure-based function in proteins has been chal-
lenged in recent years by the realisation that many proteins exist in a disordered
yet functional state [38, 39]. These intrinsically disordered proteins (IDPs) exist in
a conformational equilibrium of states with low interconversion energy barriers
[40], others become spontaneously ordered in response to triggered binding events
[41]. In addition, the entire protein can be disordered or only selected regions can
adopt a disordered conformation.
Our results suggest that, on this time scale, HIV-1 FP is mainly disordered and
constitutes a diverse, flexible and rapidly interconverting conformational ensemble
in solution. However, it remains unclear whether FP23 displays a similar flexibility
when attached to the much larger gp41 protein or in its oligomerised state. Crystal
structures of gp41 either exclude FP due to its hydrophobicity decreasing solubility
and/or because of its flexibility. Nonetheless, we postulate that FP23 as part of a
much larger gp41 protein in vivo is likely to be disordered based on (a) the disorder
exhibited in free FP23 in our study, (b) the fact that several crystal structures of
gp41 are not resolved even upon inclusion of the first 23 N-terminal residues
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Figure 5.10: Clustering of the ensemble in the DSSP space. Clusters are labelled numerically in order
of population size within the ensemble. Residue labelling has been removed for clarity. Structural color
scheme is blue:α-helix, red:β-sheet, white:coil, black:β-bridge, green:bend, yellow:turn, purple:pi-helix
and grey:3-10-helix. (A) A k-means clustering algorithm with a cluster number of 50 was used. Each
panel width is the size of the largest cluster (12813 snapshots). (B) DSSP representations (flags) of the
50 clusters, clustered in the DSSP space. Frequent amino acid regions (frequency>0.8) are labelled with
their corresponding DSSP state, all others are denoted as coiled. Relative population of each cluster
within the whole ensemble is denoted by the length of each flag. Labels in bold correspond to clusters
with mean backbone RMSD < 0.75 Å relative to the average structure of the corresponding amino acid
region in each ensemble.
(for example PDB-codes 2X7R and 3P30), (c) the fact that, to our knowledge, the
only crystal structure where a fusion peptide has been resolved, that of Influenza
Haemagglutinin in complex with an inhibitor (PDB-code: 3EYJ, chain B), the FP is
indeed disordered, and (d) several protein disorder prediction methods indicate
that the peptide could be disordered (see Figure 5.8b). In fact, it has been suggested
previously that viral fusion peptides may form autonomous folding units in the
membrane [32]. We propose that future simulations of gp41 including fusion
peptide will be able to test this hypothesis.
Intriguingly, most IDPs are characterised by a high concentration of polar amino
acids, yet FP23 lacks these, except for Ser117, Thr118 and Arg122 in the C-terminus.
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Nevertheless, FP23 has a high fraction of Ala and Gly residues, which are known
for disorder inducing tendencies [42]. The conformational ensemble will evidently
be different upon oligomerisation and upon attachment to the entire gp41 protein,
which will influence long-range interactions. Nonetheless, the FP23 as such is
inserted into the membrane in a monomeric form and is only oligomerised after
conformational change of gp41 into a six-helix bundle [43], warranting the analysis
of FP23 in its monomeric form to understand membrane insertion.
Recently, an acid-denatured 80 amino acid ACPB protein which has a natural
tertiary fold was found to maintain residual ordering and slow interconversions
across a long time scale of 200µs [44]. Our findings cannot rule out the possibility
of stable solution structures with relaxation times >30µs. Such structures would
not conform to existing membrane-bound conformations, although they might be
composed of a combination of the secondary structural elements identified in our
study. However, FP23 is four times smaller than ACPB, lacks a tertiary fold and
even structured proteins of slightly larger size fold at significantly shorter time
scales [45], suggesting that a stable solution structure of FP23 at longer time scales
is unlikely.
5.6 Conclusion
Our work opens up future studies that could elucidate the conformational mod-
ulation of FP (a) upon formation of a trimer, (b) in the transition from solvent
to membrane environment and (c) upon inhibitor binding. The transition from
solvent to membrane-bound FP as well as formation of the FP trimer may be crucial
in fully understanding the nature of fusogenicity. Importantly, our results show
that the key secondary structural features of experimentally observed membrane
bound structures are not substantially populated within the solution ensemble
due to a large diversity of disordered states, although they partially overlap with
the most prevalent of the small minority of ordered conformations. A full kinetic
treatment of conformational change upon membrane association, analogous to
kinetic studies of fast-folding proteins [46, 47], protein autocatalysis [48] and
enzyme inhibitor binding [49] would, in principle, determine the degree to which
both conformational selection and induced fit account for FP membrane-insertion
and stabilisation. Large-scale simulation of several FPs may determine whether
FP readily oligomerises in solution and whether specific conformations facilitate
this process.
Our findings suggest that the FP inhibitor VIRIP, which binds a non-fusogenic
structure, may function by modulating the conformational ensemble of FP. A
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comprehensive view of conformational modulation acknowledges the existence of
a distribution of conformations even among the drug-bound states of a protein
[40, 50, 51]. The VIRIP bound structure and those that are proximal to it also
pre-exist within the solution ensemble, yet occur seldomly. Stabilisation of these
structures upon VIRIP binding may shift the conformational equilibrium away
from fusogenic structures that co-exist in solution. This would partially explain
the high dose requirements of VIRIP in experiments and clinical trials [11] and
future investigations may establish this shift quantitatively.
Finally, we suggest an improved strategy to guide the design of new inhibitors.
The minority of prevalent ordered elements in the ensemble would be potential
targets for inhibition. However, as the most prevalent of these partially overlap
with the membrane-bound N-terminal α-helical structures, inhibitors targeting
such structures would primarily need to disrupt subsequent membrane insertion
and/or FP multimerisation. An alternative FP inhibitor design strategy may thus
be to thermodynamically characterise the most prominent ordered non-fusogenic
structures as targets for inhibition.
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Scrutiny of the Rev multimerisation
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calculations and analysis. I wrote the paper with advice and corrections from the co-authors.
6.1 Summary
The HIV Rev protein mediates the nuclear export of viral mRNA, and is thereby
essential for the production of late viral proteins in the replication cycle. Rev forms
a large organised multimeric protein-protein complex for proper functioning.
Recently, the three-dimensional structures of a Rev dimer and tetramer have been
resolved and provide the basis for a thorough structural analysis of the binding
interaction. Here, MD and binding free energy calculations were performed to
elucidate the forces thriving dimerisation and higher order multimerisation of
the Rev protein. It is found that despite the structural differences between each
crystal structure, both display a similar behaviour according to our calculations.
Our analysis based on a MM-GBSA and a configurational entropy approach
demonstrates that the higher order multimerisation site is much weaker than
the dimerisation site. In addition, a quantitative hot spot analysis combined
with a mutational analysis reveals the most contributing amino acid residues for
protein interactions in agreement with experimental results. Additional residues
were found in each interface, which are important for the protein interaction.
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The investigation of the thermodynamics of the Rev multimerisation interactions
performed here could be a further step in the development of novel antiretrovirals
using structure based drug design. Furthermore, the variability of the angle
between each Rev monomer as measured during the MD simulations suggests a
role of the Rev protein in allowing flexibility of the ARM domain to accommodate
RNA binding.
6.2 Introduction
Recently, two research groups independently solved the crystal structure of the
HIV-1 Rev protein [1, 2]. It is unknown whether the affinity differs between
these structures and whether the interfaces have a similar binding free energy
contribution per residue, which can differ depending on the conformation of
each interface. In addition, an angle of 120◦ was reported between the β inter-
face monomers of 3LPH, while a broader angle of 140◦ is present between the
2X7L monomers. The question why these subunits have different angles remains
unanswered. The difference could originate from protein-protein crystal-packing
effects, from respectively the point mutations in 3LPH, and/or the presence of the
Fab-fragments in 2X7L.
In this chapter, MD simulation, binding free energy calculations using the MM-
GBSA approach [3, 4] and configurational entropy predictions [5, 6] were applied
to elucidate the structural integrity and dynamics of the HIV-1 Rev protein as
well as to address the questions raised above. Not only the dimer and tetramer
crystal structure were investigated, but also a hexamer was constructed to verify
the stability of a larger Rev complex. MD simulations allow investigation of the
mobility of multiple Rev complexes and individual monomers, while binding
free energy calculations and entropy predictions reveal valuable information
about the interaction strength and the contribution of individual amino acids
at the binding interface. Such information can be very useful to initiate a ratio-
nal drug design approach. For example, binding free energy calculation on the
LEDGF/p75—integrase complex [7, 8] revealed the essential amino acid interac-
tions that have been mimicked by rationally designed inhibitors of the protein-
protein interaction [9–11]. As such, our results can be advantageous in the quest
for rationally designed protein-protein interaction (PPI) inhibitors targeting the
Rev multimerisation process.
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6.3 Materials and methods
6.3.1 System preparation
This chapter is based on the information from two recent crystal structures of
the HIV-1 Rev protein: the wild type dimeric structure in complex with two Fab-
fragments (PDB entry: 2X7L) and a mutant structure consisting of two dimers,
together forming a tetrameric complex (PDB entry: 3LPH). The structure 2X7L
comprises two Rev chains with residues 9 to 65, as the disordered C-terminus
was not resolvable [1]. The initial structure of 2X7L was constructed from the
dimeric Rev protein while retaining Fab fragments at each side. To reduce the
amount of atoms in the system, the constant domains of the Fab fragment were
deleted. Incomplete arginine residues were modelled in MOE (Chemical Comput-
ing Group, Montreal, Canada). The N- and C-terminus of each monomer and the
Fab fragments were capped with respectively acetyl and methylamide groups to
avoid aspecific interactions. For 3LPH, the protein construct for crystallisation, des-
ignated Rev70-dimer, excluded the C-terminus and contained two polar mutations
disrupting higher order multimerisation (L12S and L60R) [2]. The 3LPH structure
contains a few residues with missing side chains due to low electron density. These
missing residues were added with MOE as well. Counterions and crystal waters
were stripped. Two amino acids of 3LPH were mutated to leucine (S12L and
R60L) to generate the wild type sequence. The termini of each monomer were
capped as well. Additional mutant structures of 2X7l and 3LPH were constructed
with the MOE software package, where the side chain of the mutated residue was
placed according to the rotamer conformation with the lowest energy. To study the
behaviour of individual monomers, separate monomers of 2X7L and 3LPH were
constructed. To further investigate the different interfaces of the Rev monomers,
MOE was used to construct a hexamer using the symmetric crystal packing of
3LPH. This way, symmetric crystal copies were created in all dimensions, but
only the two copies interacting through a multimeric assembly were kept. Next,
the outer three monomers in each copy were removed. As such, the hexamer
contained the original tetramer, but with one monomer added to each side.
6.3.2 Naming conventions
The structure 3LPH consists of four resolved chains, each with a different length
(monomer A: residue 9 to 70, monomer B: residue 9 to 63, monomer C: residue
8 to 65, and monomer D: residue 8 to 64). The tetramer contains three different
interfaces: two similar α interfaces (between chains A and B, and between C and D)
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and one β interface (between chains B and C). As 3LPH is a tetramer comprising
chains ABCD, the hexamer model of 3LPH was named as ZABCDE, with E and Z a
copy of monomer A and D respectively. Consequently, five different interfaces are
present in the hexamer: two α interfaces (AB and CD) and three β interfaces (ZA,
BC, and DE). Structure 2X7L comprises two Rev chains with residues 9 to 65. The
two monomers in 2X7L form a dimeric conformation, corresponding to the 3LPH
BC interface. Therefore, in this chapter, the Rev monomers of 2X7L are named
monomer B and C. The MD simulations will be referred to as 2X7L and 3LPH
for the main simulations, while derived MD simulations are 3LPH-hexamer and
the separate monomers: 3LPH-monomerA, 3LPH-monomerB, 3LPH-monomerC,
3LPH-monomerD, 2X7L-monomerB, and 2X7L-monomerC. In total 9 simulations
on Rev protein structures were performed.
6.3.3 MD simulations
MD simulations were performed with the GROMACS package (version 4.5.3) [12].
Each structure was placed in a dodecahedral box with a minimum distance of 8.5 Å
from the edge of the box. The system was solvated with TIP3P water molecules and
counterions to neutralise the intrinsic positive charge of the Rev protein. Next, two
rounds of energy minimisation were performed, first with 50,000 steps of steepest
descent, next with 50,000 steps of conjugate gradient. The system was equilibrated
using 100 ps of NVT ensemble with the V-rescale thermostat, followed by 100 ps
of NPT ensemble with the V-rescale thermostat [13] and the Parrinello-Rahman
barostat [14]. The protein atoms were position restrained during equilibration
with a force of 1000 kJ mol−1 nm−2. After equilibration, a full production MD was
executed for 60 ns. The first 10 ns of the run were treated as a further equilibration
stage, while data analysis was performed in the remaining 50 ns. To avoid aspecific
interactions between the termini of the monomers, position restraints with a force
of 1000 kJ mol−1 nm−2 were applied during the MD production stage on the
backbone atoms from the revolved N-terminal residues (residue 8 or 9 depending
on the chain) up to Asp11 and from Ser61 up to the resolved C-terminal residues
(until residue 63 or higher depending on the chain). The AMBER ff99SB force field
[15] was used in all simulations and periodic boundary conditions were applied.
The van der Waals interaction cut-off was set to 1.4 nm. For calculation of the
long-range electrostatic interactions, the PME summation method was used.
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6.3.4 Binding free energy calculations
The binding free energy of each protein interface was obtained with the AMBER 8
package [16] using the MM-GBSA method [3] based on the Onufriev-Bashford-
Case model [4] as described in section 3.4.1.
Although the Rev molecule is highly charged, the binding interface is mainly hy-
drophobic, therefore we used an internal dielectric constant (p = 2) recommended
for a moderately charged interface [17].
For comparative purposes, all binding free energy calculations, decomposition
and entropy calculations were performed on the unrestrained residues 12 to 60.
The average binding free energy was calculated from 2500 snapshots, taken from
the last 10 ns of each production MD simulation. The entropy calculations, as
well as the decomposition of the amino acid contribution, were performed on the
whole 60 ns to obtain converging results (see Figure 6.4).
6.3.5 Analysis tools
The interaxial angle between different monomers during the MD simulations is
defined by the intersection of two axes formed by the Cα atoms of Arg35 and
Arg58 in each monomer. The angles between the axes of separate monomers were
measured in each simulation with 100 ps intervals. Hydrogen bonds were detected
between acceptor and donor atom with a cut-off radius of 3.5 Å and cut-off angle
of 120◦. Using these cut-offs the occupancy of hydrogen bonds was calculated
during the last 50 ns of the simulation. Protein structure figures were visualised
with Pymol [18].
6.4 Results
6.4.1 Structural comparison of the different crystal structures
using MD simulations
The RMSD of the backbone atoms of each Rev protein MD snapshot structure
versus the starting structure is calculated after a backbone least square fit. As is
visible in Figure 6.1A, a stable RMSD profile is found for all simulations. The 3LPH-
hexamer is a larger structure than 3LPH, but both share a similar RMSD behaviour,
with average deviations around 0.2 nm. While the dimeric Rev protein complex of
2X7L is smaller than the tetrameric 3LPH structure, a comparable RMSD profile
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is observed during the 60 ns trajectory. The mobility of individual monomer
conformations was investigated as well with separate simulations. The average
RMSD value for individual monomers was calculated from these simulations (two
based on 2X7L and four on 3LPH). As indicated in Figure 6.1B, all monomers
display a similar behaviour, although the 2X7L monomers have a slightly higher
RMSD profile. A representation of the structures before and after 60 ns of MD
simulation is depicted in 6.1C for 2X7L and Figure 6.1D for 3LPH.
The flexibility of different parts of the Rev protein was explored by calculating
the root mean square fluctuations (RMSF) of the Cα atoms during the last 50
ns of all simulation systems (see Figure 6.2A). A highly symmetric profile was
found, with most mobility in the loop areas ranging from amino acid 30 to 42,
intermediate flexibility in the ARM and relatively rigid interfaces where separate
monomer conformations interact. This pattern corresponds with the presence of
secondary structure in the Rev monomers, though the interaction sites are less
flexible due to additional amino acid contacts from vicinal Rev monomers. This
behaviour was conserved over all simulation systems. As such, the interfaces
seem to act as an anchor point while the loop regions containing the ARM are able
to explore the vicinity of the protein, for instance to interact with and adapt to viral
RNA binding. Evidently, binding with the RRE would reduce the RMSF of the
loop regions and it can be hypothesised that an increased rigidity upon binding
could stabilise the overall Rev complex. Comparing the RMSF profiles also shows
that the absolute RMSF differences varied between the different monomers in
each complex, although the relative differences are conserved over all simulation
systems.
Simulations on separate monomers were performed and indicate that all individ-
ual monomers have a comparable behaviour: the loop regions containing the ARM
show the highest flexibility, but the difference with the other protein segments
is reduced compared to the simulations of the complexes (data not shown). The
effect of Rev oligomerisation was investigated by calculating the average RMSF
difference of all protein atoms for all 2X7L and 3LPH monomers in complex and
free simulations (see Figure 6.2B). As such, this RMSF difference explains why
amino acids have the most reduced mobility upon binding. As expected, smaller
amino acids and regions not important for oligomerisation (such as the ARM)
have only limited RMSF difference between complex and free form. Larger amino
acids in the interaction sites, however, have a notable reduction in flexibility, for
example Arg58 (0.18 nm), Arg48 (0.11 nm), Tyr23 (0.09 nm), Phe21 (0.08 nm), and
Glu57 (0.08 nm).
Although 2X7L and 3LPH are highly similar when individual monomers are
superposed, the dimers have a different interaxial angle between the monomers.
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Figure 6.1: RMSD profile of the backbone atoms of the different Rev protein simulation systems.
(A) RMSD profile of the Rev protein complex simulations. (B) Average RMSD profile per protein
structure of independent monomer conformations. (C) Starting structure of the 2X7L dimer (green)
and final structure after 60 ns of simulation (yellow). The engineered antibody is omitted for clarity.
The chain names of each monomer are shown in grey. (D) Starting structure of the 3LPH tetramer
(green) and final structure after 60 ns of simulation (yellow). The chain names of each monomer are
shown in grey.
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Figure 6.3: Calculated interaxial angle difference in degrees between the Rev monomers during
the 60 ns trajectory with 100 ps intervals. The Cα atom of the top (Arg35) and bottom (Arg58) amino
acid of each monomer was used to determine each axis. (A) Angles of the 3LPH and 2X7L systems (B)
Angles of the 3LPH-hexamer system.
In the 3LPH structure an angle of 140◦ was found for the α interfaces [2], while an
angle of 120◦ is present in the β interface. In contrast, this angle is 140◦ in the 2X7L
crystal structure [1]. However, it is not clear whether these angle conformations
are conserved or simply the result of (i) the mutations in 3LPH, (ii) the different
protein constructs, (iii) different crystallisation conditions, or (iv) a combination
of previous factors. In Figure 6.3A, the angles between the monomers of 2X7L
and 3LPH were calculated from the MD trajectories. During the simulations,
fluctuations between roughly 10◦ and 20◦ were observed. Interestingly, the angle
between monomer A and B and monomer C and D was almost identical in 3LPH.
There was, however, a notable angle difference between monomer B and C. This
angle was more perpendicular for 3LPH than for 2X7L, resulting in a large angle
difference of the β interface between both structures. The hexamer of 3LPH was
simulated as well and the angles as a function of the MD progress are shown
in Figure 6.3B. This structure contains two additional β interfaces (ZA and DE)
with an interaxial angle corresponding to the angles found in the α interfaces, but
differing from the angle formed by the BC monomers. Thus, the presence of two
different angle conformations in the 3LPH in the β interfaces suggests that the
presence of the mutations in the 3LPH protein construct does not explain the angle
difference.
Larger fluctuations were observed upon removal of the restraints (data not shown).
In fact, permanent transitions were observed in both the unrestrained 3LPH and
3LPH-hexamer simulations, where the interaxial angle increased to the more paral-
lel angle reported in the 2X7L structure. Therefore, different angle conformations
can exist in the Rev protein, with anchored interfaces but flexible loop regions
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allowing interaction with viral RNA at the ARMs. It should be underlined that
these calculations were conducted in the absence of RNA. It can be hypothesised
that binding of Rev molecules onto the RRE of viral RNA would stabilise the over-
all complex and as such would reduce the interaxial angle fluctuations between
the Rev monomers. Evidently, the interaxial angle may not be too small in vivo,
since steric hindrance should be avoided for binding to the RRE.
Overall, the results using RMSD, RMSF, and interaxial angle analysis allow us to
conclude that the monomers display a similar behaviour and that no significant
difference exists between the crystal structures from a structural point of view.
6.4.2 Comparison of the α and β interface using binding free
energy calculations
It can be hypothesised that the α interface would have more beneficial binding
affinity than the β interface, since dimerisation occurs before higher order multi-
merisation [1, 2, 19]. Therefore, binding free energy calculations were conducted
using the MM-GBSA method to estimate the affinity between the interaction sites.
The results of these calculations are shown in Table 6.1. The binding free energy
calculations indicate that the β site (BC interface) is considerably less favourable
than the α site (AB and CD interface). This does not necessarily imply that each
β interface binds much weaker than the α interface in all cases. After all, each
monomer not only binds to vicinal Rev proteins but also to the RRE motif in a
cooperative fashion, and the latter effects have not been taken into account in our
calculations. Furthermore, kinetic effects could be present as well [19] but these
are omitted from our simulations due to the limitations of the current setup and
because these effects are outside the scope of the current research. Interestingly,
the binding free energy values of the 3LPH tetramer and hexamer interfaces
show a high similarity. The interface of 2X7L has a less favourable binding free
energy as compared to the other β sites. The difference is not very large though,
indicating that the angle differences between the monomers of the 2X7L and the
3LPH simulations do not correlate with the affinity.
6.4.3 Apolar contributions
As observed in all simulated systems, the apolar interactions, and more specifically
the intermolecular van der Waals forces, are the largest contribution and drive
the interaction between the monomers. This hydrophobic nature does not come
as a surprise since each binding interface is composed out of a large number of
hydrophobic amino acids. Furthermore, most protein-protein interactions are
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Table 6.1: Binding free energy values (given in kcal mol−1) calculated with the MM-GBSA method
for all Rev simulation systems, with averages of each interface shown in bold.
System ∆Gcoul ∆Gvdw ∆GSA ∆GGB ∆Gele−tot ∆Gsub−tot −T∆S ∆Gtot
α Interfaces
3LPH-AB 217.0±7.8 -86.3±1.4 -12.6±0.2 -201.6±7.5 15.4±0.4 -83.5±1.5 61.9 -21.6
3LPH-CD 237.7±6.9 -70.5±1.2 -10.2±0.2 -222.0±6.6 15.7±0.3 -64.9±1.3 58.6 -6.4
3LPH-hex-AB 242.4±7.2 -80.8±1.3 -11.5±0.2 -224.0±6.9 18.5±0.3 -73.8±1.4 61.7 -12.1
3LPH-hex-CD 235.6±6.7 -70.0±1.2 -10.1±0.2 -220.4±6.5 15.2±0.3 -65.0±1.3 58.9 -6.0
Avg-AB/CD 233.2±11.2 -76.6±8.0 -11.1±1.2 -217.0±10.4 16.2±1.5 -71.8±7.1 60.3±1.8 -11.5±7.3
β Interfaces
3LPH-BC 130.7±4.8 -39.4±0.9 -6.4±0.2 -123.3±4.7 7.5±0.2 -38.4±1.0 57.4 19.1
3LPH-hex-BC 148.4±5.3 -38.8±0.9 -6.2±0.2 -140.0±5.1 8.4±0.2 -36.5±1.0 58.5 22.0
3LPH-hex-DE 115.5±3.9 -40.1±0.8 -6.4±0.1 -109.3±4.0 6.1±0.2 -40.4±0.9 64.2 23.8
3LPH-hex-ZA 110.3±3.9 -38.6±0.8 -6.3±0.1 -104.3±3.8 6.0±0.3 -38.9+0.9 64.3 25.4
2X7L-BC 137.4±4.1 -38.5±0.7 -6.1±0.2 -127.2±4.0 10.3±0.1 -34.4±0.8 74.0 39.6
Avg-BC 128.4±15.7 -39.1±0.7 -6.3±0.1 -120.8±14.3 7.6±1.8 -37.7+2.3 63.7±6.6 26.0±8.0
known to be dominated by hydrophobic interactions, while the introduction of
polar interactions are usually disruptive [20]. This effect has been shown by
earlier wet lab experiments on the Rev protein [21, 22]. The absolute value of the
hydrophobic interactions is much larger for the α interface than for the β interface
in all simulations. In fact, both the intermolecular van der Waals force ∆Gvdw as
the apolar solvation contribution ∆GSA are almost twice as large for the α sites
as compared to the β sites. The value of ∆GSA is proportional to the solvent
accessible surface area buried upon complexation, thus the beneficial effect of
burying hydrophobic residues when forming complexes is much more favourable
for the α interface.
6.4.4 Electrostatic contributions
The total electrostatic contribution ∆Gele−tot is very small compared to the other
binding free energy terms such as the apolar contributions. The values are positive
and therefore unfavourable for binding, as is the case for many other protein-
protein interactions studied before. A closer examination reveals the nature of
this unfavourable contribution: the electrostatic contribution in the gas phase
∆Gcoul is positive and therefore unfavourable for binding, while the desolvation
contribution ∆GGB is beneficial, though not large enough to obtain an advanta-
geous total electrostatic contribution ∆Gele−tot. This can be explained by the large
number of positively charged residues in the Rev protein, mostly in the ARM
region. In fact, each Rev monomer has an eight net positive charge. Therefore, the
Rev monomers repel each other and this repulsion is too strong to be compensated
by the beneficial solvation effects. Evidently, binding to RNA will counterbalance
the repulsive effect by neutralising the positive charges. Here, we mainly focus
on the Rev oligomerisation domains, but it should be stressed that the presence
of RNA could have a strong effect on the situation in vivo. However, dimers are
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Figure 6.4: Convergence of the quasi-harmonic approximation of the configurational entropy for
each interface in the 2X7L and 3LPH systems. Data before 10 ns was omitted and considered as
equilibration time.
known to form in vitro, even in the absence of RNA, as is the case for the crystal
structures investigated here. There have been indications as well that Rev is able to
form complexes in vivo in the absence of RRE RNA [23]. As such, our calculations
are still relevant for the study of the protein-protein interactions between the Rev
monomers.
6.4.5 Entropic contributions
An important binding affinity contribution is the overall entropic contributions
between the Rev monomers. As entropy is a time-dependent measure, suffi-
cient sampling is required to obtain convergence of the configurational entropy
contribution. Since the entropy calculations did not entirely converge, despite
60 ns of simulation time (see Figure 6.4), the calculations provide only a rough
estimate. As seen in Table 6.1, no significant differences were found between the α
and β interfaces. The entropy contributions are remarkably similar between all
interfaces and therefore do not explain the difference in binding between initial
dimerisation and higher order multimerisation. This is not unexpected as it has
been shown that similar molecules usually do not have distinct configurational
entropy contribution, and therefore this involvement is often ignored in MM-
GBSA calculations [7, 8, 24–26]. However, it is observed that the 2X7L simulation
shows the highest entropic penalty as compared with 3LPH systems, indicating
that the dynamics between the monomers are less tightly coupled in the 2X7L
system.
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6.4.6 Hot spot residues at the binding interfaces unraveled by
binding free energy decomposition and mutational analysis
Binding free energy decomposition per residue was performed with the MM-GBSA
method to identify hot spot residues in each interface and to explain the different
binding behaviour between the strong α interface and the weaker β interface. To
unravel the most crucial amino acids in each binding interface, the binding free
energy of all simulation systems was averaged, as shown in Table 6.2. Averaging
over all systems ensures that only the most important amino acids in each interface
are found. These results are depicted visually in Figure 6.5. Concerning important
amino acids, different residues compared to the higher order multimerisation
interface guide the initial dimerisation. Specific residues crucial in the α interface
barely contribute in the β interface, and vice versa. It is notable from Figure 6.5
that the most important residues of the α interface are positioned on both α-helices,
while the β interface interaction is dominated by interactions in the N-terminal
α-helix. In fact, only one residue (Leu60) in the C-terminal α-helix of the Rev
monomer makes a significantly strong binding free energy contribution. While
Leu64 also exhibited high binding affinity, this residue was not present in all
crystallised protein chains and should probably be abandoned as a hot spot.
Comparing respectively the α and β interfaces from the 2X7L and 3LPH structures,
each interface seems to be conserved and is thus not crystal structure dependent.
This is somewhat surprising as two point mutations (L12S and L60R) are present
in the 3LPH structure that inhibit multimerisation largely due to electrostatic
repulsion. However, it can be postulated that this repulsion is compensated by
a stronger hydrophobic effect in the highly saturated conditions of the protein
crystal. This is corroborated by the binding free energy calculations shown in Table
6.2. Polar residues in the interfaces like Lys14, Arg17, Ser25, Arg48, and Arg58 are
able to represent a favourable binding affinity due to hydrophobic van der Waals
interactions that compensate unfavourable electrostatic repulsions. Therefore,
it can be concluded that the presence of mutations in 3LPH probably does not
influence the overall interaction pattern significantly, despite the crystal-packing
process which forces the dimers against each other. Furthermore, the hot spots
found in the 3LPH structure were also found in the 2X7L structure, indicating that
the complexation with the Fab fragments does not have a disturbing influence on
the structural organisation of the 2X7L β interface.
The decomposition performed here mainly focuses on enthalpic contributions,
but a thorough investigation of the configurational entropic effects upon binding
might be necessary as well. Both interfaces show similar entropic binding values,
but the entropic penalty could be caused by distinct amino acids in each interface.
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Figure 6.5: Decomposition of the Rev MM-GBSA binding free energy. The stereo views of the inter-
actions display one Rev monomer in transparent cartoon representation and the other Rev monomer
in electrostatic surface representation. The most important residues in the stereo view are coloured by
element in brown, while less important residues are coloured by element in yellow. (A) The α interface
per residue, averaged over all simulation systems. (B) The β interface per residue, averaged over all
simulation systems. (C) Stereo view of the AB interface of 3LPH, as an example of the α interface. D)
Stereo view of the BC interface of 2X7L, as an example of the β interface.
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Table 6.2: Binding free energy decomposition (given in kcal mol−1) calculated with the MM-GBSA
method and averaged over all Rev simulation systems.
Residuea ∆Gcoul ∆Gvdw ∆GSA ∆GGB ∆Gele−tot ∆Gsub−tot −T∆S ∆Gtot
α Interfaces
Lys14 15.5 -1.8 -0.3 -14.8 0.8 -1.3 5.7 4.4 ± 0.2
Leu18b,c 0.2 -4.3 -0.6 0.0 0.2 -4.8 3.7 -1.1 ± 0.4
Phe21b -0.0 -5.2 -0.9 0.4 0.4 -5.7 3.5 -2.2 ± 0.5
Leu22b,c 0.1 -5.2 -0.3 0.1 0.2 -2.7 2.8 0.2 ± 0.3
Ser25 -1.2 -1.6 -0.4 1.2 0.0 -2.1 1.4 -0.7 ± 0.4
Arg48 13.5 -2.5 -0.5 -12.6 0.9 -2.1 4.3 2.3 ± 0.4
Gln51 -0.5 -3.4 -0.6 1.3 0.9 -3.1 2.0 -1.1 ± 0.4
Ile52c -0.3 -1.3 -0.1 0.3 0.0 -1.4 2.8 1.4 ± 0.2
Ile55b,c -0.2 -3.8 -0.6 0.3 0.1 -4.3 1.6 -2.7 ± 0.4
Arg58 22.4 -3.0 -0.6 -21.1 1.3 -2.3 10.0 7.7 ± 0.4
Ile59b,c 0.0 -1.7 -0.3 0.1 0.0 -1.9 4.8 2.8 ± 0.3
β Interfaces
Leu12b,c,d 0.7 -2.3 -0.4 -0.5 0.2 -2.5 2.3 -0.1 ± 0.3
Leu13b 0.3 -2.5 -0.4 -0.2 0.1 -2.8 1.8 -0.9 ± 0.3
Val16b,c,d 0.3 -2.8 -0.5 0.0 0.2 -3.0 2.2 -0.8 ± 0.4
Arg17 0.4 -2.8 -0.3 -1.1 -0.7 -1.6 5.7 4.2 ± 0.5
Ile19c,d 0.3 -1.1 -0.1 -0.1 0.1 -1.1 0.7 -0.4 ± 0.2
Lys20e 2.1 -2.2 -0.5 -1.5 0.6 -2.1 5.7 3.6 ± 0.5
Tyr23e -0.2 -2.4 -0.4 0.4 0.3 -2.5 3.6 1.1 ± 0.4
Leu60b,c,d -0.8 -1.8 -0.4 0.8 0.1 -2.2 3.2 1.0 ± 0.3
The four most important residues for each interface (around -3 kcal mol−1 subtotal binding free energy per residue
or better) according to the computational estimations are shown in bold. (a) Only residues with a subtotal binding
free energy more favourable than -1 kcal mol−1 are shown. (b) Key residues identified by Daugherty et al. by buried
surface area analysis. (c) Key residues identified by Jain and Belasco by mutational analysis. (d) Key residues
identified by Dimattia et al. by buried surface area analysis. (e) Residues interacting with the multimerisation
inhibiting llama single-domain nanobody (Nb190) as shown by Vercruysse et al.
Therefore, an entropy decomposition based on the quasi-harmonic approximation
was performed [5, 6]. The results are shown in Figure 6.6. Positive numbers
imply a large entropic cost, while negative numbers are beneficial to binding. As
expected, the configurational entropy correlates well with the RMSF difference
values of the amino acids calculated above (see Figure 6.2B). The configurational
entropy per residue calculated here allows a thermodynamical estimation of the
amount of restructuring of the amino acid side chains upon binding. This entropy
can be added to the subtotal binding free energy ∆Gsub−tot to obtain a total
binding free energy per residue. Usually, entropic contributions are overestimated
using quasi-harmonic analysis, so the magnitude of the entropy values might
differ from the actual thermodynamic picture. As a remark, only unrestrained
amino acids were investigated (Leu12 until Arg60 in each chain), so it cannot be
excluded that amino acids outside this region could play a role in the binding of
adjacent monomers. However, most of these amino acids are positioned away
from the binding sites and therefore they can be neglected.
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Figure 6.6: Decomposition of the Rev configurational entropy The decomposition is averaged over
all simulation systems.
6.4.7 Hot spot residues in the dimerisation interface
For the α interface, Leu18, Phe21, Gln51, and Ile55 show the strongest binding
free energy, both when excluding and including configurational entropy. These
four residues form a central interaction core and are positioned at the intersection
of the N- and C-terminal α-helix. Leu18, Phe21, and Ile55 have been identified
previously as essential residues by experimental methods [1, 2, 21]. In addition to
these already reported hot spots, Lys14, Ser25, Arg48, Gln51, and Arg58 stabilise
the Rev dimerisation interface. In this interface, Arg58 has the largest entropic
penalty, indicating that the inherent flexibility of this amino acid might counteract
the binding event. Other notable residues with a strong entropic penalty upon
binding are Lys14, Leu18, Phe21, Leu22, Arg48, Ile52, and Ile59. In contrast, some
residues have an advantageous entropic difference, but the differences are in all
cases only small and therefore not significant.
6.4.8 Hot spot residues in the higher order multimerisation in-
terface
In the β interface, mainly Leu12, Leu13, Val16, Lys20, Tyr23, and Leu60 contribute
to the binding between the monomers. Arg17 is another key residue and has not
been identified as such before, although the subtotal binding free energy might be
counteracted by an entropic penalty. As such, the two point mutations that were
introduced to generate the crystal structure of 3LPH (L12S and L60R) seem to play
a crucial role in the oligomerisation of the Rev protein from an affinity point of
view. However, from our calculation it can be concluded that these mutations do
not contribute at all to the affinity of the initial dimerisation site. Thus, the results
support the notion that these mutations allow the formation of dimers but not of
higher order complexes, which is in line with experimental evidence [21, 22]. In
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Table 6.3: Relative binding free energy differences (given in kcal mol−1) of the mutated Rev struc-
tures compared to the corresponding wild type structures.
Complexa ∆∆Gcoul ∆∆Gvdw ∆∆GSA ∆∆GGB ∆∆Gele−tot ∆∆Gsub−tot
α Interfaces
3LPH-L18T 15.3 -1.9 -0.3 -13.7 1.6 -0.6±1.6
3LPH-I55N 16.6 10.5 0.4 -14.5 2.1 13.0±1.4
β Interfaces
2X7L-L12S/L60R 42.0 15.1 1.6 -40.5 1.5 18.1±0.9
3LPH-L12S/L60R 91.3 2.2 0.7 -88.0 3.3 6.1±1.2
2X7L-V16D -40.7 18.4 2.0 39.7 -1.0 19.3±1.0
3LPH-V16D -42.7 3.8 0.3 43.4 0.7 4.8±1.0
(a) Positive numbers imply a weakened interaction of the mutated structure interface compared to the wild type.
addition, Lys20 and Tyr23 were mapped as epitope of the multimerisation inhibit-
ing llama single-domain antibody (Nb190) and are essential for the higher order
multimerisation [27] and in agreement with our computational results. Indeed, it
has been shown that Nb190 disrupts the higher order Rev multimerisation but not
its dimerisation. It is notable that the region comprising Lys20 and Tyr23 shows
a strong reduction in RMSF upon binding of individual monomers (Figure 6.2B).
As such, Lys20 and Tyr23 have a relatively high entropic penalty, so the inherent
flexibility of these amino acids is reduced upon multimerisation of individual
monomers at the β interface. Of note, conserved residues have been proven to be
less flexible in protein-protein interactions [28].
6.4.9 Mutational analysis of hot spot residues
To support the binding free energy decomposition explained above, the effect of
mutating residues in the interfaces was pursued. A selection of experimentally
known mutants were modelled and simulated using the same methodology as
on the wild type structures (Table 6.3). All these mutations were introduced by
replacing a hydrophobic with a polar residue. The mutations L18T and I55N were
applied for investigation of the α interface, while L12S/L60R and V16D were
selected to validate the β interface. The L12S and L60R mutations were chosen
since the 3LPH structure contains these mutations to disrupt the higher order
multimerisation site. In addition, L18T is prevalent in HIV-infected patients and
the oligomeric assembly is thought to be only partially impaired [21, 22]. No
significant entropy contribution differences were found in the previous measure-
ments, therefore these calculations were excluded and shorter production MD
simulations (5 ns each) were conducted for efficiency reasons.
The results of these calculations are present in Table 6.3, which displays the
relative binding free energy difference of each contribution compared to the wild
type sequence. As such, it is possible to compare the strength of each mutation
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and to verify which binding free energy contribution changes the most upon
mutation. For the α interface, no significant difference was found for the L18T
mutation compared with wild type Rev. A minor decrease is found in the relative
total electrostatic contribution (∆∆Gele−tot), but this is compensated by slightly
stronger apolar interactions (∆∆Gvdw and ∆∆GSA). Although threonine is a polar
residue, it contains a methyl group, which is able to make beneficial hydrophobic
interactions. Intriguingly, the effects of the L18T mutation are very limited. In
contrast, a much stronger effect is seen for the I55N mutation due to a loss of
both electrostatic and hydrophobic contributions. Stronger effects are also seen
for mutations in the β interface, where both the L12S/L60R and V16D mutations
reduce the affinity between the monomers. These effects are much stronger for
the 2X7L crystal structure than for the 3LPH structure. The interface in 2X7L is
weaker than the 3LPH interface (see Table 6.1), therefore mutation of a hot spot
residue has the strongest effect in the already weakest interaction site.
Evidently, the mutational analysis is flawed to some extent, as the mutations
are formed in the complex of Rev monomers, and possibly these complexes are
never formed in vivo. In fact, many mutations are also known to disrupt the
secondary structure of the Rev protein. Nevertheless, these calculations show
that a prediction of the relative binding free energies is feasible. Edgcomb et al.
have ranked the effect of mutating the oligomerisation domains in the following
order: V16D > I55N > L60R > L18T > WT [22]. Our measurements correspond
with this trend, as the V16D has the strongest effect, L18T the weakest effect, and
L60R, L12S, and I55N result in an intermediate disruption. Moreover, it seems that
L18T, compared to the other mutations, does not abolish oligomeric binding from
a thermodynamical point of view, which is also in line with previous experimental
evidence [21, 22].
6.4.10 Hydrogen bonds analysis of the interfaces
Hardly any hydrogen bonds involving side chains were present between individ-
ual monomers in the simulations due to the hydrophobic nature of the interactions.
Hydrogen bond interactions were measured in the last 50 ns of the simulations and
studied when more than 20% occupancy was calculated. The few hydrogen bonds
found are mainly originating from charged arginine and aspartate residues. In
the α interface, hydrogen bonds were found between Arg58 and Ser25 in adjacent
monomers and these were present in all simulation systems. Other hydrogen
bonds were found only in the 3LPH-AB interaction and thus these interactions are
probably not conserved. In the β interface, only the Arg17 and Asp9 residues seem
to form a stable ionic interaction. This hydrogen bond could be less fixed in vitro
150 SCRUTINY OF THE REV MULTIMERISATION
because the backbone of Asp9 has been restrained to avoid aspecific interactions
between the termini of individual Rev monomers. No hydrogen bonds were found
in the β interface of the 2X7L system with more than 20% occupancy, although
some polar interactions between the Fab and the Rev monomers were present
(data not shown).
6.5 Discussion
In this chapter we have explored the structural integrity of the Rev multimerisation
by performing MD simulations and binding free energy calculations. Recently,
two distinct Rev crystal structures have been published. Despite their structural
differences, both display a similar behaviour according to our calculations. The
MD simulation showed a similar flexibility profile, while the binding free energy
calculations indicate quantitatively that the binding interaction and importance
of amino acids in each interface is conserved in both crystal structures. The
observed hot spot residues are in line with earlier experimental reports [1, 2, 21,
22]. For example, Lys20 and Tyr23 were mapped previously as epitope of the
multimerisation inhibiting llama single-domain antibody (Nb190) [27] and were
identified as key residues using our binding free energy calculations. Furthermore,
the calculations suggest additional hot spot residues, such as Lys14, Ser25, Arg48,
Gln51, and Arg58 in the α interface and Arg17 in the β interface. These residues
could be worthwhile for further biophysical investigation. Interestingly, it was
shown using a quantitative ranking of the hot spot residues that the residues in
the α interface are divided equally over both the N- and C-terminal α-helix. In
contrast, the most important residues in the β interface are positioned on the N-
terminal α-helix, with only one residue in the C-terminal α-helix (Leu60) making
a significantly large contribution. The MD simulations also demonstrated that
the angle difference between monomers of both crystal structures can adapt to
a certain degree. This implies that crystal-packing effects probably cause the
reported angle differences between the crystal structures. The variability of the
angle also indicates a role of the Rev protein in allowing flexibility at the ARMs to
accommodate RNA binding.
6.6 Conclusion
Our results have important implications for future drug design efforts from a
thermodynamic point of view. Using binding free energy calculations we have
shown using a dynamic representation of the Rev protein that the α interface
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is much more favourable than the β interface. Therefore, the calculated affinity
suggests that the dimerisation interface of the Rev protein would be a much more
difficult target than the higher order multimerisation. Generally it is challenging to
develop small molecule inhibitors, especially against α-helical proteins. However,
inhibitors against mainly helical interfaces have already been developed, such
as the c-Myc/Max inhibitors or PUMA-binding inhibitors [29, 30]. As such, an
approach based on the development of small molecule protein-protein interaction
inhibitors (SMPPII’s) targeted against the Rev multimerisation seems feasible and
might allow the generation of a new class of antiviral drugs.
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Part IV
General conclusions
The advent of molecular modelling in biochemical research has spurred novel
strategies to investigate protein-protein interactions (PPIs). The increased amount
of possibilities can improve our understanding of the interactions between pro-
teins. More importantly, modelling techniques can support rational drug design
strategies to seek novel peptidic inhibitors or small molecule protein-protein
interactions inhibitors (SMPPIIs).
In this thesis, we have used a combination of MD simulations and binding free
energy calculations to decipher the binding interactions between viral proteins
and peptides. We believe that such a combination of techniques is essential to
achieve success in computer-aided drug design (CADD), as both conformation
as affinity prediction problems need to be tackled. The conformation problem states
that biomolecules are inherently mobile and therefore a sufficient number of
conformations of the molecules of interest should be provided. In an introductory
chapter (chapter 2), we have outlined MD simulations as a technique to sample
the conformational space of biomolecules. However, a reasonable amount of
conformations is not sufficient as such, because an accurate estimation of the
predicted binding affinity should be provided as well. This issue, termed affinity
prediction in biomolecular modelling, depends on the accuracy of the binding free
energy method and has been discussed in chapter 3 in detail. The combination
of both techniques can be applied to many different fields, such as the two viral
targets in this thesis, HIV-1 gp41 FP and Rev (chapter 1).
First, we applied our biomolecular toolbox on the VIRIP:FP interaction (chapter
4). An adapted binding free energy method was proposed and allowed a detailed
investigation of the driving forces of the peptide-peptide complex. A number
of hot spots were identified that provide hints for further optimisation. Indeed,
additional VIRIP derivatives were suggested based on a virtual screening trial.
A selection of peptides were tested in cellulo and a number were shown to con-
tain improved potency. However, improving the derivatives even further is not
straightforward and would possibly require the inclusion of non-classical amino
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acids. Alternatively, the peptide backbone can be modified to sterically constrain
the conformation of the peptide with its target. The synthesis of these peptides,
termed peptidomimetics, is an interesting approach because the configurational
entropy of VIRIP was revealed as an important contributor to the binding affinity
with gp41 FP. For example, the VIR-165 derivative, which contains an internal
disulphide bridge, is sterically more constrained than wild type VIRIP. The re-
duced entropic penalty in VIR-165 is therefore a partial explanation of the increased
potency of this peptide. Next to an increase in potency, the modification of the
peptide backbone would also increase the half-life in the human body. However,
replacement of the peptide backbone by non-classical scaffolds requires organic
chemistry. Considering the many manufacturing steps required for peptidic drug
synthesis, such as T20, modifying the peptide backbone would be an expensive
and time-consuming task.
Ultimately, it would be more interesting to replace the peptide with an orally
administrative small molecule. A rational drug design strategy however depends
on an accurate representation of the target of interest. Nevertheless, there have
been conflicting reports of the FP conformation in the literature. To this end, we
applied multiscale simulations of gp41 FP in solution (chapter 5) and found a
highly diverse conformational ensemble in the investigated time scale. To our
surprise, we found very few conformations that are proximal to the membrane
and VIRIP bound structures. We hypothesize that VIRIP and its derivatives might
function by modulating the conformational ensemble, thereby perturbing the
fusogenic conformations that co-exist in solution. We can also question how many
VIRIP:FP binding modes are present in reality. In contrast to a classical protein-
ligand binding case, FP and VIRIP both display a substantial degree of flexibility.
Therefore, we propose unrestrained simulations of improved VIRIP derivatives
and FP in solution in the future. By simulating both active and inactive peptides,
we can perform a full kinetic treatment of the binding process to identify initial
binding modes and characterise the most populated binding states. In addition, a
number of simulations of the FP in membrane environments will allow a better
understanding of the insertion event. We have already performed a number of
such studies that will be analysed more in depth in the near future.
We also suggest that the FP might be intrinsically disordered, or at least contains
considerably higher mobility compared to standard globular proteins. So-called
IDPs are functional proteins that lack a well-defined structure due to a high degree
of structural polymorphism. By virtue of the intrinsic disorder of FP, molecular
modelling techniques such as MD simulations can be applied to characterise IDP
structures, which are usually difficult to obtain accurately from experimental mea-
surements. IDPs are often involved in diseases, such as α-synuclein in Parkinson’s
disease. Those IDPs are however much larger than the viral peptides studied here,
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and therefore the conformation problem is considerably more complex. To solve the
structural ambiguity of IDPs, we propose that the VIRIP:FP complex could be a
suitable test case to solve the conformational ensemble of larger IDPs in the future.
The HIV-1 Rev protein is another target of our research (chapter 6). The molec-
ular modelling toolbox was applied to elucidate the binding modes between
individual Rev monomers. MD simulations demonstrate substantial fluctuations
of the interaxial angles between the monomers. The flexibility of Rev could be
essential to recognise multiple RNA binding sites. However, we preferred to
study the protein-protein interactions between the Rev monomers and found
a number of hot spot residues in each interface. Interestingly, the quantitative
ranking of the hot spot binding free energy contributions was in correlation
with experimental measurements, which clearly demonstrates the strength of the
MM-GBSA method. We also learned that the dimerisation interface is stronger
than the higher order multimerisation interface. Therefore, the latter interface
would be more interesting to inhibit. Not surprisingly, the nanobody Nb190 was
identified as a Rev inhibitor by attaching to this higher order multimerisation
interface as opposed to the dimerisation interface. Although not discussed in
this thesis due to intellectual property protection reasons, a preliminary virtual
screening using a 3D pharmacophore model suggested a number of interesting
molecules for inhibition of the Rev multimerisation interface. A selection of these
molecules from commercial small molecule databases were tested and a number
of hit compounds were identified. Possible future experiments could consist of
additional virtual screening runs by adjustment of the 3D pharmacophore model
based on the active compound alignment. In addition, crystal structures of Rev-
Nb190 or Rev-compound complexes would give novel clues for the inhibition of
Rev multimerisation. Because the Rev protein does not contain a well-defined
small molecule binding pocket, the development of effective lead compounds will
not be easy. To this end, a number of experimental measurements will be carried
out to assess and possibly improve the potency of these antiretroviral compounds
in the near future.
Finally, we like to point out that this thesis would not have been possible without
the recent advances in computational chemistry. Increases in computer capabilities
and the development of improved algorithms have revealed possibilities that
were previously unthinkable. Predicting molecular conformations and estimating
affinities using binding free energy methods can now be performed much more
effectively than just ten years ago. While computational chemistry is not yet able
to design drugs "à la carte" against a given target, the amount of possibilities has
increased tremendously. Therefore, we believe that this thesis is a clear example of
the advantages of rational drug design strategies using computational methods.
And it mostly makes us excited of what the future will bring.
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